Clearside Biomedical

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to __________
Commission File Number: 001-37783
Clearside Biomedical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
45-2437375
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
900 North Point Parkway, Suite 200
Alpharetta, GA
30005
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (678) 270-3631
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CLSD
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes ☒
No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒
No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in
the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐
No ☒

The aggregate market value of Clearside Biomedical, Inc. voting and non-voting common equity held by non-affiliates as of June 28, 2024 (the last
business day of the registrant's most recently completed second fiscal quarter) based on the closing sale price of $1.30 as reported on the Nasdaq Global
Market on that date was approximately $92,000,000.
As of March 24, 2025, the registrant had 77,143,872 shares of common stock, par value $0.001 per share, outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Company’s definitive proxy statement, to be filed (no later than 120 days after December 31, 2024) pursuant to Regulation 14A under
the Securities Exchange Act of 1934, for its 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of the Form 10-K.

1
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K (this “Annual Report”) contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 1.
“Business,” Part I, Item 1A. “Risk Factors,” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and
Results of Operations,” but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking
statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,”
“believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable
terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the
information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each
forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts
and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements
include statements about:
•
our ability to obtain funding for our future operations;
•
our estimates regarding future revenue, expenses and needs for additional financing;
•
our ability to continue as a going concern;
•
our future capital requirements and sources and uses of cash;
•
our expectations regarding the commercialization of XIPERE by our licensing partners;
•
our plans for the development and potential commercialization of our product candidates;
•
our ongoing and planned preclinical studies and clinical trials for our product candidates;
•
the timing of the availability of data from our clinical trials;
•
the timing of our planned regulatory filings;
•
the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
•
the timing and amount of milestone and royalty payments we are required to make or that we may receive under our license
agreements;
•
the clinical utility of our product candidates;
•
our or our partners’ ability to obtain and maintain regulatory approval of our product candidates in any of the indications
for which we or our partners plan to develop them, and any related restrictions, limitations or warnings in the label of an
approved product;
•
our manufacturing capabilities and strategy;
•
our intellectual property position;
•
our plans to enter into and maintain collaborations with other companies;
•
our ability to identify additional product candidates with significant commercial potential that are compatible with
suprachoroidal injection and which are consistent with our commercial objectives;
•
our ability to attract and retain qualified employees and key personnel;
•
our ability to maintain compliance with the continued listing standards of the Nasdaq Global Market;
•
the duration, severity and impact on our operations and clinical trials of geopolitical and macroeconomic events; and
•
our estimates regarding our cash resources, our future expenses and needs for additional financing.
You should refer to Item 1A. “Risk Factors” in this Annual Report for a discussion of important factors that may cause our
actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we
cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our
forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we
will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Annual Report

2
represent our views as of the date of this Annual Report. We anticipate that subsequent events and developments may cause our views
to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no
obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any
date subsequent to the date of this Annual Report.
We have proprietary rights to a number of trademarks used in this Annual Report which are important to our business, including
Clearside, XIPERE, SCS, SCS Microinjector and the Clearside logo. Solely for convenience, the trademarks and trade names in this
prospectus are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their
respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and
service marks appearing in this Annual Report are the property of their respective owners.

3
Risk Factors Summary
The risk factors summarized below could materially harm our business, operating results, and/or financial condition, impair our
future prospects and/or cause the price of our common stock to decline. These risks are discussed more fully in the section titled "Risk
Factors." Material risks that may affect our business, financial condition, results of operations, and trading price of our common stock
include the following:
•
We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never
achieve or maintain profitability.
•
We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are
unable to raise capital when needed, we could be forced to delay, reduce or altogether cease our drug development programs
or commercialization efforts.
•
We do not currently have sufficient working capital to fund our planned operations for the next twelve months and
substantial doubt exists as to our ability to continue as a going concern.
•
Our efforts are focused on the development of product candidates for treatment of eye disease through suprachoroidal
injection and partnering with companies who can leverage our SCS Microinjector to deliver their ophthalmic product
candidates to the suprachoroidal space, or SCS. Suprachoroidal injection is a novel approach and may fail to achieve and
sustain market acceptance.
•
If we are unable to obtain regulatory approval for, and commercialize either on our own or with a third party, CLS-AX or our
other product candidates, or if we experience significant delays in doing so, our business may be harmed.
•
Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional
costs or experience delays in completing, or ultimately be unable to complete, the development of our product candidates.
•
We have entered into, and intend to continue to enter into, collaborations with third parties for the development and
commercialization of XIPERE. In addition, we may seek commercialization partners for our product candidates. If those
collaborations are not successful, we may not be able to capitalize on the market potential of XIPERE and our product
candidates.
•
If we are unable to obtain and maintain patent protection for our technology and product candidates, or if our licensors are
unable to obtain and maintain patent protection for the technology or product candidates that we license from them, or if the
scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize
technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product
candidates may be impaired.

4
Table of Contents
Page
PART I
Item 1.
Business..................................................................................................................................................................................
5
Item 1A. Risk Factors............................................................................................................................................................................
28
Item 1B. Unresolved Staff Comments ..................................................................................................................................................
61
Item 1C. Cybersecurity .........................................................................................................................................................................
62
Item 2.
Properties................................................................................................................................................................................
62
Item 3.
Legal Proceedings..................................................................................................................................................................
63
Item 4.
Mine Safety Disclosures ........................................................................................................................................................
63
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities............
63
Item 6.
[Reserved] ..............................................................................................................................................................................
63
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations................................................
64
Item 7A. Quantitative and Qualitative Disclosures About Market Risk...............................................................................................
75
Item 8.
Financial Statements and Supplementary Data......................................................................................................................
76
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure................................................ 102
Item 9A. Controls and Procedures ........................................................................................................................................................ 102
Item 9B. Other Information................................................................................................................................................................... 102
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections................................................................................... 102
PART III
Item 10. Directors, Executive Officers and Corporate Governance..................................................................................................... 103
Item 11. Executive Compensation........................................................................................................................................................ 103
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.............................. 103
Item 13. Certain Relationships and Related Transactions, and Director Independence ...................................................................... 103
Item 14. Principal Accountant Fees and Services ................................................................................................................................ 103
PART IV
Item 15. Exhibits, Financial Statement Schedules ............................................................................................................................... 104
Item 16 Form 10-K Summary ............................................................................................................................................................. 108
Signatures.............................................................................................................................................................................................. 109

5
PART I
ITEM 1. BUSINESS
Overview
We are a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the
suprachoroidal space, or SCS. Our novel SCS injection platform, utilizing our proprietary SCS Microinjector, enables an in-office,
repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina
or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Our SCS injection platform can
be used in conjunction with existing drugs designed for delivery to the SCS, novel therapies and future therapeutic innovations. We
believe our proprietary suprachoroidal administration platform has the potential to become a standard for delivery of therapies
intended to treat chorioretinal diseases.
We are leveraging our SCS injection platform by building an internal research and development pipeline targeting retinal
diseases and by creating external collaborations with other companies. We are developing our own pipeline of small molecule product
candidates for administration via our SCS Microinjector, and we also strategically partner with companies developing other
ophthalmic therapeutic innovations to be administered using our SCS injection technology. Our first product, XIPERE (triamcinolone
acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration, or the FDA, in
October 2021. Approval of XIPERE was a significant milestone for us as it is the first approved therapeutic delivered into the SCS,
the first commercial product developed by us and the first therapy for macular edema associated with uveitis.
We believe that we are creating a broad therapeutic platform for developing product candidates to treat serious eye diseases.
Our Suprachoroidal Space (SCS) Injection Platform
Our suprachoroidal injection platform is a novel, patented approach for delivering pharmacotherapy to the back of the eye via
the SCS. When fluid is injected between the choroid and sclera, the elasticity of the SCS allows the fluid to migrate and spread
spherically toward the posterior regions of the eye where it is absorbed into adjacent tissue. Our proprietary SCS microinjector is able
to precisely administer drugs into the SCS utilizing a needle that is approximately one millimeter in length. This non-surgical method
of administration facilitates more targeted delivery of therapeutic agents to chorioretinal structures and can be accomplished in an in-
office setting. The suprachoroidal injection procedure is depicted in the picture below.
We believe treatment of eye disease via suprachoroidal injection may provide a number of benefits, including a non-surgical
procedure, lower frequency of administration, limited exposure to non-targeted tissues, faster onset of therapeutic effect and an
improved safety profile. With suprachoroidal injections, product candidates are administered to the retina and choroid, limiting
exposure to non-target tissues. In contrast, intravitreal injections, the current standard for delivery of many drugs for eye diseases, rely
on diffusion of drug outward from the vitreous, a jelly-like substance that occupies the central portion of the eye, to the retina and
choroid. This diffusion can result in lower concentrations of drug in these targeted areas and the drug spreading to unintended parts of
the eye, potentially causing significant side effects. Furthermore, a natural pressure gradient between the intraocular pressure, or IOP,
and the SCS pressure drives suprachoroidal injectates posteriorly towards the macula, which facilitates treatment of macular disorders
with this office-based approach, without the need for an intraocular catheter or other surgical techniques. In summary, delivery of
agents via suprachoroidal administration offers potential advantages to other ocular drug administration techniques.

6
On January 1, 2024, a permanent Category 1 Current Procedural Terminology, or CPT, code was granted for the suprachoroidal
injection of pharmacologic agents. We believe the Category 1 code may facilitate better access, insurance coverage and adoption of
the suprachoroidal injection procedure.
Our extensive patent portfolio provides us with the right to develop and commercialize pharmacological agents for treatment of
eye diseases via suprachoroidal injection. We believe this proprietary method of administration has the potential to become the
standard for the delivery of therapies intended to treat retinal and choroidal diseases. Our intellectual property portfolio consists of 34
issued U.S. patents and more than 80 European and international patents broadly directed to the use of the SCS Microinjector,
administration of any drug into the SCS by injection, as well as XIPERE and our product candidates.
Our SCS Microinjector
Our proprietary SCS Microinjector can be used to inject a wide variety of therapies into the SCS, including our internally
developed and our collaborators’ drug candidates. Our SCS Microinjector provides targeted delivery to potentially improve efficacy
and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. Suprachoroidal injection enables
the rapid dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the
surrounding healthy parts of the eye.
Our SCS Microinjector has been used in thousands of suprachoroidal injections in our clinical trials and the clinical trials of our
partners. It has been commercially accepted by retinal physicians following the launch of XIPERE in the United States by Bausch +
Lomb with over 1,200 retinal physicians trained to date. Suprachoroidal injections using our SCS Microinjector have demonstrated a
clinical safety profile comparable to intravitreal injections.
The SCS Microinjector, shown in the picture below, is composed of a syringe and two 30-gauge hollow microneedles of varying
lengths, each approximately one millimeter, within a custom-designed hub that optimizes insertion and suprachoroidal administration
of drugs.
Current intravitreal injections are performed in a procedure similar to that of suprachoroidal injections, except that the
hypodermic needles and syringes used in intravitreal injection procedures are designed so that the needle penetrates through all of the
layers of the eye and drug is injected into the vitreous cavity. Intravitreal injections are typically performed using a needle that is
approximately five millimeters in length, or five times the length of our microneedle. Using a needle of this length, the physician
penetrates past the sclera, choroid and retina until reaching the vitreous and does not receive any tactile feedback as to when the
needle reaches one of the layers between the sclera and the vitreous.
By contrast, our SCS Microinjector is designed to inject drug into the SCS. This suprachoroidal injection is designed to be
carried out under local anesthesia, perpendicular to the sclera, at a site similar to an intravitreal injection. Once the microneedle

7
penetrates the sclera and reaches the SCS, the boundary between the sclera and the choroid, the open bevel of the needle releases the
drug between these two layers. Once drug is injected into the SCS, it spreads to the back of the eye, due to a natural pressure gradient
between the IOP and the SCS pressure, precisely targeting the cells of interest without the need for intraocular catheters or other
surgical techniques.
Our Pipeline
We have research capabilities focused on developing proprietary therapeutic formulations to utilize with our SCS
Microinjector. Our current internal research and development initiatives are focused on small molecules to address serious diseases
that affect the back of the eye. In addition to growing our internal pipeline, we are also focused on strategically collaborating with
other companies to provide access to the suprachoroidal space through the use of our SCS Microinjector.
The current development status of our pipeline of internal product candidates and external collaborations is summarized in the
chart below:
Clinical Development Pipeline
We are building a clinical development pipeline focused on small molecules. Our first product, XIPERE, was approved by the
FDA in October 2021. The XIPERE approval supports our approach both clinically and preclinically to advance small molecule
suspensions delivered into the SCS.
Our most advanced clinical development product candidate is a proprietary suspension of axitinib, a tyrosine kinase inhibitor, or
TKI, for suprachoroidal injection, which we refer to as CLS-AX. We have successfully completed two clinical trials with CLS-AX in
participants with neovascular age-related macular degeneration, commonly referred to as wet AMD.

8
CLS-AX (axitinib injectable suspension)
CLS-AX, our most advanced product candidate, is our proprietary suspension of the TKI axitinib for suprachoroidal injection
delivered via our SCS Microinjector. CLS-AX is an inhibitor of vascular endothelial growth factor receptor-1, -2 and -3 that we
believe may benefit patients as a potential longer duration maintenance therapy alongside other anti-vascular endothelial growth
factor, or anti-VEGF, therapies. We are developing CLS-AX for administration to the SCS as a long-acting therapy for wet AMD, a
retinal degenerative disease that causes a progressive loss of central vision.
AMD is the leading cause of irreversible blindness in adults over 55 years old in developed countries. Approximately 20 million
individuals in the United States aged 40 and older are affected with AMD, with a global prevalence of 170 million. Aging is the
greatest risk factor; therefore, the United States prevalence of AMD is anticipated to increase to 22 million by 2050, while the global
prevalence is expected to increase to 288 million by 2040. An estimated 10% to 15% of people with AMD will develop the wet form,
which refers to the advanced neovascular stage of the disease in which blood vessels leak blood and fluid into the macula and damage
photoreceptor cells. Wet AMD often progresses rapidly and causes substantial loss of central vision if left untreated. Current wet
AMD therapy has a ceiling of efficacy as increased dosage or more intense regimens yield limited or no additional visual benefit and
require adherence to a regimen of frequent injections. This treatment burden is further highlighted by recent large “real-world”
retrospective studies of wet AMD which underscore the difficulty in adhering to regimens. These real-world studies demonstrate that
patients are undertreated, receiving only 6 to 7 injections per year on average, resulting in mean improvement of only one to three
letters in visual acuity after one year of treatment. The current anti-VEGF market for the treatment of retinal diseases consists of
several drugs that generated aggregate 2020 sales of approximately $14.3 billion globally.
Axitinib is currently approved to treat renal cell cancer. Because it is a well-characterized small molecule instead of a novel
complex biologic, we believe there is potential for less immune response and inflammation compared to some new, contemporary
biologic agents. Also, compared to other TKIs, axitinib has shown better biocompatibility with ocular cells, including retinal pigment
epithelial cells, which may potentially translate to safety benefits. Other TKIs have shown biologic effect in wet AMD clinical trials
when delivered systemically, topically and intravitreally, including with device implants. However, each of these routes of
administration have been associated with off-target effects. Consequently, a limitation of TKIs may be associated with the delivery of
the drug and not a result of the mechanism of action. Importantly, we believe that administration of CLS-AX to the SCS using our
SCS Microinjector, may minimize the occurrence of related adverse events, such as vitreous floaters, "snow globe" effect or corneal
off-target effects seen with other TKI administration techniques.
With its broad VEGF blockade, we believe axitinib may have efficacy advantages over existing retinal therapies, which
predominantly focus on VEGF-A blockade and may upregulate other forms of VEGF. Axitinib achieves pan-VEGF blockade by
acting at a different level of the angiogenesis cascade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and
specificity. In preclinical studies, axitinib was observed to be greater than ten times more potent than other TKIs. In multiple
preclinical animal studies conducted by independent investigators, axitinib has inhibited corneal, retinal and choroidal angiogenesis.
In addition, in preclinical models, axitinib more effectively inhibited and regressed experimental corneal neovascularization than other
TKIs.
In our internal preclinical studies, CLS-AX delivered through suprachoroidal injection was well tolerated and showed durability
over several months. This could lead to a longer lasting, highly effective treatment that may reduce the number of treatments and visits
required for wet AMD patients to achieve optimal results. These studies have also demonstrated up to eleven times higher drug levels
in affected tissues versus intravitreal administration of the same dose of axitinib. Therefore, suprachoroidal delivery of CLS-AX has
the potential to compartmentalize therapy away from unaffected tissues for potential safety benefits and target the affected
chorioretinal tissue layers for potential efficacy benefits.
In August 2020, we announced that the FDA had accepted our Investigational New Drug application, or IND, for CLS-AX.
OASIS Phase 1/2a Clinical Trial
OASIS was our Phase 1/2a clinical trial of CLS-AX in participants with wet AMD. OASIS was an open-label, dose-escalation
clinical trial to assess the safety and tolerability of single doses of CLS-AX administered through suprachoroidal injection following
two or more prior treatments with aflibercept, an intravitreal anti-VEGF agent, dosed at screening. All participants were highly
treatment-experienced wet AMD participants with active disease at screening. The primary endpoint for the trial assessed the safety
and tolerability of CLS-AX for the three months following the administration of CLS-AX, and secondary endpoints evaluated the
pharmacokinetics, visual function, ocular anatomy and the need for additional treatment with intravitreal aflibercept during the three-
and six-month periods.

9
The trial consisted of four cohorts at the following doses of CLS-AX delivered via suprachoroidal injection: Cohort 1 at 0.03
mg; Cohort 2 at 0.1 mg; Cohort 3 at 0.5 mg; Cohort 4 at 1.0 mg. We enrolled a total of 27 participants across the four cohorts. These
four cohorts allowed us to collect more CLS-AX patient data to help guide our selection of the most appropriate dosing protocol for
ODYSSEY, our Phase 2b clinical trial of CLS-AX for the treatment of wet AMD. Participants in Cohorts 2, 3, and 4 who elected to
participate in an extension study were followed for an additional 3 months.
In November 2022, we reported positive results that included final three-month data from Cohorts 3 and 4, and interim data
from the extension study. CLS-AX demonstrated a positive safety profile in all four cohorts. There were no serious adverse events and
no treatment emergent adverse events related to aflibercept, CLS-AX, or the suprachoroidal injection procedure. There were also no
dose limiting toxicities. There were no adverse events related to inflammation, vasculitis or vascular occlusion, and there were no
vitreous “floaters” or dispersion of CLS-AX into the vitreous.
On February 2, 2023, we announced positive results from the completed OASIS extension study. CLS-AX was well-tolerated
and demonstrated a favorable safety profile across all cohorts in both the three-month dose-escalation portion (n=27) and the extension
study (n=14). No serious adverse events, treatment emergent adverse events related to study or dose limiting toxicities were observed.
In addition, there were no adverse events related to inflammation, vasculitis or vascular occlusion, no vitreous “floaters” or dispersion
of CLS-AX into the vitreous and no retinal detachments, endophthalmitis or adverse events related to IOP. The full extension data for
Cohorts 3 and 4 (n=12) showed promising durability, with a 77% - 85% reduction in treatment burden observed compared to the
average monthly injections in the six months before CLS-AX administration. In Cohorts 3 and 4 of the extension study, CLS-AX
showed signs of biologic effect with stable mean best corrected visual acuity, or BCVA, and stable mean central subfield thickness to
the six-month timepoint. On Optical Coherence Tomography, or OCT, images, anatomical signs of TKI biologic effect were observed
in anti-VEGF treatment experienced sub-responders.
ODYSSEY Phase 2b Clinical Trial
Based on the results from the OASIS trial, we conducted ODYSSEY, a randomized, active-controlled, double-masked, parallel-
group, multicenter, 36-week, Phase 2b clinical trial of CLS-AX in participants with wet AMD previously treated with intravitreal anti-
vascular, or VEGF, which is the standard of care therapy for the treatment of wet AMD. A total of 60 participants were treated for 36
weeks and randomized to either CLS-AX (1 mg) or aflibercept (2 mg) with a 2:1 randomization schedule (40 participants in CLS-AX
arm and 20 participants in aflibercept arm). CLS-AX was administered by suprachoroidal injection via our SCS Microinjector, and
aflibercept was administered via intravitreal injection. Participants in the trial were determined to have active disease with a median
duration of wet AMD diagnosis of 9.9 months. Eligible participants underwent diagnostic imaging at their screening visit, followed by
masked reading center confirmation of persistent active disease.
In October 2024, we announced positive topline results from the ODYSSEY trial. The ODYSSEY trial achieved its primary and
secondary outcomes including the mean change from baseline in BCVA, changes from baseline in visual function and ocular anatomy,
the need for supplemental treatment, treatment burden as measured by total injections over the trial duration, and safety measures.
Participants in the trial maintained stable BCVA throughout the trial as measured by the mean change in BCVA from baseline to
week 36. In addition, participants maintained stable central subfield retinal thickness, or CSRT, throughout the trial as measured by
the mean change in CSRT from baseline to week 36, as confirmed by the independent reading center.
In terms of durability, after receiving the baseline CLS-AX dose, 100% (40/40) of participants went 3 months without receiving
any additional treatment, 90% (35/39) of participants went 4 months without receiving any additional treatment, 81% (30/37) of
participants went five months without receiving any additional treatment and 67% (26/39) of participants went 6 months without
receiving any additional treatment before mandatory re-dosing at week 24. If intervention were strictly based on the disease activity
assessment criteria, 100% (40/40) of participants would have gone 3 months without receiving any additional treatment, 95% (37/39)
of CLS-AX participants would have gone 4 months without receiving any additional treatment, 87% (32/37) of participants would
have gone five months without receiving any additional treatment and 79% (30/38) of participants would have gone six months
without receiving any additional treatment before mandatory re-dosing at week 24.
Additionally, we observed reduced injection frequency by 84% in the 24 weeks after baseline compared to the average monthly
injections in the 24 weeks prior to screening.
CLS-AX was well-tolerated with a safety profile through 36 weeks that included mandatory re-dosing of CLS-AX at week 24.
There were no reported ocular serious adverse events, or SAEs, and no treatment or injection procedure-related SAEs. All ocular
adverse events were considered clinically mild in both groups. We observed similar discontinuation rates in the CLS-AX and
aflibercept arms.

10
CLS-AX Phase 3
Although our Phase 3 plans are in development and subject to change, we currently plan to run two pivotal, non-inferiority
Phase 3 trials with aflibercept 2 mg as a comparator. We are likely to conduct the studies in treatment-naïve patients with a flexible
dosing component, consistent with the Phase 3 trial designs for recently approved aflibercept high dose and faricimab. As part of the
planned protocol, at screening, participants will be required to have a BCVA reading between 20/80 to 20/32. In addition, the CST
reading on the OCT must be less than 500 microns.
We conducted an End-of-Phase 2 meeting with the FDA in the first quarter of 2025 and gained alignment on the essential
components of our Phase 3 program. We are preparing to be ready to initiate both clinical trials in the second half of 2025, subject to
our ability to pay for the trials. We are actively pursuing options to fund our Phase 3 CLS-AX program, including potentially
partnering with one or more third parties.
Preclinical
We have an experienced team of scientists and researchers evaluating small molecules that may be utilized as potential
treatment options for back of the eye diseases utilizing our SCS Microinjector for delivery in the suprachoroidal space. Our research
team is currently evaluating two small molecules through in vivo models for the potential treatment of geographic atrophy, or GA. We
believe that GA is primarily a choroidal disease and that delivery of small molecules via suprachoroidal injection enables
comprehensive drug coverage of both the retina and choroid, while also potentially minimizing systemic and anterior segment side
effects. We are also exploring CLS-AX for the treatment of diabetic retinopathy and the combination of CLS-AX and a steroid,
triamcinolone acetonide, or TA, for diabetic macular edema, or DME.
XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use
Our first product, XIPERE, formerly known as CLS-TA, is a proprietary, preservative-free suspension of the corticosteroid
triamcinolone acetonide for suprachoroidal use. Corticosteroids are the standard of care in uveitis. They are effective at treating the
inflammatory aspect of ocular disease, but when delivered locally, either topically as drops, intravitreally or by periocular injection,
they have been associated with significant side effects, such as cataract formation or exacerbation and elevated IOP, which can lead to
glaucoma.
XIPERE was approved for the treatment of macular edema associated with uveitis. Uveitis is a set of ocular inflammatory
conditions affecting approximately 350,000 patients in the United States and more than one million worldwide. Approximately one-
third of uveitis patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp,
straight-ahead vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis
affecting any anatomic location—anterior, intermediate, posterior or panuveitis.
XIPERE is commercially available in the United States through Bausch + Lomb, our commercialization partner, as described
below.
External Collaborations Pipeline
In order to expand the global reach of our suprachoroidal injection platform, we have strategically partnered the use of our SCS
Microinjector and some of our assets for development and/or commercialization and intend to continue partnering our assets. By
entering into these partnerships, we have been able to expand the use of our suprachoroidal injection platform to other indications and
geographies globally. We currently have collaborations with Bausch + Lomb, Arctic Vision, REGENXBIO, Inc., Aura Biosciences,
Inc. and BioCryst Pharmaceuticals, Inc. As discussed below in “—Royalty Purchase and Sale Agreement”, under certain conditions we
are obligated to pay HealthCare Royalty Management, LLC, or HCR, any such royalties or milestone payments until we have satisfied
our obligations under the Purchase and Sale Agreement.
License agreement for commercialization of XIPERE in United States and Canada
On October 22, 2019, we entered into a License Agreement with Bausch + Lomb or, as amended, the Bausch License
Agreement. Pursuant to the Bausch License Agreement, we granted an exclusive license to Bausch to develop, manufacture,
distribute, promote, market and commercialize XIPERE using our SCS Microinjector, as well as specified other steroids,
corticosteroids and NSAIDs in combination with the SCS Microinjector, or together with XIPERE, the Products, subject to specified
exceptions, in the United States and Canada, or the Territory, for the treatment of ophthalmology indications, including non-infectious
uveitis.

11
Pursuant to the Bausch License Agreement, Bausch paid us an upfront payment of $5.0 million in October 2019. In October
2021, the FDA approved XIPERE, and we received $5.0 million from Bausch as a result of the approval. In January 2022, we
received an additional payment of $10.0 million related to the completion of pre-launch activities for XIPERE. In addition, Bausch
agreed to pay up to an aggregate of $55.0 million in additional milestone payments upon the achievement of (i) specified regulatory
approvals for specified additional indications of XIPERE and (ii) specified levels of annual net sales (as defined in the Bausch License
Agreement). Further, during the applicable royalty term, we will also be entitled to receive tiered royalties at increasing percentages
from the high-teens to twenty percent, based on XIPERE achieving certain annual net sales thresholds in the Territory, as well as a
lower royalty on annual net sales of other products, in each case subject to reductions in specified circumstances. However, we will
not receive any royalties on the first $45.0 million of cumulative net sales of all products in the Territory. Bausch launched XIPERE in
the United States in the first quarter of 2022. Our rights to these royalties and milestone payments have been sold pursuant to the terms
and conditions of the Purchase and Sale Agreement described below in "—Royalty Purchase and Sale Agreement."
The Bausch License Agreement will expire upon expiration of the royalty terms for all Products and countries in the Territory,
with each royalty term for a given Product and country ending on the latest of (i) the date of expiration of the last-to-expire valid claim
of any licensed patent rights covering such Product in such country in the Territory, (ii) the date of the loss of regulatory exclusivity
for such Product in such country in the Territory, or (iii) ten years from the later of the first sale of such Product in such country in the
Territory. Bausch may also terminate the Bausch License Agreement for convenience upon 180 days’ written notice. In addition, we
can terminate the Bausch License Agreement if Bausch commences a legal action challenging the validity, enforceability or scope of
any of the licensed patents. Both parties may terminate the Bausch License Agreement (i) upon a material breach of the Bausch
License Agreement, subject to a specified cure period and specified exceptions, or (ii) if the other party encounters bankruptcy or
insolvency.
License agreement for commercialization of XIPERE in China, Hong Kong, Macau, Taiwan and South Korea, India,
ASEAN Countries, Australia and New Zealand
On March 10, 2020, we entered into a license agreement, or the Arctic Vision License Agreement, with Arctic Vision (Hong
Kong) Limited, or Arctic Vision. Pursuant to the Arctic Vision License Agreement, we granted an exclusive license to Arctic Vision
to develop, distribute, promote, market and commercialize XIPERE, subject to specified exceptions, in China, Hong Kong, Macau,
Taiwan and South Korea, or the Arctic Territory. Under the terms of the Arctic Vision License Agreement, neither party may
commercialize XIPERE in the other party’s territory. Arctic Vision has agreed to use commercially reasonably efforts to pursue
development and commercialization of XIPERE for indications associated with uveitis in the Arctic Territory. In addition, with our
consent, Arctic Vision will have the right, but not the obligation, to develop and commercialize XIPERE for additional indications in
the Arctic Territory.
Arctic Vision refers to XIPERE as ARVN001 or the brand name ARCATUS in its territory.
In March 2022, Arctic Vision announced dosing of the first patient in a Phase 1 clinical trial of ARVN001 in China for the
treatment of diabetic macular edema.
In September 2023, Arctic Vision completed enrollment in its Phase 3 randomized, double-blind, placebo-controlled clinical
trial in China for suprachoroidal use of ARCATUS for the treatment of uveitic macular edema. In July 2024, Arctic Vision announced
positive topline results from its Phase 3 uveitic macular edema clinical trial in China.
In November 2024, Arctic Vision announced that it signed a new commercial collaboration agreement with Santen
Pharmaceutical Co., Ltd. for ARVN001 for the treatment of uveitic macular edema and certain other ophthalmic indications under
development. Under the terms and conditions of the agreement, Arctic Vision has granted the rights of ARVN001 to Santen to
commercialize ARVN001 in China excluding Taiwan, Hong Kong and Macau.
In January 2025, Arctic Vision announced that its NDAs for ARCATUS for the treatment of uveitic macular edema were
approved by the Therapeutic Goods Administration of Australia and the Health Sciences Authority in Singapore.
In February 2025, Arctic Vision announced its NDA for ARCATUS for the treatment of uveitic macular edema was formally
accepted for review by the Center for Drug Evaluation of China National Medical Products Administration.
Pursuant to the Arctic Vision License Agreement, Arctic Vision paid us an upfront payment of $4.0 million in March 2020. In
December 2021, we received a milestone payment of $4.0 million following receipt of FDA approval of XIPERE in the United States.
In addition, Arctic Vision agreed to pay us up to a total of $22.5 million in development and sales milestone payments. Further,
during the applicable royalty term, we are also entitled to receive tiered royalties of 10% to 12% of net sales based on achieving
certain annual net sales thresholds in the Arctic Territory, subject to customary reductions, payable on a product-by-product and

12
country-by-country basis, commencing at launch in such country and lasting until the latest of (i) the date that all valid claims within
the licensed patent rights covering XIPERE have expired, (ii) the date of the loss of marketing or regulatory exclusivity of XIPERE in
a given country or (iii) ten years from the first commercial sale of XIPERE in a given country. Our rights to these royalties and
milestone payments have been sold pursuant to the terms and conditions of the Purchase and Sale Agreement described below in "—
Royalty Purchase and Sale Agreement."
The Arctic Vision License Agreement will expire upon the expiration of the last-to-expire royalty term. Arctic Vision may
terminate the Arctic Vision License Agreement for convenience upon 45 days’ notice if before regulatory approval in the Arctic
Territory or 90 days’ notice if after regulatory approval in the Arctic Territory. In addition, we can terminate the Arctic Vision
License Agreement if Arctic Vision commences a legal action challenging the validity, enforceability or scope of the licensed patents.
Both parties may terminate the Arctic Vision License Agreement (i) upon a material breach of the Arctic Vision License Agreement,
subject to a specified cure period, or (ii) if the other party enters bankruptcy. Upon termination, all licenses and other rights granted to
Arctic Vision pursuant to the Arctic Vision License Agreement would revert to us. If Arctic Vision exercises its termination right for
convenience or if the Arctic Vision License Agreement terminates as a result of Arctic Vision’s material breach or bankruptcy, Arctic
Vision will assign and transfer all regulatory approvals, related documents and trademarks (with respect to trademarks, only those
specific to) pertaining to XIPERE in the Arctic Territory to us. If Arctic Vision terminates the Arctic Vision License Agreement as a
result of material breach by us or our bankruptcy after regulatory approval of XIPERE in the Arctic Territory, we are obligated to pay
Arctic Vision royalties equal to a low-single digit percentage of net sales of XIPERE in the Arctic Territory.
In August 2021, we entered into an amendment to the Arctic Vision License Agreement to expand the territories covered by the
license to include India and the ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines,
Singapore, Thailand, and Vietnam). In September 2021, we entered into a second amendment to the Arctic Vision License Agreement
to expand the Arctic Territory to include Australia and New Zealand. We received an aggregate of $3.0 million in consideration for
the expansion of the Arctic Territory.
Gene Therapy
We believe our platform offers the potential for safer, targeted ocular gene therapy without some of the risks of surgery and
subretinal administration. Suprachoroidal administration of gene therapy could ultimately enhance access to care because it does not
require specialized gene therapy surgery treatment centers. The procedure for suprachoroidal injection is conducted in an office setting
and is similar in terms of patient preparation and duration to the procedure for intravitreal injection. Therefore, we believe our
products could be incorporated into retina specialists’ standard medical practice.
During the past several years, gene therapy has demonstrated in preclinical studies and clinical trials conducted by third parties
that genetic material can be effectively and tolerably introduced to the retinal tissues, most often using an adeno-associated virus, or
AAV. Safe and reproducible delivery of gene therapy vector into the subretinal space is essential for successful targeting of the retinal
pigment epithelium, or RPE, and photoreceptor rods or cones. Currently, the only approved retinal gene therapy and most
investigational retinal gene therapies are delivered via retinal surgery at a limited number of specialized ocular gene therapy treatment
centers. During the pars plana vitrectomy surgery, the surgeon creates a small hole in the retina to inject the gene therapy beneath the
retina to the subretinal space without tearing or damaging the retina and macula. This process creates a small retinal detachment,
which separates and exposes the photoreceptors and RPE to the gene therapy. The retina is in a diseased state and already
compromised and the procedure carries iatrogenic risk. However, the success of this surgery is critical for the clinical efficacy of
retinal gene therapy. Consequently, the surgery requires extensive training, and the limited number of specialized ocular gene therapy
centers creates patient access issues. Unlike vitrectomy, suprachoroidal administration does not require detachment of the
photoreceptors from the RPE, and consequently, avoids the risk of iatrogenic subretinal injection to an already-compromised retina.
Suprachoroidal injection procedure training is minimal and could ultimately enhance access to care because it would not have to be
administered at a specialized gene therapy surgery treatment center.
Inherited retinal diseases, or IRDs, such as Stargardt disease and Usher syndrome, represent some of the most challenging
diseases that ophthalmologists encounter. They cause progressive and relentless vision loss due to changes in genes critical to the
survival of photoreceptors and RPE cells, yet delivery of therapeutics to these cells is challenging. In preclinical animal studies from
which data was presented at the American Academy of Ophthalmology 2019 Annual Meeting in October 2019, the suprachoroidal
injection of luciferase DNA nanoparticles, or DNPs, in rabbits produced activity comparable to that seen from subretinal injections of
luciferase DNPs. In these studies, SCS injections of DNPs were generally well tolerated across both rabbits and non-human primates,
and no significant abnormalities were observed on ophthalmic exams. DNPs can also transfer large genes at potentially higher doses
without the risks of subretinal surgery, which may allow for gene therapy in some of the most common IRDs.
We believe suprachoroidal administration may further enhance the value proposition of ocular gene therapy by potentially
improving safety and expanding access. In preclinical studies we have observed that SCS injection can administer both viral and non-

13
viral gene therapy. Using marker genes like green fluorescent protein and luciferase in both rabbits and non-human primates, gene
therapy was delivered with our SCS injection to achieve expression in the retina and choroid. To expand our overall development
pipeline, we are looking to selectively partner our proprietary technology for use with novel gene therapies.
REGENXBIO, Inc.
We have expanded the reach of our SCS Microinjector technology in AAV-based gene therapy through a development and
commercial partner.
In August 2019, we entered into an option and license agreement, or the REGENXBIO Option and License Agreement, with
REGENXBIO Inc., or REGENXBIO, pursuant to which we granted REGENXBIO an exclusive option, or the Option, to enter into a
commercial license agreement granting REGENXBIO an exclusive, worldwide and sublicensable license to our SCS Microinjector for
the in-office delivery of AAV-based gene therapies for the treatment of wet AMD, diabetic retinopathy and other conditions for which
anti-VEGF treatment is currently the standard of care.
In October 2019, REGENXBIO exercised the Option and paid us an option fee equal to $2.0 million less $0.5 million received
under a prior technology access agreement. Under the license agreement, REGENXBIO paid us $3.0 million in connection with a
development milestone and agreed to additional payments to us of up to an aggregate of $31.0 million upon the achievement of
specified development milestones and up to $102.0 million in sales-based milestone payments, as well as mid-single digit royalties on
net sales of products using the SCS Microinjector during the royalty term. Our rights to these royalties and milestone payments have
been sold pursuant to the terms and conditions of the Purchase and Sale Agreement described below in "—Royalty Purchase and Sale
Agreement."
REGENXBIO will be responsible for all development, regulatory and commercialization activities for their gene therapy
product candidates. We will be responsible for supplying the SCS Microinjector in support of REGENXBIO’s preclinical studies,
clinical studies and commercial use.
In January 2025, REGENXBIO announced that a global Phase 3 clinical program in DR for their gene therapy ABBV-RGX-
314, now referred to as Sura-vec, is planned to start later in 2025. Their Phase 2 ALTITUDE® trial is enrolling a cohort of patients
with center-involved DME. Their Phase 2 AAVIATE® trial is enrolling a new cohort to evaluate sura-vec at dose level 4 with a short
course of prophylactic steroid eye drops.
Ocular Oncology
Ocular cancers are a group of rare, life-threatening conditions that affect one or both eyes. The main indications include
choroidal melanoma, choroidal metastases, cancers of the ocular surface and retinoblastoma, among others. Diagnosing and treating
these cancers early is important because they have the potential to spread both within the eye and to other organs. The risk for ocular
cancer increases with age and increases significantly after the age of 50. For cancers that occur inside the eye (e.g., choroidal
melanoma), the typical treatment is radiotherapy in the form of plaque brachytherapy and proton beam therapy, but these treatments
are highly invasive and result in major vision loss and other comorbidities for many patients.
Choroidal melanoma is the most common intraocular cancer in adults, with an incidence of approximately 11,000 patients per
year in the United States and Europe. This comprises approximately 90% of all cases of uveal melanoma, consisting of melanomas in
the choroid, ciliary body and iris, which are collectively referred to as the uvea. It is estimated that 96% of patients are diagnosed early
without clinical evidence of metastatic disease. There are approximately 2,000 new cases treated each year in the United States and
1,600 new cases treated each year in Europe. However, despite the current treatments with radiotherapy, the long-term prognosis is
poor with death occurring in more than 50% of cases. There are no FDA-approved therapies for choroidal melanoma. There is a need
for treatment of early-stage disease which includes small melanomas and indeterminate lesions representing approximately 9,000
patients in the United States and Europe.
Aura Biosciences, Inc.
On July 9, 2019, we entered into a worldwide licensing agreement with Aura Biosciences, Inc., or Aura, for the use of our SCS
Microinjector to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers,
including choroidal melanoma. Our SCS Microinjector may offer a non-surgical alternative to intravitreal delivery of Aura’s oncology
drug candidates, and we believe suprachoroidal administration may further enhance the value proposition of choroidal melanoma by
potentially improving safety and expanding access. Pursuant to the licensing agreement, we have received an aggregate of $1.6
million in connection with upfront license fees and development milestones. We are eligible to receive up to an additional $19.5
million in payments related to pre-specified development and regulatory milestones, as well as low to mid-single digit royalties on net

14
sales that utilize the SCS Microinjector. Our rights to these royalties and milestone payments have been sold pursuant to the terms and
conditions of the Purchase and Sale Agreement described below in "—Royalty Purchase and Sale Agreement."
Aura is utilizing our SCS Microinjector to deliver their viral like drug conjugate, bel-sar, for the treatment of choroidal
melanoma. In November 2023, Aura reported positive clinical safety and efficacy updates from its ongoing Phase 2 clinical trial with
suprachoroidal administration. The results, with 90% of patients at twelve months of follow-up who received three cycles of therapy
in Cohorts 5 and 6 and who match the criteria for the planned global Phase 3 trial, showed a tumor control rate of 80% and the visual
acuity preservation rate was 90%. Aura is currently enrolling its global Phase 3 clinical trial, entitled CoMpass.
BioCryst Pharmaceuticals, Inc.
On November 1, 2023, we entered into a license agreement, or the BioCryst License Agreement, with BioCryst
Pharmaceuticals, Inc., or BioCryst, pursuant to which we granted BioCryst an exclusive, worldwide and sublicensable license to our
SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor known as avoralstat for the treatment and
prevention of DME.
We received an upfront license fee payment of $5.0 million in connection with signing of the BioCryst License Agreement. In
addition, we are eligible to receive up to an additional $30.0 million in clinical and regulatory milestone payments, and up to a total of
$47.5 million in a series of post-approval sales-based milestone payments based on the achievement of annual global net product sales
milestones up to $2.0 billion. Further, during the royalty term, BioCryst has also agreed to pay us tiered mid-single digit royalties on
annual global net product sales, with the highest royalty rate applied to sales over $1.5 billion, subject to reductions in specified
circumstances. Our rights to these royalties and milestone payments have been sold pursuant to the terms and conditions of the
Purchase and Sale Agreement described below in "—Royalty Purchase and Sale Agreement."
BioCryst will be responsible for all development, regulatory and commercialization activities for avoralstat. We are responsible
for supplying SCS Microinjectors to meet BioCryst’s reasonable needs.
The BioCryst License Agreement, unless earlier terminated, will expire (a) on a country-by-country basis upon the expiration of
the royalty term in such country or (b) in its entirety upon the expiration of all payment obligations of BioCryst under the BioCryst
License Agreement in all countries pursuant to clause (a). Each party has the right terminate the BioCryst License Agreement (i) upon
a material breach of the BioCryst License Agreement by the other party, subject to a specified cure period and specified exceptions, or
(ii) if the other party encounters bankruptcy or insolvency. We may terminate the BioCryst License Agreement if BioCryst or any of
its sublicensees, or a Sublicensee commences a legal action challenging the validity, enforceability or scope of any of the licensed
patents, provided that with respect to any such action initiated by a Sublicensee, or Sublicensee Action, we may terminate the
BioCryst License Agreement if the Sublicensee Action is not terminated within a specified period of time following BioCryst’s receipt
of written notice from us or if BioCryst does not terminate the applicable sublicense, in each case within a specified period of time.
BioCryst may terminate the BioCryst License Agreement (i) immediately upon written notice to us if, after exercising commercially
reasonable efforts, BioCryst determines in good faith that it is not advisable to continue development or commercialization of
avoralstat as a result of a material safety issue and (ii) in its entirety or in part on a country-by-country basis, for any or no reason,
upon prior written notice to us, provided that in the event of such a termination, BioCryst shall not, for a period of two years from the
date of such a termination, initiate in the territory subject to the termination a Phase 3 clinical trial in which avoralstat is administered
to the suprachoroidal space using a device other than the SCS Microinjector.
In February 2025, BioCryst announced that it plans to advance avoralstat into a clinical trial of patients with DME by the end of
2025.
Royalty Purchase and Sale Agreement
On August 8, 2022, or the Closing Date, we, through our wholly-owned subsidiary Clearside Royalty LLC, a Delaware limited
liability company, or Royalty Sub, entered into a Purchase and Sale Agreement, or the Purchase and Sale Agreement, with entities
managed by HealthCare Royalty Management, LLC, or HCR, pursuant to which Royalty Sub sold to HCR certain of its rights to
receive royalty and milestone payments payable to Royalty Sub under the Arctic Vision License Agreement, the Bausch License
Agreement, that certain License Agreement, effective as of July 3, 2019, by and between us and Aura Biosciences, Inc., or the Aura
License Agreement, the REGENXBIO Option and License Agreement and any and all out-license agreements following the Closing
Date for, or related to XIPERE or the SCS Microinjector technology (to be used in connection with compounds or products of any
third parties delivered, in whole or in part, by means of the SCS Microinjector technology), excluding, for the avoidance of doubt, any
in-licensed or internally developed therapies following the Closing Date, or the Royalties, in exchange for up to $65 million. In
connection with this transaction, we assigned the Arctic Vision License Agreement, Bausch License Agreement, Aura License

15
Agreement, REGENXBIO Option and License Agreement, our license agreement with Emory University and The Georgia Tech
Research Corporation and related intellectual property rights to Royalty Sub.
Under the terms of the Purchase and Sale Agreement, Royalty Sub received an initial payment of $32.1 million, representing the
$32.5 million to which we were entitled, net of certain of HCR's transaction-related expenses which we agreed to reimburse. An
additional $12.5 million was deposited by HCR in an escrow account which, was released to HCR pursuant to the Letter Agreement
described below.
The Purchase and Sale Agreement will automatically expire, and the payment of Royalties from the Royalty Sub to HCR will
cease, when HCR has received payments of the Royalties equal to 3.4 times the aggregate amount of payments under the Purchase and
Sale Agreement, the Cap. In the event of a change in control, acquiror will have the option to make a payment to HCR of the Cap less
the aggregate amount of Royalty payments made by Royalty Sub to HCR under the Purchase and Sale Agreement as a one-time
payment at which time, payment of Royalties to HCR will cease. Alternatively, in the event of a change in control, the acquiror will
have the option to make an initial payment of 1.0 times the aggregate amount of payments made by HCR under the Purchase and Sale
Agreement as of the date of such change in control, then in that event, payment of Royalties from Royalty Sub to HCR will cease
when HCR has received total Royalties payments (including the initial payment) equal to the Cap. After the Purchase and Sale
Agreement expires, all rights to receive the Royalties return to Royalty Sub.
On December 22, 2023, we, through Royalty Sub, entered into a letter agreement, or the Letter Agreement, with HCR and HCR
Clearside SPV, LLC (as assignee of HCR Collateral Management, LLC), or Agent, amending the Purchase and Sale Agreement.
Pursuant to the terms of the Letter Agreement, Royalty Sub and Agent mutually agreed that Royalty Sub waived any and all rights to
the $12.5 million milestone payment which was deposited in an escrow account, or the First Milestone Payment, in connection with
the closing of the transactions contemplated by the Purchase and Sale Agreement and agreed to the release of the First Milestone
Payment to Agent.
Manufacturing
We do not own any manufacturing facilities. We utilize contract manufacturing organizations, or CMOs, to formulate and
produce our drug candidates and to produce our SCS Microinjector. We procure active pharmaceutical ingredients for our drugs from
third-party suppliers. We expect to continue to utilize third-party manufacturers to produce quantities of our drug candidates and the
SCS Microinjector.
On May 8, 2018, we entered into a supply agreement with Gerresheimer Regensburg GmbH to supply our SCS Microinjector.
Unless terminated earlier pursuant to its terms, the Gerresheimer agreement had an initial term of five years, after which it renews in
three-year increments unless either party gives notice of non-renewal at least one year in advance. Each party has the right to terminate
the agreement for customary reasons such as material breach and bankruptcy. The Gerresheimer agreement contains provisions
relating to compliance by Gerresheimer with current Good Manufacturing Practices, regulations promulgated by the FDA,
confidentiality and other customary matters for an agreement of this nature. We may enter into commercial supply agreements with
our other suppliers.
Commercialization
We have entered into exclusive license agreements for the commercialization and development of XIPERE with Bausch +
Lomb in the United States and Canada and with Arctic Vision in China, Hong Kong, Macau, Taiwan, South Korea, India, the ASEAN
Countries, Australia and New Zealand. We may enter into distribution or licensing arrangements for commercialization rights for
other regions. We have also entered into an exclusive license agreement for the use of our SCS Microinjector with BioCryst. If any of
our future product candidates, including CLS-AX, are approved by the applicable regulatory authorities, we may either commercialize
those product candidates ourselves or through license or collaboration agreements with third parties.
Competition
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a
strong emphasis on proprietary drugs. While we believe that our technologies, knowledge, experience and scientific resources provide
us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical
companies, specialty pharmaceutical and biotechnology companies, government agencies and public, and private research and
academic institutions. Any product candidate that we successfully develop and commercialize will compete with existing therapies
and new therapies that may become available in the future.

16
XIPERE faces competition from other commercially available forms of TA and other topical, injectable and implantable
corticosteroids, although none are specifically approved for the indication of macular edema associated with uveitis. Bristol-Myers
Squibb markets TA, under the brand name Kenalog, for which a number of generic equivalents are currently available. Kenalog is
indicated only for intramuscular or intraarticular injection; however, it is used off-label for intraocular inflammation using intravitreal
and periocular administration. In addition, Harrow's injectable TA, Triesence (acquired from Alcon), is approved in the United States
for the treatment of uveitis and other ocular inflammatory conditions unresponsive to topical corticosteroids, but it is not specifically
indicated for the treatment of macular edema associated with uveitis. Ozurdex, marketed by Allergan, is a bio-erodible, extended-
release implant that delivers dexamethasone, and is approved for the treatment of non-infectious uveitis affecting the posterior
segment of the eye and for macular edema due to retinal vein occlusion, or RVO, in both the United States and in the European Union.
Ozurdex is also approved in the United States for the treatment of diabetic macular edema, or DME. Retisert and Yutiq, both
intravitreal implants of fluocinolone acetonide, are marketed by Bausch and Alimera, respectively, and are approved in the United
States for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, Oxular is developing
OXU-001 which is dexamethasone delivered via the Oxulumis suprachoroidal device for the treatment of DME. It is possible
physicians may use OXU-001 off label to treat macular edema associated with uveitis if approved. Oxular was acquired by Regeneron
in December 2024.
CLS-AX faces competition with anti-VEGF drugs, the current standard of care for RVO and wet AMD, as well as other drug
candidates in development for ocular use for the treatment of wet AMD, such as other TKIs. Axitinib, also known by its brand name
Inlyta, is not currently approved for an ocular indication but is approved by the FDA and marketed by Pfizer for the treatment of
advanced renal cell carcinoma. Genentech has several products which serve as competitors in this space, including anti-VEGF agents
Lucentis, Avastin, and Susvimo. Lucentis is currently approved in the United States and European Union for the treatment of wet
AMD, macular edema following RVO, and diabetic retinopathy in patients with DME. Avastin is an anti-VEGF drug routinely used
off-label by uveitis and retina specialists in both the United States and in certain countries of the European Union for the treatment of
numerous retinal diseases. Susvimo, an ocular implant that releases ranibizumab over time, received approval from the FDA in
October 2021 for the treatment of wet AMD in patients who have previously responded to anti-VEGF therapy. Additionally,
Genentech’s product, Vabysmo (faricimab-svoa), an intravitreal injection which blocks two disease pathways, including (Ang-2) and
vascular endothelial growth factor-A (VEGF-A), received approval in January 2022 for the treatment of wet AMD and diabetic
macular edema.
In addition to Genentech’s products, Regeneron’s anti-VEGF product, Eylea 2 mg and 8 mg and Novartis’ product, Beovu, also
present potential competition for CLS-AX in both the United States and Europe. Eylea is approved for the treatment of wet AMD,
macular edema following RVO and diabetic retinopathy and DME in the United States and for the treatment of wet AMD, RVO and
DME in the European Union.
Additional future competition may emerge from biosimilar anti-VEGF products as they are approved and enter the market.
Ocular drug candidates being investigated for treatment of wet AMD may also represent potential competition for CLS-AX.
Ocular Therapeutics and Eyepoint are companies currently investigating TKIs for ocular use in late-stage clinical trials. We expect
other established companies will seek to develop new products in the ocular space with the goal of superior efficacy and duration over
the current standard of care.
REGENXBIO, Adverum, and 4D Molecular Therapeutics are currently conducting mid to late-stage clinical trials with various
ocular gene therapies for the treatment of wet AMD. These gene-based treatments could potentially compete with CLS-AX due to
their potential to be long-acting treatments.
The SCS Microinjector faces competition from other devices being developed to access ocular posterior tissues via the SCS.
Everads Therapy, Ltd and Uneedle B.V. have developed competing products and are in various stages of early-stage clinical
development.
Both large and established companies, as well as smaller or early-stage companies could represent challenges in the competitive
space. Larger established companies may have greater resources such as greater financial resources, deeper expertise and personnel in
nonclinical development, clinical development, manufacturing and regulatory sectors. Smaller or early-stage companies could pose a
challenge competitively through collaborative arrangements with large and established companies. Lastly, both small and large
companies will compete in areas such as recruiting and retaining qualified scientific and management personnel and establishing
clinical trial sites and patient recruitment for competing clinical trials.
Several key competitive factors affecting the potential success of our product candidates are likely to be the efficacy, safety,
method of administration, convenience, price and the availability of coverage and reimbursement from government and other third-
party payors. Additionally, our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize

17
drugs that are safer, more effective, more convenient or are less expensive than any drugs we develop. The timing of competitors’
regulatory approval and patent protection could also impact commercial opportunities. Competitors receiving approval prior to us
could result in stronger market positioning and/or obtaining FDA market exclusivity. Competitors’ patent protection could potentially
delay FDA approval of our product candidates for up to 30 months, as well as subject us to potential patent litigation that might arise
beyond the 30 months.
Intellectual Property
Our success depends in part on our ability to obtain and maintain patent and other intellectual property and proprietary
protection for our technologies and methods of accessing the SCS, drug candidates and formulations as well as patent and other
intellectual property and proprietary protection for novel applications, uses and technological innovations related to our drug
candidates, proprietary delivery devices and core technologies. We also rely on trade secrets, know-how and continuing technological
innovation to develop and maintain our proprietary position.
Patents and patent applications
Our patent estate, on a worldwide basis, includes 34 granted U.S. patents broadly directed to devices and methods of
administering drugs into the SCS by injection, including one design patent. In addition, our patent estate includes 21 patent
applications pending in the United States, 109 issued foreign patents, 1 pending international PCT application and 28 patent
applications pending in major international markets, including the European Union, Canada, India, Japan, China and Australia,
relating to our SCS delivery technology, as well as the formulations of our current therapeutic drug candidates and delivery device. Of
these patents and patent applications, we license 8 issued U.S. patents, 4 pending U.S. applications, and 23 of the issued foreign
patents in major international markets, each relating to devices or methods of delivering drugs to the eye by microneedle
administration, pursuant to a license agreement with Georgia Tech Research Corporation and Emory University that is described
below. With respect to in-licensed international PCT applications, according to the terms of the license agreement, we advise Georgia
Tech and Emory regarding the countries in which patent applications should be pursued. Subject to payment of required maintenance
fees, annuities and other charges, our issued in-licensed U.S. patents are expected to expire between 2027 and 2029, without taking
into account possible patent term adjustments or extensions. Applications relating to SCS delivery technology and methods, our
current therapeutic drug candidates and formulations, various therapeutic uses, including treatment of specific indications such as
macular edema associated with uveitis and RVO, wet AMD as well as DME and improvement of specified clinical parameters, are
expected to expire, if issued, between 2027 and 2042, without taking into account possible patent term adjustments or extensions.
The term of individual patents depends on the legal term for patents in the countries in which they are granted. In most
countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional
patent application in the applicable country. In the United States, a patent’s term may, in certain cases, be extended by patent term
adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and
granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a
common inventor and having an earlier expiration date. The Drug Price Competition and Patent Term Restoration Act of 1984, or the
Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial
compensation for the length of time the drug is under regulatory review.
Our product candidates are protected against genericization through numerous patents. In the case of XIPERE injected into the
SCS, an applicant who files a paragraph 4 Abbreviated New Drug Application, or ANDA, or 505(b)(2) NDA certifying they may
circumvent our patents must also demonstrate comparability of the proposed drug, which we believe may require a clinical trial in
macular edema associated with uveitis, against our product, unless a biowaiver is obtained.
Third-party patent filings
Numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are
developing products, including patents and applications related to surgical methods of accessing the SCS and certain formulations of
TA. Because patent applications can take many years to issue, there may be applications unknown to us, which may later result in
issued patents that our product candidates or proprietary technologies may infringe.
Under U.S. law, a person may be able to patent a discovery of a new way to use a previously known compound, even if such
compound itself is patented, provided the newly discovered use is novel and nonobvious. Such a method-of-use patent, however, if
valid, only protects the use of a claimed compound for the specified methods claimed in the patent. This type of patent does not
prevent persons from using the compound for any previously known use of the compound. Further, this type of patent does not
prevent persons from making and marketing the compound for an indication that is outside the scope of the patented method.

18
License agreement with Emory and Georgia Tech
We have entered into a license agreement, or the Georgia Tech License Agreement, with Emory University, or Emory, and the
Georgia Tech Research Corporation, or GTRC and together with Emory, the Licensor, under which we received a worldwide
exclusive license to specified patents relating to methods and devices for drug delivery using a microinjector. The field of the license
covers all ophthalmic uses of the microinjector for mammals and birds. Under this license agreement, we have agreed to direct all
prosecution of intellectual property to the licensors’ patent counsel and have agreed to pay for all intellectual property expenses
associated with the licensed patents.
To date, we have paid an aggregate of $265,000 in upfront and milestone payments pursuant to the Georgia Tech License
Agreement. Additionally, we are currently paying a low single-digit royalty on any worldwide net product sales related to the licensed
patents, with minimum annual royalties starting at $15,000 per year after commercialization. The minimum annual royalty increases
each year after the first commercial sale, up to a maximum amount of $100,000 per year in the sixth calendar year and in subsequent
years.
On January 31, 2024, or the Amendment Execution Date, we and the Licensor entered into an amendment, or the Amendment,
to the Georgia Tech License Agreement.
Pursuant to the Amendment, the parties agreed to reduce the Sublicense Percentage (as defined in the Georgia Tech License
Agreement) from a low double digit percentage to a high single digit percentage that we will pay the Licensor applicable to any fees
or payments paid to us by any Sublicensee (as defined in the Georgia Tech License Agreement) of the Licensed Patents and/or
Licensed Technology (each as defined in the Georgia Tech License Agreement), on or after July 1, 2023, excluding (i) amounts paid
to us by a Sublicensee to reimburse us for certain research and development costs pursuant to a written agreement between us and
such Sublicensee, (ii) the value of intellectual property transferred or granted to us if necessary or helpful to the development or
commercialization of Licensed Products (as defined in the License Agreement) and (iii) amounts paid for shares of our stock. The
payment to Licensor of any such Sublicense Percentage is due within 30 days of receipt by us of a qualifying payment from a
Sublicensee, provided however, with respect to any qualifying payments received by us from a Sublicensee after July 1, 2023 but prior
to January 1, 2025, the payment to Licensor of any such Sublicensee Percentage is due to Licensor by March 31, 2025.
In addition, the parties agreed to a revised annual license maintenance fee due each year, or the Maintenance Fee, starting in
2023 through 2028, as follows: $250,000 for 2023 through 2025, $350,000 for 2026, $400,000 for 2027 and $500,000 for 2028. We
paid the Maintenance Fee for 2023 in February 2024 and the Maintenance Fee for 2024 in October 2024. The remaining annual
Maintenance Fee payments are due on October 1st of each year.
The remaining terms of the Georgia Tech License Agreement, including the low single digit royalty rate paid to the Licensor by
us on sales of Licensed Products, were unchanged by the Amendment.
We are solely responsible for the development and commercialization of products related to the licensed patients. We are
obligated to provide Emory and GTRC a written report detailing our activities related to the development and commercialization of
products twice a year.
Royalties are calculated based on net sales of products covered by a patent licensed under the agreement and are due on each
such product sold as long as the patent covering that particular product is valid and unexpired. Unless otherwise terminated pursuant
to its termination provisions, the Georgia Tech License Agreement will expire upon the expiration of the last to expire of the licensed
patents. We have the right to terminate the Georgia Tech License Agreement at any time upon 60 days’ written notice to Emory and
GTRC. Emory and GTRC may also terminate the Georgia Tech License Agreement in the event of a material breach by us. The
Georgia Tech License Agreement will immediately terminate if we challenge the validity or enforceability of any of the licensed
patents in a court or other governmental agency of competent jurisdiction.
Trademarks, trade secrets and know-how
Our trademark portfolio currently consists of two registered trademarks in Australia and Korea, one registered trademark in
Russia, two registered trademarks in Singapore, six registered trademarks in Brazil, six registered and one pending application in
Canada, six registered trademarks, and two pending trademarks in China, six registered trademarks in the European Union, two
registered trademarks in each of India and New Zealand, one registered trademarks in Japan, three registered and one pending
applications in Israel, nine registered trademarks, five registered and two pending applications in South Africa, six registered
trademarks and four pending applications in the United States and six registered trademarks in the United Kingdom. We also have
three international registrations: the first with registered protection in the European Union, India, Japan, New Zealand, Korea and
Singapore; the second with registered protection in Australia, China, European Union, India, Israel, Japan, Korea, New Zealand,

19
Russia, and Singapore; and the third with registered protection in Australia, Brazil, Japan and pending extension in Canada, and
Mexico.
Government Regulation
In the United States, the FDA regulates drug and device products under the Food, Drug and Cosmetic Act, or FDCA, and its
implementing regulations. This includes combination products where a drug and a device are used together.
In the case of our product candidates, the primary mode of action is attributable to the drug component of the product, which
means that the FDA’s Center for Drug Evaluation and Research, has primary jurisdiction over the premarket development, review and
approval of our product candidates.
Drugs
The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and
marketing, among other things, of our product candidates are governed by extensive regulation by governmental authorities in the
United States and other countries. The FDA, under the FDCA, regulates pharmaceutical products in the United States. The steps
required before a drug may be approved for marketing in the United States generally include:
•
preclinical laboratory tests and animal tests conducted under good laboratory practice;
•
the submission to the FDA of an IND application for human clinical testing, which must become effective before human
clinical trials commence;
•
adequate and well-controlled human clinical trials to establish the safety and efficacy of the product and conducted in
accordance with Good Clinical Practices, or GCP;
•
the submission to the FDA of an NDA;
•
FDA acceptance, review and approval of the NDA, which might include an Advisory Committee review; and
•
satisfactory completion of an FDA inspection of the manufacturing facilities at which the product is made to assess
compliance with current Good Manufacturing Practices, or cGMPs.
The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any
approval is uncertain. The FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or
patients are being exposed to an unacceptable health risk.
Preclinical studies include laboratory evaluations of the product candidate, as well as animal studies to assess the potential
safety and efficacy of the product candidate. The results of the preclinical studies, together with manufacturing information and
analytical data, are submitted to the FDA as part of the IND, which must become effective before clinical trials may be commenced.
The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the
conduct of the trials as outlined in the IND prior to that time. In this case, the IND sponsor and the FDA must resolve any outstanding
concerns before clinical trials can proceed. The FDA or an independent institutional review board, or IRB, may nevertheless initiate a
clinical hold after the 30 days if, for example, significant health risks arise.
In the United States, each clinical trial must be reviewed and approved by an IRB at each of the sites at which the trial will be
conducted. The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the
institution.
Clinical trials are typically conducted in three sequential phases prior to approval, but the phases may overlap. These phases
generally include the following:
Phase 1. Phase 1 clinical trials represent the initial introduction of a product candidate into human subjects, frequently healthy
volunteers. In Phase 1, the product candidate is usually tested for safety, including adverse effects, dosage tolerance, absorption,
distribution, metabolism, excretion and pharmacodynamics.
Phase 2. Phase 2 clinical trials usually involve studies in a limited patient population to (1) evaluate the efficacy of the product
candidate for specific indications, (2) determine dosage tolerance and optimal dosage and (3) identify possible adverse effects and
safety risks.

20
Phase 3. If a product candidate is found to be potentially effective and to have an acceptable safety profile in Phase 2 clinical
trials, the clinical trial program will be expanded to Phase 3 clinical trials to further demonstrate clinical efficacy, optimal dosage and
safety within an expanded patient population at geographically dispersed clinical trial sites.
Phase 4 clinical trials may be conducted after approval to gain additional experience from the treatment of patients in the
intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval
regulations, or when otherwise requested by the FDA in the form of post-market requirements or commitments. Failure to promptly
conduct any required Phase 4 clinical trials could result in enforcement action or withdrawal of approval.
The results of preclinical studies and clinical trials, together with detailed information on the manufacture, composition and
quality of the product, are submitted to the FDA in the form of an NDA, requesting approval to market the product. The application
must be accompanied by a significant user fee payment, although waivers may be granted and exemptions apply in limited cases. The
FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient
for approval and require additional preclinical, clinical or other studies.
Review of application
Once an NDA has been accepted for filing, which occurs, if at all, 60 days after submission, the FDA sets a user fee goal date
that informs the applicant of the specific date by which the FDA intends to complete its review. This is typically 10 months from the
date of submission for drugs that are not new molecular entities, such as our product candidates. The review process can be expedited
if priority review is granted. In such a case, the FDA review period is only 6 months. Alternatively, the FDA review process can be
extended by FDA requests for additional information or clarification. The FDA reviews NDAs to determine, among other things,
whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance
with cGMPs to assure and preserve the product’s identity, strength, quality and purity. Before approving an NDA, the FDA may
inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facility complies
with cGMPs and may also inspect clinical trial sites for integrity of the data supporting safety and efficacy. The device component of
our products will also be subject to review as part of the NDA review process and its manufacturers subject to inspection for
compliance with device cGMPs embodied in the Quality System Regulation, or QSR. During the approval process, the FDA also will
determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product. If the FDA
concludes a REMS is needed, the sponsor of the application must submit a proposed REMS, and the FDA will not approve the
application without an approved REMS, if required. A REMS can substantially increase the costs of obtaining approval. The FDA
could also require a special warning, known as a boxed warning, to be included in the product label in order to highlight a particular
safety risk. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to
risk, benefit and interpretation of clinical trial data. The FDA may delay approval of an NDA if applicable regulatory criteria are not
satisfied and/or the FDA requires additional testing or information. The FDA may require post-marketing testing and surveillance to
monitor safety or efficacy of a product. The FDA will issue either an approval of the NDA or a complete response letter, or CRL,
detailing the deficiencies and information required for reconsideration of the application.
Post-approval requirements
Approved drugs that are manufactured or distributed in the United States are subject to pervasive and continuing regulation by
the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product distribution, advertising
and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as
adding new indications or other labeling claims and some manufacturing and supplier changes are subject to prior FDA review and
approval. There also are continuing, annual program user fee requirements for approved products, as well as new application fees for
certain supplemental applications.
The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA
may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product’s
safety and effectiveness after commercialization. The FDA may also require a REMS, which could involve requirements for, among
other things, a medication guide, special training for prescribers and dispensers, and patient registries.
In addition, entities involved in the manufacture and distribution of approved devices or drugs are required to register their
establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state
agencies for compliance with cGMP requirements. The FDA has promulgated specific requirements for drug cGMPs, device cGMPs
embodied in the QSR and combination product cGMPs that, for drug/device combination products, specify the requirements within
the drug cGMPs and the QSR with which manufacturers must comply. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any
deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party

21
manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the
area of production and quality control to maintain cGMP compliance.
Once an approval is granted, the FDA may issue enforcement letters or withdraw the approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay
product distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a
product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market
studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other
potential consequences include, among other things:
•
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls;
•
fines, warning letters or holds on post-approval clinical trials;
•
refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of
product approvals;
•
product seizure or detention, or refusal to permit the import or export of products; or
•
injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may
be promoted only for the approved indications and in accordance with the provisions of the approved label. Physicians, on the other
hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician’s choice
of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from
companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However,
companies may share truthful and not misleading information that is otherwise consistent with the product’s FDA approved labeling.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, including without
limitation the FDCA, the federal civil False Claims Act, other federal and state health care fraud and abuse laws and state consumer
protection laws. A company that is found to have improperly promoted off-label uses may be subject to significant liability, including
investigation by federal and state authorities.
The Hatch-Waxman amendments
One of our regulatory strategies is to pursue development of our drugs as Section 505(b)(2) NDAs under the FDCA. As an
alternative path to FDA approval for modifications to formulations or uses of drugs previously approved by the FDA, an applicant
may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman
Amendments. A Section 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but
where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which
the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type
of application permits reliance for such approvals on literature or on an FDA finding of safety, effectiveness or both for an approved
drug product. As such, under Section 505(b)(2), the FDA may rely, for approval of an NDA, on data not developed by the applicant.
Therefore, if we can satisfy the conditions required for a Section 505(b)(2) NDA submission, it may eliminate the need for us to
conduct some of the preclinical studies or clinical trials for the new product candidate that might otherwise have been required,
although the review time is not shortened. As a condition for approval, the FDA may also require us to perform additional studies or
measurements, including clinical trials, to support the change from the approved branded reference drug.
Orange Book listing
In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain
patents whose claims cover the applicant’s product. Upon approval of an NDA, each of the patents listed in the application for the
drug is then published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book.
Any applicant who files an Abbreviated New Drug Application, or ANDA, seeking approval of a generic equivalent version of a drug
listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify, for each patent listed in the
Orange Book for the referenced drug, to the FDA that (1) no patent information on the drug product that is the subject of the
application has been submitted to the FDA, (2) such patent has expired, (3) the date on which such patent expires or (4) such patent is
invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. The
fourth certification described above is known as a paragraph IV certification. A notice of the paragraph IV certification must be
provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA

22
or 505(b)(2) application refers. The applicant may also elect to submit a “section viii” statement certifying that its proposed label does
not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. This
section viii statement does not require notice to the patent holder or NDA owner. There might also be no relevant patent certification.
If the reference NDA holder and patent owners file patent litigation directed to one of the Orange Book listed patents within 45
days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30
months from the receipt of the paragraph IV certification, expiration of the patent, settlement of the lawsuit or a decision in the case
that is favorable to the applicant. Even if the 45 days expire, a patent infringement lawsuit can be brought and could delay market
entry, but it would not extend the FDA-related 30-month stay of approval.
The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange
Book for the branded reference drug has expired as described in further detail below.
Non-patent exclusivity
In addition to patent exclusivity, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity,
during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the listed drug.
A drug, including one approved under a 505(b)(2) application, may obtain a three-year period of non-patent market exclusivity
for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product,
if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the
application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any
ANDA or 505(b)(2) application until after that three-year exclusivity period has run. However, the FDA can accept an application and
begin the review process during the three-year exclusivity period. A 505(b)(2) NDA may also be subject to a five-year exclusivity
period for a new chemical entity, whereby the FDA will not accept for filing, with limited exception, a product seeking to rely upon
the FDA’s findings of safety or effectiveness for such new chemical entity.
Orphan drugs
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition
affecting fewer than 200,000 individuals in the United States, or in other limited cases. Orphan drug designation does not convey any
advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan drugs are
eligible for certain incentives, including tax credits for qualified clinical testing. In addition, an NDA for a product that has received
orphan drug designation is not subject to a prescription drug user fee unless the application includes an indication other than the rare
disease or condition for which the drug was designated.
If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which
it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other
applications to market the same active moiety for the same indication for seven years, except in limited circumstances, such as another
drug’s showing of clinical superiority over the drug with orphan exclusivity. Competitors, however, may receive approval of different
active moieties for the same indication or obtain approval for the same active moiety for a different indication. In addition, doctors
may prescribe products for off-label uses and undermine our exclusivity. Orphan drug exclusivity could block the approval of one of
our products for seven years if a competitor obtains approval for the same active moiety for the same indication before we do, unless
we are able to demonstrate that our product is clinically superior.
We may seek orphan drug designation for products in the future. We cannot guarantee that we will obtain orphan drug
designation for any products in any jurisdiction. Even if we are able to obtain orphan drug designation for a product, we cannot be
sure that such product will be approved, that we will be able to obtain orphan drug exclusivity upon approval, if ever, or that we will
be able to maintain any exclusivity that is granted.
Foreign regulation
In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory
requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical
trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a
product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence
clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with
respect to the United States apply similarly in the context of the European Union and other geographies, the approval process varies
between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time

23
required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA
approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in
obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.
Federal and state fraud and abuse, data privacy and security and transparency laws
In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws restrict our
business practices. These laws include, without limitation, anti-kickback and false claims laws, data privacy and security laws, as well
as transparency laws regarding payments or other items of value provided to healthcare providers.
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or
receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce or in return
for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service
reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term “remuneration” has been
broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve
remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if
they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory
exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the
legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances.
Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving
remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated.
Therefore, even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not
need to defend ourselves against enforcement or litigation due to the fact that there is significant enforcement interest in life sciences
companies in the United States and some of the applicable laws are broad in scope.
Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, to a stricter
standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to
have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False
Claims Act.
The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to
be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to
be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes “any
request or demand” for money or property presented to the U.S. government. The federal civil False Claims Act also applies to false
submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not
required to establish liability under the federal civil False Claims Act. Pharmaceutical, device and other healthcare companies have
been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the
customers would bill federal programs for the product. Companies have been prosecuted for causing false claims to be submitted
because of the companies’ marketing of products for unapproved, and thus non-covered, uses.
The government may further prosecute conduct constituting a false claim under the federal criminal False Claims Act. The
federal criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false,
fictitious, or fraudulent and, unlike the federal civil False Claims Act, requires proof of intent to submit a false claim.
The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal and
civil statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any
healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare
benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the
delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, the Affordable Care Act
amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to
have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or
service that was not provided as claimed or is false or fraudulent.

24
Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of
payor, in addition to items and services reimbursed under Medicaid and other state programs.
Under HIPAA, the U.S. Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and
security of protected health information used or disclosed by covered entities including certain health care providers, health plans, and
healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in health care transactions
and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act of 2009, or HITECH and their regulations, including the omnibus final rule published on January
25, 2013, also imposes certain obligations on the business associates of covered entities that obtain protected health information in
providing services to or on behalf of covered entities and their subcontractors that use, disclose, access, or otherwise process protected
health information. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security
of health information that are applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA
violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA
and seek attorney’s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general (along with
private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA’s privacy
and security rules. New laws and regulations governing privacy and security may be adopted in the future as well.
Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security.
For example, the European Union’s General Data Protection Regulation, or EU GDPR, and the United Kingdom’s GDPR, or UK
GDPR, impose strict requirements for processing personal data. Under the EU GDPR, companies may face temporary or definitive
bans on data processing and other corrective actions; fines of up to 20 million Euros or 4% of annual global revenue, whichever is
greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection
organizations authorized at law to represent their interests. In Canada, the Personal Information Protection and Electronic Documents
Act and various related provincial laws, as well as Canada’s Anti-Spam Legislation, may, in the future, apply to our operations.
In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or
other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal
data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted
the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Although there are
currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance
with law, such as the EEA and UK’s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no
assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful
manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a
legally-compliant transfer are too onerous, we could face significant adverse consequences, including increased exposure to regulatory
actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and
injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that
transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny
from regulators, individual litigants, and activist groups.
Additionally, California has enacted legislation that has been dubbed the first “GDPR-like” law in the United States. Known as
the California Consumer Privacy Act, or CCPA, it applies to personal information of consumers, business representatives, and
employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to
exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants
affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the
context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain
about California residents. In addition, the California Privacy Rights Act of 2020, or CPRA, expands the CCPA’s requirements,
including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to
implement and enforce the law. Other states, such as Virginia, Colorado, Utah, and Connecticut have also passed comprehensive
privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these states,
like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance
efforts, and increase legal risk and compliance costs for us, the third parties upon whom we rely.
With the GDPR, CCPA, CPRA, and other state and Federal laws, regulations and other obligations relating to privacy and data
protection imposing new and relatively burdensome obligations, and with substantial uncertainty over the interpretation and
application of these and other obligations, we may face challenges in addressing their requirements and making necessary changes to
our policies and practices, and may incur significant costs and expenses in an effort to do so. Additionally, if third parties we work
with, such as vendors or service providers, violate applicable laws or regulations or our policies, such violations may also put our or
our customers’ data at risk and could in turn have an adverse effect on our business.

25
Additionally, a trend has continued of increased federal and state regulation of payments and transfers of value provided to
healthcare professionals and/or entities. On February 8, 2013, the Centers for Medicare & Medicaid Services, or CMS, released its
final rule implementing the Physician Payments Sunshine Act that imposes annual reporting requirements on certain manufacturers of
drugs, devices, biologicals and medical supplies for payments and other transfers of value provided by them, directly or indirectly, to
physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as
physicians assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians
and their family members. Certain states also mandate implementation of commercial compliance programs, impose restrictions on
pharmaceutical manufacturer and device manufacturer marketing practices, require registration of pharmaceutical sales
representatives, require drug manufacturers to report information on the pricing of certain drugs, or require tracking and reporting of
gifts, compensation and other remuneration to particular types of healthcare professionals and entities.
Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under
such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing
practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such
laws. The heightening compliance environment and the need to build and maintain robust and expandable systems to comply with
different compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company
may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the health care
laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties,
including potentially significant criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment,
exclusion from participation in government healthcare programs, contractual damages, reputational harm, diminished profits and
future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar
agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of
which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our product
candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws, which may include, for instance,
applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate
compliance programs and reporting of payments or transfers of value to healthcare professionals.
Coverage and reimbursement
The physicians who use XIPERE and our other product candidates, if approved, may be reimbursed by third-party payors for
both the suprachoroidal injection using our SCS Microinjector and for the drug itself. On July 1, 2016, the American Medical
Association, or AMA, approved a new Category III Current Procedural Terminology, or CPT, code for the suprachoroidal injection of
pharmacologic agents. Category III codes are a set of temporary codes maintained by the AMA for emerging technology, services and
procedures. Payment for these services or procedures are based on the coverage policies of individual third-party payors, including
private insurers and government-funded programs, like Medicare, and Medicare administrative contractors. In November 2023, AMA
assigned XIPERE the Category 1 CPT code 67516. We believe the Category 1 code may facilitate better access and adoption of
XIPERE and the suprachoroidal injection method.
Our strategy will include efforts to engage third-party payors to establish coverage, coding and reimbursement that will facilitate
access to XIPERE and our product candidates and the SCS injection procedure as we expand our commercialization efforts in the
United States. Our success in these efforts depends in part on the extent to which third-party payors provide coverage and establish
adequate reimbursement levels for the procedures during which XIPERE and our product candidates are administered and for the
drugs themselves. Failure by physicians, hospitals, ambulatory surgery centers and other users of our products to obtain sufficient
coverage and adequate reimbursement from third-party payors for the procedures to administer XIPERE and our product candidates or
for XIPERE and the product candidates themselves, or adverse changes in third-party payors’ policies would have a material adverse
effect on our business, financial condition, results of operations and future growth prospects.
In the U.S., third-party payors continue to implement initiatives that restrict the use of certain technologies to those that meet
certain clinical evidentiary requirements. Coverage policies and third-party payor reimbursement rates may change. Thus, even if
favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be
implemented in the future. Failure to obtain favorable coverage policies could have a material adverse effect on our business and
operations.
In addition to uncertainties surrounding coverage policies, third-party payors from time to time update reimbursement amounts
and also revise the methodologies used to determine reimbursement amounts. This includes annual updates to payments to ambulatory
surgery centers, hospitals and physicians for the procedures performed administering our products, which could directly impact the
demand for XIPERE and any of our product candidates that may be approved. An example of payment updates is the Medicare
program updates to physician payments, which is done on an annual basis using a prescribed statutory formula. In the past, when the
application of the formula resulted in lower payment, Congress has passed interim legislation to prevent the reductions. However, the

26
Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, ended the use of the statutory formula and established a quality
payment program, also referred to as the Quality Payment Program. The quality payment program has two tracks, one known as the
merit-based incentive payment system for providers in the fee-for service Medicare program, and the advanced alternative payment
model for providers in specific care models, such as accountable care organizations. Under both Advanced Alternative Payment
Models, or APMs, and Merit-based Incentive Payment System, or MIPS, performance data collected each performance year will
affect Medicare payments in later years, including potentially reducing payments. In addition, beginning on January 1, 2023, certain
manufacturers were required to pay quarterly refunds to CMS for discarded amounts of single-dose container and single-use package
drugs covered under Medicare Part B. Refunds will be based on the discarded volume above 10% of the total allowed amount, except
in unique circumstances as determined by CMS. Any changes in coverage and reimbursement that further restricts coverage of our
products or lowers reimbursement for procedures using our products could materially affect our business.
Healthcare reform
Current and future legislative proposals to further reform healthcare or reduce healthcare costs may result in lower
reimbursement for our products, or for the procedures associated with the use of our products, or limit coverage of our products. The
cost containment measures that third-party payors and providers are instituting and the effect of any healthcare reform initiative
implemented in the future could significantly reduce our revenues from the sale of our products.
For example, implementation of the Affordable Care Act has the potential to substantially change healthcare financing and
delivery by both governmental and private insurers, and significantly impact the pharmaceutical and medical device industries.
There have been judicial and Congressional challenges and amendments to certain aspects of the Affordable Care Act. For
example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which, among other things, extends
enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025.
The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the
beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear any additional healthcare
reform measures of the second Trump administration will impact the Affordable Care Act and our business.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August 2,
2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select
Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not
achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation’s automatic
reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which
went into effect on April 1, 2013 and, due to subsequent amendments, will remain in effect until 2032.
Further, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for
their marketed products, which have resulted in several Congressional inquiries and proposed and enacted federal and state legislation
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement
methodologies for drug products. For example. the IRA, among other things, (i) directs HHS to negotiate the price of certain high-
expenditure, single-source drugs that have been on the market for at least seven years covered under Medicare, and subject drug
manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated
“maximum fair price” for such drugs and biologics under the law (the “Medicare Drug Price Negotiation Program”), and (ii) imposes
rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that
outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the
initial years. These provisions began to take effect progressively in fiscal year 2023. On August 15, 2024, HHS announced the agreed-
upon price of the first ten drugs that were subject to price negotiation, although the Medicare Drug Price Negotiation Program is
currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional drugs covered under Part D for price
negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation
Program. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights
under the Bayh-Dole Act was announced. On December 8, 2023, the National Institute of Standards and Technology published for
comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes
the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not
previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further,
there may be additional health reform measures, particularly in light of recent U.S. Presidential and Congressional elections.

27
The Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of
influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The
FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the
company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international
subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that
violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment,
disgorgement, oversight, and debarment from government contracts.
Employees and Human Capital Resources
We strive to recruit people who share our vision to develop technology that provides a ground-breaking impact to medicine and
superior care to patients. We are proud of what we do and believe we create an excellent working environment that is empowering
with meaningful compensation, benefits and wellness programs that continue to facilitate the attraction, retention and motivation of
talented employees.
As of December 31, 2024, we had 32 employees, all of whom were full-time and were located in the United States. None of our
employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our
employees to be good.
Corporate Information
We were incorporated under the laws of the State of Delaware in May 2011. Our principal executive offices are located at 900
North Point Parkway, Suite 200, Alpharetta, Georgia 30005. Our telephone number is (678) 270-3631.
Available Information
Our internet website address is www.clearsidebio.com. In addition to the information about us and our subsidiaries contained in
this Annual Report, information about us can be found on our website. Our website and information included in or linked to our
website are not part of this Annual Report.
Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those
reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of
charge through our website as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and
Exchange Commission, or SEC. Additionally the SEC maintains an internet site that contains reports, proxy and information
statements and other information. The address of the SEC's website is www.sec.gov.

28
ITEM 1A. RISK FACTORS
You should carefully consider the risks described below, as well as general economic and business risks and the other
information in this Annual Report on Form 10-K. The occurrence of any of the events or circumstances described below or other
adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the
trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we currently deem
immaterial may also harm our business.
Risks Related to Our Financial Position and Capital Needs
We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never
achieve or maintain profitability.
We incurred a net loss of $34.4 million and $32.5 million, respectively, in 2024 and 2023. We expect to incur significant
expenses and operating losses over the next several years. Our financial results may fluctuate significantly from quarter to quarter and
year to year.
We have devoted substantially all of our financial resources and efforts to research and development, including preclinical
studies and clinical trials. We anticipate that our expenses will increase substantially as we:
•
conduct and complete our ongoing and planned clinical trials;
•
seek to discover, research and develop additional product candidates;
•
seek regulatory approvals for any product candidates that successfully complete clinical trials;
•
establish additional partnerships for the development and commercialization of our assets;
•
maintain, expand and protect our intellectual property portfolio; and
•
hire additional clinical, manufacturing and scientific personnel.
To become and remain profitable, we must succeed in developing drugs that can generate significant revenue once
commercialized. This will require us to be successful in a range of challenging activities, including completing preclinical testing and
clinical trials of our product candidates, manufacturing, obtaining regulatory approval and potentially entering into agreements for the
commercialization of any products for which we may obtain regulatory approval, as well as discovering and developing additional
product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and,
even if we do, may never generate sufficient revenue to achieve profitability.
Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the
timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to
perform studies in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials
or the development of any of our product candidates, our expenses could increase.
Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our
failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business,
maintain our research and development efforts, diversify our product offerings or continue our operations. A decline in our value
could also cause you to lose all or part of your investment.
We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are
unable to raise capital when needed, we could be forced to delay, reduce or altogether cease our drug development programs or
commercialization efforts.
We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure
requirements into the fourth quarter of 2025. However, we will need to obtain substantial additional funding in connection with our
continuing operations beyond the fourth quarter of 2025, including additional funding to initiate the Phase 3 trials of CLS-AX. Our
future capital requirements will depend on many factors, including:
•
the progress and results of our ongoing, planned and future clinical trial programs;
•
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product
candidates;

29
•
the number and development requirements of other product candidates that we may pursue;
•
the costs, timing and outcome of regulatory review of our product candidates;
•
the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and
distribution, for any of our product candidates for which we receive marketing approval and intend to commercialize
ourselves;
•
the amount of revenue, if any, received pursuant to our license and collaboration agreements;
•
the amount of revenue, if any, received from commercial sales of any of our product candidates for which we receive
marketing approval;
•
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending any intellectual property-related claims; and
•
the extent to which we acquire or in-license other product candidates and technologies.
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and
uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory
approval of our product candidates and achieve product sales. In addition, XIPERE and our other product candidates, if approved, may
not achieve commercial success. Accordingly, we will need to continue to rely on additional financing to achieve our business
objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional
capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or
future operating plans. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or
altogether cease our research and development programs or future commercialization efforts.
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates.
Until such time, if ever, as we can generate substantial product revenue to fund our operations, we expect to finance our cash
needs through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. For
example, in February 2024, we completed a registered direct offering of 11,111,111 shares of common stock and accompanying
warrants to purchase 11,111,111 shares of common stock for gross proceeds of approximately $15.0 million, before deducting
placement agent fees and estimated offering expenses. We do not currently have any committed external source of funds, although as
described in this report we have also entered into an at-the-market sales facility that allows us to sell shares of our common stock at
prevailing market prices and on specified terms, depending on market conditions. To the extent that we raise additional capital through
the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such
as incurring additional debt, making capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with
third parties, we may be required to grant licenses on terms that may not be favorable to or relinquish valuable rights to our
technologies, research programs, product candidates or future revenue streams. For example, we, through our wholly-owned
subsidiary, sold our rights to receive certain royalty and milestone payments under the Arctic Vision License Agreement, Bausch
License Agreement, the Aura License Agreement, the REGENXBIO Option and License Agreement and any out-license agreements
for, or related to, XIPERE or our SCS Microinjector technology to be used in connection with compounds or products of any third
parties in exchange for up to $65 million. If we are unable to raise additional funds through equity or debt financings when needed, we
may be required to delay, limit, reduce or terminate our drug development efforts or future commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves.
We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial
doubt exists as to our ability to continue as a going concern.
Our historical financial statements have been prepared under the assumption that we will continue as a going concern. As of
December 31, 2024, we had an accumulated deficit of $355.3 million and had cash and cash equivalents of $20.0 million. These
conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial
statements are issued. Based on our current plans and forecasted expenses, we expect that our cash, cash equivalents and short-term
investments as of the filing date, March 27, 2025, will enable us to fund our planned operating expenses and capital expenditure
requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could

30
exhaust our capital resources sooner than expected. Until we can generate sufficient revenue, if ever, to fund our operations, we will
need to finance future cash needs through public or private equity offerings, license agreements, debt financings or restructurings,
collaborations, strategic alliances and marketing or distribution arrangements.
The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing for the
continuation of our operations and could result in the loss of confidence by investors and employees. Additional financing may not be
available to us when needed or, if available, it may not be obtained on commercially reasonable terms. If we are not able to obtain the
necessary additional financing on a timely or commercially reasonable basis, we will be forced to delay or scale down some or all of
our development activities (or perhaps even cease the operation of our business). If we are unable to continue as a going concern, our
stockholders may lose some or all of their investment in the Company.
Our agreements with HCR contain various covenants and other provisions, which, if violated, could materially adversely affect our
financial condition.
In August 2022, we, through Royalty Sub, entered into the Purchase and Sale Agreement with HCR pursuant to which we sold
our rights to royalty and milestone payments due to us from XIPERE and certain license agreements related to our SCS Microinjector,
or the Royalties, subject to a cap of 3.4 times the total purchase price paid by HCR under the Purchase and Sale Agreement. Under the
terms of the Purchase and Sale Agreement, Royalty Sub received an initial payment of $32.5 million, less certain expenses.
In connection with the Purchase and Sale Agreement, we entered into a Contribution and Servicing Agreement with Royalty
Sub, pursuant to which we assigned the Arctic Vision License Agreement, Bausch License Agreement, Aura License Agreement,
REGENXBIO Option and License Agreement, our license agreement with Emory University and The Georgia Tech Research
Corporation and related intellectual property rights, or collectively the Contributed Assets, to Royalty Sub. The Contribution and
Servicing Agreement contains various representations and warranties, covenants, indemnification obligations and other provisions
related to the contribution of the Contributed Assets and our maintenance and servicing obligations with respect to the same.
In connection with the Purchase and Sale Agreement, we also entered into a Pledge and Security Agreement with HCR. The
Pledge and Security Agreement contains various representations, warranties and covenants, and includes a limited recourse guaranty
of Royalty Sub’s obligations under the Purchase and Sale Agreement which is secured by the pledge in favor of HCR all of the capital
stock of Royalty Sub. HCR is entitled to foreclose on the capital stock of Royalty Sub following the occurrence of certain remedies
events, including, without limitation, a bankruptcy of us, our failure of to perform our obligations under the Contribution and
Servicing Agreement or in the event of a change of control of us, any failure to make the payment required under Section 2.3 of the
Purchase and Sale Agreement within the time period required thereunder. Such foreclosure, if it were to occur, could have a material
adverse effect on our financial condition as HCR, by virtue of owning Royalty Sub, would own the Royalties and the Contributed
Assets.
Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters,
public health crises, political crises, geopolitical events, such as the conflicts in Ukraine and the Middle East, or other
macroeconomic conditions.
The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including,
among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic
growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. In 2023, the
Federal Reserve raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest
rates, coupled with reduced government spending and volatility in financial markets may increase economic uncertainty and affect
consumer spending. Similarly, the ongoing military hostilities in Russia, Ukraine and the Middle East have created extreme volatility
in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply
chain and energy markets. Any such volatility and disruptions may adversely affect our or our partners’ business. If the equity and
credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more
costly or more dilutive or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can
adversely affect us by increasing our costs, including clinical trials costs and labor and employee benefit costs.
Risks Related to the Development of Our Product Candidates
Our efforts are focused on the development of product candidates for treatment of eye disease through suprachoroidal injection
and partnering with companies who can leverage our SCS Microinjector to deliver their ophthalmic product candidates to the SCS.
Suprachoroidal injection is a novel approach and may fail to achieve and sustain market acceptance.
Injecting drugs into the SCS is a novel approach for ophthalmic therapies, and there is no guarantee this approach will provide
adequate patient benefit or be accepted by physicians, patients or third-party payors. We have also licensed our SCS Microinjector

31
technology to third parties to deliver their proprietary drug candidates into the SCS for the potential treatment of certain ocular
indications.
Although the FDA approved XIPERE for suprachoroidal use for the treatment of macular edema associated with uveitis, we
cannot guarantee that suprachoroidal injection of other drugs will prove in ongoing and future clinical trials to be a safe or effective
approach for treating eye diseases in humans, nor can we ensure that such other drugs will achieve regulatory approval, even if the
clinical trials are successful.
In addition, the novelty of suprachoroidal injection may make it difficult to demonstrate to physicians and third-party payors
that suprachoroidal injection of drugs is an appropriate approach for treating eye diseases and provides advantages compared to the
current standards of care. Further, if we or our commercialization and collaboration partners are not successful in conveying to
physicians, patients and third-party payors that the suprachoroidal administration of drugs with our proprietary SCS Microinjector
provides useful patient outcomes, we or our commercialization and collaboration partners may experience reluctance, or refusal, on
the part of physicians to order and use, and third-party payors to cover and provide adequate reimbursement for, such drugs.
Additionally, in some cases, drugs delivered using our SCS Microinjector will complement the current standard of care, rather than
serve as a replacement for the current standard of care. Therefore, we or our commercialization and collaboration partners may
encounter significant difficulty in gaining broad market acceptance by physicians, third-party payors and potential patients.
Our licensing partners may require that we modify our SCS Microinjector to deliver their product candidates, and we may be
unable to do so.
We are currently partnering with companies who can leverage our SCS Microinjector to deliver their ophthalmic product
candidates to the SCS. Our current and future licensing partners may request modifications to the design of our SCS Microinjector to
accommodate the delivery of their respective product candidates. If we are unable to make such modifications, we may not receive
regulatory and development milestone payments that we otherwise would be eligible to receive after we have satisfied our obligations
under the Purchase and Sale Agreement, which could significantly harm our financial position.
If we are unable to obtain regulatory approval for, and commercialize either on our own or with a third party, CLS-AX or our
other product candidates, or if we experience significant delays in doing so, our business may be harmed.
Given our experience with our clinical programs, the successful development of any of our product candidates is extremely
uncertain, and we cannot guarantee that we will be successful in developing any of our product candidates. Further, the FDA may
conclude that our clinical trials are not sufficient to support approval of our product candidates.
We have invested substantially all of our efforts and financial resources in the development of our proprietary SCS
Microinjector for suprachoroidal injection of drugs and the identification of potential drug candidates using that technology. Our
ability to generate revenue from our product candidates will depend heavily on their successful development and eventual
commercialization, either by us or third parties. The success of those product candidates will depend on several factors, including the
following:
•
successful completion of preclinical studies and requisite clinical trials;
•
performing preclinical studies and clinical trials in compliance with FDA requirements;
•
receipt of marketing approvals from applicable regulatory authorities;
•
ability to import sufficient quantity of product for trials or potential commercialization;
•
obtaining marketing approvals with labeling for sufficiently broad patient populations and indications, without unduly
restrictive distribution limitations or safety warnings, such as black box warnings or a risk evaluation and mitigation
strategy, or REMS, program;
•
obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product
candidates;
•
making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities;
•
launching commercial sales of products, if and when approved, whether alone or in collaboration with others;
•
successful training of physicians in the proper use of our SCS Microinjector;
•
the ability to market our products for use with our SCS Microinjector without a requirement from the FDA that we obtain
a separate medical device authorization;

32
•
acceptance of the therapies and of the concept of suprachoroidal injection of drugs, if and when approved, by physicians,
patients and third-party payors;
•
competing effectively with other therapies;
•
obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors;
•
protecting our rights in our intellectual property portfolio; and
•
maintaining a continued acceptable safety profile of the drugs and our SCS Microinjector following approval.
If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an
inability to successfully commercialize our product candidates, which would materially harm our business.
Data from our clinical trials that we announce or publish from time to time may change as more patient data become available,
and such data are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we may publish data from our clinical trials. Data from clinical trials are subject to the risk that one or more
of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Data also
remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data
we previously published. As a result, data should be viewed with caution until the final data are available. Adverse differences
between preliminary or interim data and final data could significantly harm our prospects for obtaining regulatory approval of our
product candidates.
We may not be successful in our efforts to build a pipeline of product candidates.
A key element of our strategy is to build a pipeline of product candidates for the treatment of a variety of diseases of the back of
the eye via suprachoroidal injection and to progress these product candidates through developmental efforts. We may not be able to
develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential
product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have
significant side effects or other characteristics that indicate that they are unlikely to receive marketing approval or achieve market
acceptance. If we do not successfully develop product candidates based upon our approach, we will not be able to obtain product
revenue in future periods, which could significantly harm our financial position and adversely affect our stock price.
Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or
experience delays in completing, or ultimately be unable to complete, the development of our product candidates.
The risk of failure for our product candidates is high. It is impossible to predict when or if CLS-AX or any of our product
candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from
regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive
clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to
design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can
occur at any stage of testing.
The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials and interim
results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying
interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical
studies and clinical trials have nonetheless failed to obtain marketing approval of their products.
We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to
receive marketing approval for our product candidates, including:
•
regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct
a clinical trial at a prospective trial site;
•
delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with
prospective trial sites;
•
clinical trials of our product candidates may produce negative or inconclusive results, including failure to demonstrate
statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon
product development programs;

33
•
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in
these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate
than we anticipate;
•
our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a
timely manner, or at all;
•
regulators may issue a clinical hold, or regulators or institutional review boards may require that we or our investigators
suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a
finding that the participants are being exposed to unacceptable health risks;
•
the cost of clinical trials of our product candidates may be greater than we anticipate;
•
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product
candidates may be insufficient or inadequate; and
•
our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our
investigators, regulators or institutional review boards to suspend or terminate the trials.
For example, our ODYSSEY trial was delayed due to the issuance by FDA of draft guidance, requiring us to reassess our
original protocol design and we subsequently decided to amend the protocol to have aflibercept as the comparator drug.
If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently
contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these
trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:
•
be delayed in obtaining marketing approval for our product candidates;
•
not obtain marketing approval at all;
•
obtain approval for indications or patient populations that are not as broad as intended or desired;
•
obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, such as black box
warnings or a REMS program;
•
be subject to additional post-marketing testing requirements; or
•
have the product removed from the market after obtaining marketing approval.
Our drug development costs may also increase if we experience delays in testing or marketing approvals. We do not know
whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on
schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the
exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair
our or our potential collaborators’ ability to successfully commercialize our product candidates.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals
could be delayed or prevented.
We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a
sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the
United States. We cannot predict how successful we will be at enrolling patients in future clinical trials. In addition, if we are not
successful at enrolling patients in one clinical trial, it may affect when we are able to initiate our next clinical trial, which could result
in significant delays in our efforts to pursue regulatory approval of and commercialize our product candidates. In addition, some of our
competitors have ongoing clinical trials to treat the same indications as our product candidates, and patients who would otherwise be
eligible for our clinical trials may instead enroll in clinical trials of our competitors. Patient enrollment is affected by other factors
including:
•
the severity of the disease under investigation;
•
the eligibility criteria for the study in question;
•
the perceived risks and benefits of the product candidate under study;
•
the availability of drugs approved to treat the diseases under study;
•
the efforts to facilitate timely enrollment in clinical trials;

34
•
the patient referral practices of physicians;
•
the ability to monitor patients adequately during and after treatment; and
•
the proximity and availability of clinical trial sites for prospective patients.
Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to
abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for
our product candidates, which could cause our value to decline and limit our ability to obtain additional financing.
If serious adverse or unacceptable side effects are identified during the development of our product candidates, we may need to
abandon or limit our development of some of our product candidates.
If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may
need to abandon their development or limit development to more narrow uses or subpopulations in which the side effects or other
characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many product candidates that initially
showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product
candidate. In addition, in some cases, the FDA could issue a clinical hold to stop the study.
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and management resources, we focus on research programs and product candidates that we
identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other
indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize
on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development
programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately
evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product
candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for
us to retain sole development and commercialization rights to such product candidate.
Risks Related to Our Dependence on Third Parties
We have granted an exclusive license to Bausch for the commercialization and development of XIPERE in the United States and
Canada. After we have satisfied our obligations under the Purchase and Sale Agreement, if we are unable to maintain our
partnership with Bausch, or if Bausch fails to successfully commercialize XIPERE, our business and prospects will be materially
harmed.
We have granted an exclusive license to Bausch for the commercialization and development of XIPERE in the United States
and Canada. Pursuant to our agreement with Bausch, we are entitled to receive payments based on the achievement of specified sales
and regulatory milestones and tiered royalties based on annual net sales of XIPERE. We will not retain these royalties and milestone
payments until our obligations under the Purchase and Sale Agreement described above in “Business—Royalty Purchase and Sale
Agreement” are satisfied. The successful or timely achievement of many of these milestones is outside of our control because the
relevant activities will be conducted by Bausch or third parties engaged by Bausch, including manufacturers and suppliers. We expect
to depend to a large degree on the payments from Bausch after we have satisfied our obligations under the Purchase and Sale
Agreement as well as payments from future potential commercialization partners in order to fund our operations, and a failure to
receive such payments may cause us to:
•
delay, reduce or terminate certain research and development programs;
•
reduce headcount;
•
pursue the raising of additional funds through equity or convertible debt financings that could be dilutive to our
stockholders;
•
seek funds by entering into agreements that require us to assign rights to technologies or products that we would have
otherwise retained;
•
enter into new arrangements that may be less favorable than those we would have obtained under different circumstances;
or
•
consider strategic transactions or engaging in a joint venture with a third party.

35
We have entered into, and intend to continue to enter into, collaborations with third parties for the development and
commercialization of XIPERE. In addition, we may seek commercialization partners for our product candidates. If those
collaborations are not successful, we may not be able to capitalize on the market potential of XIPERE and our product candidates.
We have entered into, and intend to continue to enter into, agreements with third-party collaborators for the development and
commercialization of XIPERE and our product candidates. Our likely collaborators for any collaboration arrangements include large
and mid-size pharmaceutical companies, regional and national pharmaceutical companies and smaller biotechnology companies. Our
ability to generate revenues from these arrangements will depend on our collaborators’ abilities to successfully perform the functions
assigned to them in these arrangements.
Collaborations involving XIPERE and our product candidates would pose the following risks to us:
•
collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations;
•
collaborators may not perform their obligations as expected;
•
collaborators may refuse to perform clinical trials or other obligations required for approval in a particular jurisdiction
outside the United States;
•
our collaborators’ regulatory submissions may be denied by the applicable regulatory authorities;
•
collaborators may not pursue development and commercialization of any product candidates that achieve regulatory
approval or may elect not to continue or renew development or commercialization programs based on clinical trial results,
changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert
resources or create competing priorities;
•
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or
abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for
clinical testing;
•
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
our product candidates if the collaborators believe that competitive products are more likely to be successfully developed
or can be commercialized on terms that are more economically attractive than ours;
•
product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own
product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of
our product candidates;
•
a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory
approval may not commit sufficient resources to the marketing and distribution of such products;
•
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred
course of development, might cause delays or termination of the research, development or commercialization of product
candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation
or arbitration, any of which would be time-consuming and expensive;
•
collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their
proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or
proprietary information or expose us to potential litigation;
•
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential
liability; and
•
collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise
additional capital to pursue further development or commercialization of the applicable product candidates.
Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner
or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis
on our drug development or commercialization program could be delayed, diminished or terminated.

36
We rely on third parties to conduct our clinical trials for our product candidates, and those third parties may not perform
satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory
requirements.
We have engaged contract research organizations, or CROs, for our ongoing and planned clinical trials. We also expect to
engage CROs for any of our other product candidates that may progress to clinical development. We expect to rely on CROs, as well
as other third parties, such as clinical data management organizations, medical institutions and clinical investigators, to conduct those
clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third
parties. If we need to enter into alternative arrangements, that would delay our drug development activities.
Our reliance on these third parties for research and development activities will reduce our control over these activities but will
not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted
in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with
regulatory standards, commonly referred to as Good Clinical Practices, or GCPs, for conducting, recording and reporting the results of
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial
participants are protected. We also are required to register certain ongoing clinical trials and post the results of certain completed
clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so by us or third
parties can result in FDA refusal to approve applications based on the clinical data, enforcement actions, adverse publicity and civil
and criminal sanctions.
Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these
third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance
with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing
approvals for our product candidates and will not be able to, or may be delayed in our or our potential collaborators’ efforts to,
successfully commercialize our product candidates.
In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time
and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation
result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the
interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the
clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such
delay or rejection could prevent the commercialization of our current or future product candidates.
We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance
failure or regulatory noncompliance on the part of our distributors could delay clinical development or marketing approval of our
product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.
We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of our
current product candidates and our SCS Microinjector. This reliance on third parties increases the risk that we will not have
sufficient quantities of our drug products and our SCS Microinjector, or such quantities at an acceptable cost, which could delay,
prevent or impair our development or commercialization efforts.
We do not have any manufacturing facilities or personnel. We currently procure the active pharmaceutical ingredient of our
product candidates on a purchase order basis from a third-party manufacturer, but we do not have a commercial supply agreement in
place with that manufacturer. In addition, we have entered into a supply agreement with Gerresheimer, our SCS Microinjector
supplier. Some of our current suppliers are based outside of the United States. In addition, some of the facilities of our third-party
manufacturers have only undergone a limited number of FDA inspections or no inspections. We expect to continue to rely on third
parties as we proceed with preclinical and clinical studies using our SCS Microinjector, as well as for commercial manufacture, for
any of our product candidates that receive marketing approval. This reliance on third parties increases the risk that we will not have
sufficient quantities of our drug products including our SCS Microinjector or such quantities at an acceptable cost or quality, which
could delay, prevent or impair our ability to timely conduct our clinical trials or our other development or commercialization efforts.
In addition, we may be unable to establish any agreements with third-party manufacturers or collaborators or to do so on acceptable
terms.
Reliance on third-party manufacturers or collaborators entails additional risks, including:
•
reliance on the third party for regulatory compliance and quality assurance;
•
the possible breach of the manufacturing agreement by the third party;

37
•
the possible misappropriation of our proprietary information, including our trade secrets and know-how; and
•
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for
us.
Our product candidates, including our proprietary drug formulations packaged together with our SCS Microinjector, are subject
to the drug regulations of the FDCA. Third-party manufacturers may not be able to comply with current Good Manufacturing
Practices, or cGMP, regulations, regulations applicable to drug/device combination products, including applicable provisions of the
FDA’s drug cGMP regulations, device cGMP requirements embodied in the Quality System Regulation, or QSR, or similar regulatory
requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable
regulations could result in sanctions being imposed on us, including clinical holds, a refusal to file determination by the FDA, receipt
of a CRL, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of
product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect our ability to achieve
regulatory approval of our product candidates.
Our product candidates that we may develop may compete with other drugs and devices for access to manufacturing facilities.
There are a limited number of manufacturers that operate under the drug and device cGMP regulations applicable to our product
candidates and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future
manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant
supply or a second source for bulk drug substance or our SCS Microinjector. If our current contract manufacturers cannot perform as
agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative
manufacturers who could manufacture our drugs and the components of our SCS Microinjector, we may incur added costs and delays
in identifying and qualifying any such replacement. For example, the FDA could require supplemental data if a new supplier is relied
upon for the supply of our products. Any interruption or delay in the supply of components and materials, or our inability to obtain
components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of
our customers and cause them to cancel orders.
Our current and anticipated future dependence upon others for the manufacture of our product candidates may compromise our
future profit margins and/or our commercialization partner's ability to commercialize any product candidates that receive marketing
approval on a timely and competitive basis.
If we are not able to establish additional collaborations, we may have to alter some of our future development and
commercialization plans.
Our drug development programs and the potential commercialization of our product candidates will require substantial
additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and
biotechnology companies for the future development and potential commercialization of those product candidates.
We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and
conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include
the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States,
the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product
candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology,
which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market
conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that
may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product
candidate. We may also be restricted under existing license agreements from entering into agreements on certain terms with potential
collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant
number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential
future collaborators.
We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we
may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other
development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our
expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures
to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available
to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or
bring them to market and generate product revenue.

38
Risks Related to the Commercialization of Our Product Candidates
If we are unable to establish sales and distribution capabilities for our product candidates for which we do not out-license
commercialization rights, we may not be successful in commercializing those product candidates, if and when they are approved.
We do not have a sales infrastructure. To achieve commercial success for any product candidate for which we may obtain
marketing approval in the United States and have not licensed the commercialization rights to a third party, we will need to establish a
sales organization. There are risks involved with establishing our own sales and distribution capabilities. For example, recruiting and
training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product
candidate for which we recruit a sales force is delayed or does not occur for any reason, we would have prematurely or unnecessarily
incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our
sales and marketing personnel.
Factors that may inhibit our efforts to commercialize our drugs on our own include:
•
our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
•
the inability of sales personnel to obtain access to physicians or educate an adequate number of physicians as to the
benefits of our product candidates;
•
the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage
compared to companies with more extensive product lines; and
•
unforeseen costs and expenses associated with creating an independent sales and marketing organization.
If we are unable to establish our own sales and distribution capabilities and, instead, enter into arrangements with third parties to
perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to sell and distribute
any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third
parties to sell and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have
little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our
product candidates effectively. If we do not establish sales and distribution capabilities successfully, either on our own or in
collaboration with third parties, we will not be successful in commercializing our product candidates.
XIPERE and any of our product candidates that receive marketing approval, may fail to achieve the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
XIPERE and any of our product candidates that receive marketing approval may nonetheless fail to gain sufficient market
acceptance by physicians, patients, third-party payors and others in the medical community. Suprachoroidal injection of drugs is a
novel approach and physicians, patients or third-party payors may be hesitant to deviate from or change the current standard of care. If
XIPERE or our product candidates do not achieve an adequate level of market acceptance, we may not generate significant product
revenue and we may not become profitable. The degree of market acceptance of XIPERE and our product candidates, if approved for
commercial sale, will depend on a number of factors, including:
•
the efficacy and potential advantages compared to alternative treatments;
•
our ability to offer our drugs for sale at competitive prices;
•
the convenience and ease of administration compared to alternative treatments;
•
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
•
the willingness of the healthcare community and patients to adopt new technologies and our novel approach of SCS
injection of drugs;
•
the willingness of uveitis and retina specialists to expend the time necessary to receive proper training on injecting drugs
into the SCS using our SCS Microinjector;
•
the ability to manufacture our products in sufficient quantities and yields;
•
the strength of marketing and distribution support provided by us or our collaborators;
•
the availability of third-party payor coverage and adequate reimbursement;
•
the prevalence and severity of any side effects; and
•
any restrictions on the use of our drugs together with other medications.

39
We face substantial competition, which may result in others discovering, developing or commercializing products before or more
successfully than we do.
The development and commercialization of new products is highly competitive. We face competition with respect to our current
product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in
the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. We
also are aware of companies that are developing suprachoroidal injectors which may compete with our SCS Microinjector.
With respect to XIPERE, we face competition from other commercially available forms of TA and other injectable and
implantable corticosteroids. Bristol-Myers Squibb markets TA under the brand name Kenalog, for which a number of generic
equivalents are currently available. Kenalog is indicated only for intramuscular or intraarticular injection; however, it is commonly
used off-label for intraocular inflammation using intravitreal and periocular administration. In addition, Harrow's (acquired by Alcon)
injectable TA, Triesence, is approved in the United States for the treatment of uveitis and other ocular inflammatory conditions
unresponsive to topical corticosteroids, although it is not specifically indicated for the treatment of macular edema associated with
uveitis. Ozurdex, marketed by Allergan, is a bioerodable extended release implant that delivers the corticosteroid dexamethasone and
is approved for the treatment of non-infectious uveitis affecting the posterior segment of the eye and for macular edema due to RVO in
both the United States and in the European Union. Ozurdex is also approved in the United States for the treatment of DME. Retisert
and Yutiq, both intravitreal implants of fluocinolone acetonide, are marketed by Bausch and Alimera, respectively, and are approved
in the United Sates for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, Oxular
was developing OXU-001 which is dexamethasone delivered via the Oxulumis suprachoroidal device for the treatment of DME.
Oxular was acquired by Regeneron in December 2024. It is possible physicians may use OXU-001 off label to treat macular edema
associated with uveitis if further developed and ultimately approved.
CLS-AX faces competition with anti-VEGF drugs, the current standard of care for RVO and wet AMD, as well as other drug
candidates in development for ocular use for the treatment of wet AMD, such as other TKIs. Axitinib, also known by its brand name
Inlyta, is not currently approved for an ocular indication but is approved by the FDA and marketed by Pfizer for the treatment of
advanced renal cell carcinoma. Genentech has several products which serve as competitors in this space, including anti-VEGF agents
Lucentis, Avastin, and Susvimo. Lucentis is currently approved in the United States and European Union for the treatment of wet
AMD, macular edema following RVO, and diabetic retinopathy in patients with DME. Avastin is an anti-VEGF drug routinely used
off-label by uveitis and retina specialists in both the United States and in certain countries of the European Union for the treatment of
numerous retinal diseases. Susvimo, an ocular implant that releases ranibizumab over time, received approval from the FDA in
October 2021 for the treatment of wet AMD in patients who have previously responded to anti-VEGF therapy. Additionally,
Genentech’s product, Vabysmo (faricimab-svoa), an intravitreal injection which blocks two disease pathways, including (Ang-2) and
vascular endothelial growth factor-A (VEGF-A), received approval in January 2022 for the treatment of wet AMD and DME. In
addition to Genentech’s products, Regeneron’s anti-VEGF product, Eylea 2 mg and 8 mg and Novartis’ product, Beovu, also present
potential competition for CLS-AX in both the United States and Europe. Eylea is approved for the treatment of wet AMD, macular
edema following RVO and diabetic retinopathy and DME in the United States and for the treatment of wet AMD, RVO and DME in
the European Union. Novartis’ Beovu was approved in 2019 for the treatment of wet AMD in the United States and in 2020 in
Europe.
Ocular drug candidates being investigated for treatment of wet AMD may also represent potential competition for CLS-AX.
Ocular Therapeutics and Eyepoint are companies currently investigating TKIs for ocular use in late-stage clinical trials. We expect
other established companies will seek to develop new products in the ocular space with the goal of superior efficacy and duration over
the current standard of care.
REGENXBIO, Adverum, and 4D Molecular Therapeutics are currently conducting mid to late-stage clinical trials with various
ocular gene therapies for the treatment of wet AMD. These gene-based treatments could potentially compete with CLS-AX due to
their potential to be long acting treatments.
The SCS Microinjector faces competition from other devices being developed to access ocular posterior tissues via the SCS.
Everads Therapy and Uneedle both have developed competing products and are in various stages of early-stage clinical development.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are
safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that
we may develop. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we
may obtain approval for ours, which could result in product approval delays if a competitor obtains market exclusivity from the FDA
or our competitors establishing a strong market position before we or our collaborators are able to enter the market. In addition, our
ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs.
For some of the indications that we are pursuing, drugs used off-label, such as Kenalog and Avastin, serve as cheaper alternatives to

40
our product candidates. Their lower prices could result in significant pricing pressure, even if our product candidates are otherwise
viewed as a preferable therapy. Additional drugs may become available on a generic basis over the coming years. If our product
candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic drugs.
Many of the companies against which we are competing or against which we may compete in the future have significantly
greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and
biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller
and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our programs.
XIPERE and our product candidates may be subject to unfavorable pricing regulations, third-party coverage and reimbursement
policies or healthcare reform initiatives.
Our and our collaborators’ ability to commercialize XIPERE and any of our product candidates successfully will depend, in
part, on the extent to which coverage and adequate reimbursement for XIPERE and our product candidates will be available from
government payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers, managed care
plans and other third-party payors. Government authorities and other third-party payors, such as private health insurers and health
maintenance organizations, decide which medical products they will pay for and establish reimbursement levels. Increasingly, third-
party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for drugs and products. Coverage and reimbursement may not be available and, even if these are available, the level of
reimbursement may not be satisfactory. Inadequate reimbursement levels may adversely affect the demand for, or the price of, any
product candidate for which we obtain marketing approval. Obtaining and maintaining coverage and adequate reimbursement for our
drugs may be difficult. We or our collaborators may be required to conduct expensive pharmacoeconomic studies to justify coverage
and reimbursement or the level of reimbursement compared to other therapies. If coverage and adequate reimbursement are not
available or reimbursement is available only to limited levels, we or our collaborators may not be able to successfully commercialize
XIPERE and any other product candidates for which marketing approval is obtained.
A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party
payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. By way
of example, the Medicare Prescription Drug Improvement and Modernization Act of 2003, or MMA, changed the way Medicare
covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for outpatient drug purchases by those
covered by Medicare under a new Part D program and introduced a new reimbursement methodology based on average sales prices
for Medicare Part B physician-administered drugs, including drugs currently on the market used by physicians to treat the clinical
indications for which we are currently seeking FDA approval and likely XIPERE and our other product candidates, if approved. As a
result of this legislation and the expansion of federal coverage of drug products, there is additional pressure to contain and reduce
costs. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy
and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may
result in a similar reduction in payments from private payors. These cost reduction initiatives and other provisions of the MMA could
decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business.
Further, from time to time, typically on an annual basis, payment amounts are updated and revised by third-party payors.
Because we expect that customers who use XIPERE and our other product candidates, if approved, will be separately reimbursed for
the procedure administering our products, these updates could directly impact the demand for our products. An example of payment
updates is the Medicare program updates to physician payments, which is done on an annual basis using a prescribed statutory
formula. In the past, when the application of the formula resulted in lower payment, Congress has passed interim legislation to prevent
the reductions. However, the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, ended the use of the statutory
formula, also referred to as the Sustainable Growth Rate, for clinician payment and established a quality payment incentive program,
also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the
Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. Under both APMs and
MIPS, performance data collected each performance year will affect Medicare payments in later years, including potentially reducing
payments. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in
payments from private payors. We cannot predict how pending and future healthcare legislation will impact our business, and any
changes in coverage and reimbursement that further restricts coverage of our products or lowers reimbursement for procedures using
our products could materially affect our business.

41
There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more
limited than the indications for which the product is approved by the FDA or similar regulatory authorities outside the United States.
Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers
our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs,
if applicable, may also not be sufficient to cover our costs and may not be made permanent.
We believe that physicians who use XIPERE and our other product candidates, if approved, may be reimbursed by third-party
payors for both the suprachoroidal injection using our SCS Microinjector and for the drug itself. On July 1, 2016, the American
Medical Association, or AMA, approved a new Category III Current Procedural Terminology, or CPT, code for the suprachoroidal
injection of pharmacologic agents. Category III codes are a set of temporary codes maintained by the AMA for emerging technology,
services and procedures. Payment for these services or procedures are based on the coverage policies of individual payors, including
private insurers and government-funded programs, like Medicare, and Medicare administrative contractors. CPT code 0465T became
effective on January 1, 2017. In November 2023, AMA assigned XIPERE the Category 1 CPT code 67516. We believe the Category 1
code may facilitate better access and adoption of XIPERE and the suprachoroidal injection method. Additionally, there is no guarantee
that these billing codes or the payment amounts, if any, associated with such codes will be sufficient to successfully commercialize
any approved product and, even if adequate payment amounts are obtained, they could change in the future.
Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on
reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices
for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the
United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own
reimbursement policies. However, no uniform policy requirement for coverage and reimbursement for drug products exists among
third-party payors in the United States. Therefore, coverage and reimbursement can differ significantly from payor to payor. As a
result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and
clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will
be applied consistently or obtained at all. Additionally, coverage policies and reimbursement rates may change at any time. Thus, even
if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be
implemented in the future. For example, beginning on January 1, 2023, certain manufacturers will be required to pay quarterly refunds
to the Centers for Medicare & Medicaid Services, or CMS for discarded amounts of single-dose container and single-use package
drugs covered under Medicare Part B. Refunds will be based on the discarded volume above 10% of the total allowed amount, except
in unique circumstances, as determined by CMS. Our or our collaborators’ inability to promptly obtain coverage and adequate
reimbursement rates from both government-funded and private payors for any approved drugs that we develop could significantly
harm our operating results, our ability to raise capital and our overall financial condition. Further, any changes in coverage and
reimbursement that further restricts coverage of our products or lowers reimbursement for procedures using our products could
materially affect our business.
The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country
to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional
costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a product before it can be
marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some
foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is
granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations
that delay commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues able to be
generated from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in
XIPERE and one or more product candidates, even if our other product candidates obtain marketing approval.
There can be no assurance that XIPERE and our other product candidates, if they are approved for sale in the United States or in
other countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-
effective by third-party payors, that coverage or an adequate level of reimbursement will be available, or that third-party payors’
reimbursement policies will not adversely affect our ability to sell XIPERE and our other product candidates profitably if they are
approved for sale.

42
Product liability lawsuits against us could cause us to incur substantial liabilities.
We face an inherent risk of product liability exposure related to the sale of XIPERE as well as the testing of our product
candidates in human clinical trials. If we cannot successfully defend ourselves against claims that our product candidates or products
caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
•
decreased demand for any product candidates or products that we may develop;
•
injury to our reputation and significant negative media attention;
•
withdrawal of clinical trial participants;
•
significant costs to defend the related litigation;
•
substantial monetary awards paid to trial participants or patients;
•
loss of revenue;
•
reduced resources of our management to pursue our business strategy; and
•
our or our collaborators’ inability to commercialize any drugs that we may develop.
We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0
million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we
expand our clinical trials or if we or our collaborators commence commercialization of our product candidates. Insurance coverage is
increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy
any liability that may arise.
Risks Related to Employee Matters and Managing Our Growth
Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
We are highly dependent on the management, research and development, clinical, financial and business development expertise
of our executive officers and senior management, as well as the other members of our scientific and clinical development teams. Our
executive officers may terminate their employment with us at any time. We do not maintain “key person” insurance for any of our
executives or employees.
Recruiting and retaining qualified scientific and clinical personnel will also be critical to our success. The loss of the services of
our executive officers or other key employees could impede the achievement of our objectives and seriously harm our ability to
successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may
take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience
required to successfully develop and gain regulatory approval of our product candidates. Competition to hire from this limited pool is
intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among
numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of
scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including
scientific and clinical advisors, to assist us in formulating our strategy. Our consultants and advisors may have commitments under
consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and
retain high quality personnel, our ability to pursue our growth strategy will be limited.
Risks Related to Our Intellectual Property
If we are unable to obtain and maintain patent protection for our technology and product candidates, or if our licensors are unable
to obtain and maintain patent protection for the technology or product candidates that we license from them, or if the scope of the
patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar
or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired.
Our success depends in large part on our and our licensors’ ability to obtain and maintain patent protection in the United States
and other countries with respect to our product candidates. We and our licensors seek to protect our proprietary position by filing
patent applications in the United States and abroad related to our technology and product candidates.
The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or
desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable

43
aspects of our research and development output before it is too late to obtain patent protection or that we have published an invention
prior to filing a relevant patent application. We may not have the right to control the preparation, filing and prosecution of patent
applications, or to maintain the rights to patents licensed to third parties. For example, we do not control the prosecution of the patent
applications licensed to us under the Emory/GT License described below. Therefore, these patents and applications may not be
prosecuted and enforced in a manner consistent with the best interests of our business. If such licensors fail to maintain such patents,
or lose rights to those patents, the rights we have licensed may be reduced or eliminated.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and
factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect
our rights to the same extent as the laws of the United States or visa-versa. For example, European patent law restricts the patentability
of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature
often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published
until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make
the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent
protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are
highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or
product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs.
Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value
of our patents or narrow the scope of our patent protection.
Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-
Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These
include provisions that affect the way patent applications are prosecuted, redefine prior art and may also affect patent litigation. The
U. S. Patent and Trademark Office recently developed new regulations and procedures to govern administration of the Leahy-Smith
Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file
provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have
on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs
surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
significantly harm our business and financial condition. In addition, patent reform legislation may pass in the future that could lead to
additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our owned and licensed patents
and patent applications.
Moreover, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or
become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings
challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation
could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party
patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could
dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.
Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any
meaningful protection and may not be of sufficient scope or strength to provide us with any commercial advantage. Our competitors
may be able to design around our owned or licensed patents by developing similar or alternative technologies or drugs without
infringing on our intellectual property rights.
In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and
licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss
of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of
the patent protection of our technology and drugs. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from
commercializing drugs similar or identical to ours, and our business will suffer.

44
Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general,
thereby impairing our ability to protect our products.
The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several
patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights
of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this
combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S.
Congress, the federal courts and the U.S. Patent and Trademark Office, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might
obtain in the future. For example, recent decisions raise questions regarding the award of patent term adjustment, or PTA, for patents
in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will or will not be viewed
in future and whether patent expiration dates may be impacted. Similarly, changes in patent law and regulations in other countries or
jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces
patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may
obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In
Europe, a new unitary patent system was introduced in 2023, which significantly impacted European patents, including those granted
before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a
patent, of becoming a Unitary Patent which is subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court
system, its body of case law remains limited, increasing the uncertainty of any litigation. Patents granted before the implementation of
the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents
that remain under the jurisdiction of the UPC are potentially vulnerable to a single UPC-based revocation challenge that, if successful,
could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of
any potential changes.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time
consuming and unsuccessful.
Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may
be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived
infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent
infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s
claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the
technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or
interpreted narrowly, which would undermine our competitive position.
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which
would be uncertain and could significantly harm business.
Our commercial success depends upon our ability, and the ability of any collaborators, to develop, manufacture, market and sell
our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is
considerable intellectual property litigation in the biotechnology and pharmaceutical industries. In particular, we are focused on
developing product candidates based on widely used therapeutic agents, many of which are protected by proprietary rights of third
parties, and we are developing proprietary formulations of these therapeutic agents specifically for suprachoroidal injection using our
proprietary SCS Microinjector. Although we seek to develop our proprietary drug formulations that don’t infringe the intellectual
property rights of others, we may become party to, or threatened with, future adversarial proceedings or litigation regarding
intellectual property rights with respect to our drugs or other aspects of our technology, including interference or derivation
proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing
patents or patents that may be granted in the future.
If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from such third
party to continue developing and marketing our technology and drugs. However, we may not be able to obtain any required license on
commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our
competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing
the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and
attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing
our product candidates or force us to cease some of our business operations.

45
Competing products may be sold in countries in which our patent coverage might not exist or be as strong. If we lose a patent
lawsuit alleging our infringement of a competitor’s patent, or if FDA approval is stayed pending the outcome of patent litigation, we
could be prevented from marketing our products. As a result, our ability to grow our business and compete in the market may be
harmed.
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal
responsibilities.
Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there
could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could hurt the price of our common stock. Such litigation or proceedings could
substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing
or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of
their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could compromise our ability to compete in the marketplace.
If we fail to comply with our obligations under our existing intellectual property licenses with third parties, we could lose license
rights that are important to our business.
We are a party to a license agreement with Emory University and Georgia Tech Research Corporation, or the Emory/GT
License, and may enter into additional license agreements in the future. Our existing license agreement imposes, and we expect that
future license agreements would impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For
example, under the Emory/GT License, we are required to use commercially reasonable efforts to develop and commercialize licensed
products under the agreement and to satisfy other specified obligations, including the payment of license fees and minimum royalty
payments. If we fail to comply with our obligations under our license agreements, our licensors may have the right to terminate these
license agreements, in which event we might not be able to market any product that is covered by these agreements, or to convert the
license to a non-exclusive license, which could impair the value of the product candidate being developed under the license
agreement. Termination of these license agreements or reduction or elimination of our licensed rights may result in our having to
negotiate new or reinstated licenses with less favorable terms. If our licensors under the Emory/GT License were to terminate their
license agreement with us for any reason, we would lose access to critical technology related to our SCS Microinjector.
We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be
available on commercially reasonable terms.
A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development of
our product candidates. It may be necessary for us or our collaborators to use the patented or proprietary technology of third parties to
commercialize our product candidates, in which case we would be required to obtain a license from these third parties. Such a license
may not be available on commercially reasonable terms, or at all, and we could be forced to cease development of one or more or our
product candidates or accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable
terms, our business could be harmed.
We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or
claiming ownership of what we regard as our own intellectual property.
Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies.
Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we
may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed intellectual property, including
trade secrets or other proprietary information, of any such employee’s former employer. We may also in the future be subject to
claims that we have caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation
may be necessary to defend against these potential claims.
In addition, while it is our policy to require our employees and contractors who may be involved in the development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an
agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements
may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may
bring against us, to determine the ownership of what we regard as our intellectual property.

46
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel. A court could prohibit us from using technologies or features that are essential to our
products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information
of the former employers. Even if we are successful in prosecuting or defending against such claims, litigation could result in
substantial costs and could be a distraction to management. In addition, any litigation or threat thereof may adversely affect our ability
to hire employees or contract with independent service providers. Moreover, a loss of key personnel or their work product could
hamper or prevent our or our collaborators’ ability to commercialize our product candidates.
Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from
the products of our competitors. Other than the trade name XIPERE, we have not yet selected trademarks for our product candidates
or begun the process of applying to register trademarks for our product candidates. Once we select trademarks and apply to register
them, our trademark applications may not be approved. In addition, third parties may oppose our trademark applications, or otherwise
challenge our use of the trademarks. If our trademarks are successfully challenged, we could be forced to rebrand our products, which
could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our
competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.
Some intellectual property that we have in-licensed may have been discovered through a government funded program and may be
subject to certain federal regulations.
Some of the intellectual property rights we have licensed, including such rights licensed from Emory University and Georgia
Tech Research Corporation, may have been generated through the use of U.S. government funding and may therefore be subject to
certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or
future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights in certain
inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to
use inventions for any governmental purpose. In addition, the U.S. government may have the right to require us to grant exclusive,
partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not
been taken to commercialize the invention, (ii) government action is necessary to meet public health or safety needs or (iii)
government action is necessary to meet requirements for public use under federal regulations (also referred to as “march-in rights”).
The U.S. government also could take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the
government and fail to file an application to register the intellectual property within specified time limits. Intellectual property
generated under a government funded program is also subject to certain reporting requirements, compliance with which may require
us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying
the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The
manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but
unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture
substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference
for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual
property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the
provisions of the Bayh-Dole Act may similarly apply.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including
unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our
trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our
employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third
parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite
these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets.
Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have
taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such
breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-
consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or
unwilling to protect trade secrets.
Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets.
Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development
efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or

47
independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using
that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a
competitor, our competitive position would be harmed.
Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we and our collaborators will not be
able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.
Our product candidates and the activities associated with their development and commercialization, including their design,
research, testing, manufacture, safety, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, advertising,
promotion, sale, distribution, import, export, and reporting of safety and other post-market information, are subject to comprehensive
regulation by the FDA and other regulatory agencies in the United States and by the European Medicines Agency, or EMA, and
similar regulatory authorities outside the United States. Failure to obtain marketing approval for a product candidate will prevent us,
or any collaborator to whom we grant rights, from commercializing the product candidate. We expect to rely on third-party CROs to
assist us in preparing some or all aspects of the applications necessary to gain marketing approvals. Securing marketing approval
requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each
therapeutic indication to establish the product candidate’s safety and efficacy. Securing marketing approval also requires the
submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory
authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or
unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit
commercial use. If any of our product candidates receives marketing approval, the accompanying label may limit its approved use,
which could limit sales of the product.
The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, if
approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of
the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment
of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the
approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to
accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other
studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent
marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or
post-approval commitments that render the approved product not commercially viable.
If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial
prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.
If the FDA does not conclude that a product candidate satisfies the requirements for the Section 505(b)(2) regulatory approval
pathway, or if the requirements under Section 505(b)(2) are not as we expect, the approval pathway for our product candidates in
this pathway will likely take significantly longer, cost significantly more and entail significantly greater complications and risks
than anticipated, and in either case may not be successful.
We believe that certain of our product candidates, including our proprietary drug formulations packaged together with our SCS
Microinjector, will be regulated under the drug provisions of the FDCA, enabling us to submit NDAs for approval of our product
candidates. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments,
added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required
for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of
reference.
If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway for a product candidate as anticipated, we may
need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory
approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates, and
complications and risks associated with our product candidates, would likely substantially increase. We may need to obtain additional
funding, which could result in significant dilution to the ownership interests of our then existing stockholders to the extent we issue
equity securities or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms
acceptable to us, if at all.
Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in competitive products reaching the market
before our product candidates, which could impact our competitive position and prospects. Even if we are allowed to pursue the

48
Section 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for
commercialization, or that a competitor would not obtain approval first, including subsequent market exclusivity from the FDA,
thereby delaying potential approval of our product.
In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years,
some pharmaceutical companies and others have objected to the FDA’s interpretation of Section 505(b)(2). If the FDA’s interpretation
of Section 505(b)(2) is successfully challenged, the FDA may be required to change its Section 505(b)(2) policies and practices, which
could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).
Additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with
co-packaging a drug-device combination product.
Our product candidates require coordination within the FDA and similar foreign regulatory agencies for review of the drug
along with the SCS Microinjector. Although the FDA and similar foreign regulatory agencies have systems in place for the review and
approval of combination products such as ours, we may experience delays in the development and commercialization of our product
candidates due to regulatory timing constraints and uncertainties in the product development and approval process. In addition, to
date, the FDA has not requested a separate medical device authorization submission for our SCS Microinjector. However, the FDA
may request a separate medical device authorization submission for our SCS Microinjector in the future, which could delay the
development and commercialization of our product candidates. Additionally, other jurisdictions may have additional requirements for
any drug and device combination, which may cause delays in product approval.
Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed
abroad.
In order to market and sell our products in the European Union and any other jurisdictions, we must obtain separate marketing
approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can
involve additional testing or requirements. The time required to obtain approval may differ substantially from that required to obtain
FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining
FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement
before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the
United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or
jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in
other countries or jurisdictions or by the FDA. However, failure to obtain approval in one jurisdiction may impact our ability to obtain
approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals in order for us or our
collaborators to commercialize our products in any market.
A variety of risks associated with marketing our product candidates internationally could affect our business.
We may seek regulatory approval for our product candidates outside of the United States and, accordingly, we expect that we
will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:
•
differing regulatory requirements in foreign countries;
•
the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local
prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally;
•
unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
•
economic weakness, including inflation, or political instability in particular foreign economies and markets;
•
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
•
foreign taxes, including withholding of payroll taxes;
•
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country;
•
differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;
•
difficulties staffing and managing foreign operations;
•
workforce uncertainty in countries where labor unrest is more common than in the United States;

49
•
potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;
•
challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not
respect and protect intellectual property rights to the same extent as the United States;
•
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
•
business interruptions resulting from geo-political actions, including war and terrorism.
These and other risks associated with our international operations may compromise our ability to achieve or maintain
profitability.
We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money
laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and
international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S.
Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of
Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute
contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money
laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies
and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or
indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell
our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and
other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-
affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our
employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such
activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties,
imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational
harm, and other consequences.
Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or
withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we
experience unanticipated problems with our product candidates, when and if any of them are approved.
Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical
data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the
FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and
reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and
corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and
recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the
indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a
REMS, which could involve requirements for, among other things, a medication guide, special training for prescribers and dispensers,
and patient registries. If any of our product candidates receives marketing approval, the accompanying label may limit its approved
uses, which could limit sales of the product, or include a black box warning to highlight a specific health risk.
The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety
or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of products to ensure products are
marketed only for the approved indications and in accordance with the provisions of the approved labeling. Physicians, on the other
hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician’s choice
of drug treatment made in the physician’s independent medical judgment, they do restrict promotional communications from
companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However,
companies may share truthful and not misleading information that is otherwise consistent with the product’s FDA approved labeling.
The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use and if we do not market our drugs
for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA relating to

50
the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws,
such as the federal civil False Claims Act, as well as state consumer protection laws.
In addition, later discovery of previously unknown adverse events or other problems with our drugs, including device
malfunctions, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may have negative
consequences, including:
•
restrictions on such drugs, manufacturers or manufacturing processes;
•
restrictions on the labeling or marketing of a drug;
•
restrictions on drug distribution or use;
•
requirements to conduct post-marketing studies or clinical trials;
•
warning letters;
•
recall or withdrawal of the drugs from the market;
•
refusal to approve pending applications or supplements to approved applications that we submit;
•
clinical holds;
•
safety alerts;
•
fines, restitution or disgorgement of profits or revenues;
•
suspension or withdrawal of marketing approvals;
•
refusal to permit the import or export of our drugs;
•
product seizure; or
•
injunctions or the imposition of civil or criminal penalties.
Non-compliance with European Union requirements regarding safety monitoring, or pharmacovigilance, and with requirements
related to the development of drugs for the pediatric population, can also result in significant financial penalties. Similarly, failure to
comply with the European Union’s requirements regarding the protection of personal information can also lead to significant penalties
and sanctions.
Even though we have received orphan drug designation in the European Union for the treatment of non-infectious uveitis, we may
not be able to obtain orphan drug marketing exclusivity for this product candidate.
Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for
relatively small patient populations as orphan drugs. We have received orphan drug designation from the EMA for the treatment of
non-infectious uveitis, and we may seek orphan drug designation from the FDA or EMA for our future product candidates. However,
we cannot pursue orphan drug designation from the FDA for the treatment of uveitis.
Regulation (EC) No 141/2000 and Regulation (EC) No 847/2000 provide that a product can be designated as an orphan
medicinal product by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention
or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the
European Union when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the
European Union and that without incentives the medicinal product is unlikely to be developed. For either of these conditions, the
applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question
that has been authorized in the European Union or, if such method exists, the medicinal product will be of significant benefit to those
affected by that condition. Once authorized, orphan medicinal products are entitled to ten years of market exclusivity in all EU
Member States and in addition a range of other benefits during the development and regulatory review process including scientific
assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries
and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a
similar medicinal product with the same orphan indication during the ten-year period with the consent of the marketing authorization
holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply
sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if
this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. In addition, the period of
market exclusivity may be reduced to six years if it can be demonstrated based on available evidence that the original orphan

51
medicinal product is sufficiently profitable not to justify maintenance of market exclusivity. There is no guarantee that we will be able
to obtain or maintain orphan exclusivity even if we receive marketing authorization in Europe.
Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners and vendors may engage
in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
We are exposed to the risk of employee fraud or other misconduct or failure to comply with applicable regulatory requirements.
Misconduct by employees and independent contractors, such as principal investigators, CROs, consultants, commercial partners and
vendors, could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with
manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial
information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and other business
arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other
abusive practices. These laws may restrict or prohibit a wide range of business activities, including research, manufacturing,
distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Employee and independent contractor misconduct could also involve the improper use of individually identifiable
information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. In addition, federal procurement laws impose substantial penalties for misconduct in
connection with government contracts and require certain contractors to maintain a code of business ethics and conduct. It is not
always possible to identify and deter employee and independent contractor misconduct, and any precautions we take to detect and
prevent improper activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such
actions are instituted against us, those actions could have a significant impact on our business, including the imposition of substantial
civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in
Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, imprisonment, diminished profits
and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or
similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of
which could adversely affect our ability to operate.
Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party
payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false
claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations,
which could expose us to penalties.
Healthcare providers, including physicians, and third-party payors in the United States and elsewhere play a primary role in the
recommendation and prescription of XIPERE and any product candidates for which we obtain marketing approval. Our current and
future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may expose
us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute
and the federal civil False Claims Act, that may constrain the business or financial arrangements and relationships through which we
research, sell, market and distribute XIPERE and any product candidates for which we obtain marketing approval. In addition, we may
be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the
states and foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws (including
privacy and cybersecurity laws and regulations) that may affect our ability to operate include the following:
•
the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting,
offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return
for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or
service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as
Medicare and Medicaid;
•
federal civil and criminal false claims laws, including, without limitation, the federal civil False Claims Act which
permits private individuals, on behalf of the government, to bring civil whistleblower or qui tam actions to enforce the
law, prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the
federal government, including federal health care programs, such as, the Medicare and Medicaid programs, claims for
payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money
to the federal government;
•
the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is
determined to have presented or caused to be presented a claim to a federal health program that the person knows or
should know is for an item or service that was not provided as claimed or is false or fraudulent;

52
•
the Health Insurance Portability and Accountability Act, or HIPAA, which created additional federal civil and criminal
statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is
public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing
a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any
trick or device a material fact or making any materially false statements in connection with the delivery of, or payment
for, healthcare benefits, items or services relating to healthcare matters;
•
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2019, or HITECH,
and their respective implementing regulations, which impose obligations on “covered entities,” including certain
healthcare providers, health plans, and healthcare clearinghouses, as well as their respective “business associates” that
create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity and
their subcontractors that use, disclose, access, or otherwise process individually identifiable health information, with
respect to safeguarding the privacy, security and transmission of individually identifiable health information;
•
the Physician Payments Sunshine Act, created under Section 6002 of the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act, imposed
annual reporting requirements for certain manufacturers of drugs, devices, biologics and medical supplies for certain
payments and “transfers of value” provided to physicians (defined to include doctors, dentists, optometrists, podiatrists,
and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching
hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and
•
analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors,
including private insurers; state and foreign laws that require pharmaceutical companies to comply with the
pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the
federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict
payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report
information related to payments and other transfers of value to physicians and other healthcare providers or marketing
expenditures; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign
laws governing the privacy and security of health information in certain circumstances, many of which differ from each
other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Further, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and
the healthcare fraud statute. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate
them in order to have committed a violation. In addition, the Affordable Care Act provided that the government may assert that a
claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim
for purposes of the federal civil False Claims Act.
Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and
regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not
comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our
operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be
subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment,
disgorgement, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting
requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of
non-compliance with these laws, and the curtailment or restructuring of our operations, as well as reputational harm, which could
significantly harm our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business,
including future collaborators, are found not to be in compliance with applicable laws, they may be subject to the same criminal, civil
and administrative sanctions, including exclusions from participation in government healthcare programs, which could also affect our
business.
Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and
commercialize our product candidates and affect the prices we may obtain.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or
regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing
approval.

53
Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United
States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative
initiatives. In March 2010, the Affordable Care Act was signed into law, which intended to broaden access to health insurance, reduce
or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the
healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy
reforms.
There have been judicial and congressional challenges and amendments to certain aspects of the Affordable Care Act For
example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which, among other things, extends
enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025.
The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the
beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how any additional
healthcare reform measures of the second Trump administration will impact the Affordable Care Act and our business.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These
changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April
2013 and, due to subsequent legislative amendments, will stay in effect through 2032, unless additional Congressional action is taken.
Additionally, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs,
beginning January 1, 2024. These new laws may result in additional reductions in Medicare and other healthcare funding, which could
negatively impact customers for our product candidates, if approved, and, accordingly, our financial operations.
Further, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for
their marketed products, which have resulted in several Congressional inquiries and proposed and enacted federal and state legislation
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement
methodologies for drug products. For example, the IRA, among other things, (i) directs the U.S. Department of Health and Human
Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs biologics that have been on the market for at
least 7 years covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering
a price that is not equal to or less than the negotiated “maximum fair price” for such drugs and biologics under the law (the “Medicare
Drug Price Negotiation Program”), and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B
or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions
through guidance, as opposed to regulation, for the initial years. These provisions began to effect starting in fiscal year 2023. On
August 15, 2024, HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations, although the
Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen
additional drugs covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become
subject to the Medicare Drug Price Negotiation Program. Further, on December 7, 2023, an initiative to control the price of
prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8, 2023, the National
Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise
of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise
march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new
framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing.
We expect that other healthcare reform measures that may be adopted in the future, particularly in light of the recent U.S.
Presidential and Congressional elections, may result in additional reductions in Medicare and other healthcare funding, more rigorous
coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved
product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to
generate revenue, attain profitability, or commercialize our drugs.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional
activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations,
guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates,
if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent
marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.

54
Governments outside the United States tend to impose strict price controls, which may affect our revenue, if any.
In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the
receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be
required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If
reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could
be harmed, possibly materially.
Risks Related to Ownership of Our Common Stock
The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial
losses.
Our stock price has been and may continue to be volatile. The stock market in general and the market for biopharmaceutical
companies in particular have experienced extreme volatility that has often been unrelated or disproportionate to the operating
performance of particular companies. Broad market and industry factors, including potentially worsening economic conditions,
inflation and other adverse effects or developments may negatively affect the market price of our common stock, regardless of our
actual operating performance. As a result of this volatility, investors may not be able to sell their common stock at or above the price
paid for the shares. The market price for our common stock may be influenced by many factors, including:
•
actual or anticipated variations in our operating results;
•
changes in financial estimates by us or by any securities analysts who might cover our stock;
•
conditions or trends in our industry;
•
changes in the structure of healthcare payment systems;
•
stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the
biopharmaceutical industry;
•
announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
•
announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
•
capital commitments;
•
investors’ general perception of us and our business;
•
recruitment or departure of key personnel;
•
sales of our common stock, including sales by our directors and officers or specific stockholders; and
•
general political and economic conditions.
In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies
following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to
incur substantial costs and divert management’s attention and resources from our business.
If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or
our market, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that equity research analysts publish
about us and our business. Equity research analysts may elect not to initiate or to continue to provide research coverage of our
common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we do have
equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports.
The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable
commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us
regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.

55
The issuance of additional stock and other equity-linked securities in connection with financings, acquisitions, investments, our
stock incentive plans or otherwise will dilute all other stockholders.
Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible
into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or
otherwise. For example, we, among other things, issued warrants to purchase 11,111,111 shares of common stock to certain investors
in a registered direct offering, all of which were outstanding as of March 24, 2025. The exercise of our outstanding warrants could
result in significant dilution to existing stockholders, adversely affect the market price of our common shares and impair our ability to
raise capital through the sale of additional equity securities. In addition, the expectation of such exercises could encourage the short
selling of our common stock, which could place further downward pressure on the trading price of our common stock. Any such
issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.
If we fail to meet all applicable requirements of Nasdaq and Nasdaq determines to delist our common stock, the delisting could
adversely affect the market liquidity of our common stock and the market price of our common stock could decrease.
On February 7, 2025, we received a letter from Nasdaq, notifying us that, from December 18, 2024 to February 4, 2025, the
closing bid price for our common stock was below $1.00. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) we were provided an
initial period of 180 calendar days, or until August 6, 2025, to regain compliance with Nasdaq’s bid price requirement. If, at any time
before August 6, 2025, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business days,
we will regain compliance with the bid price requirement, unless Nasdaq staff exercises its discretion to extend this 10-day period
pursuant to Nasdaq rules.
There can be no assurance that we will regain compliance with the requirements for listing our common stock on Nasdaq. If we
are unable to satisfy the Nasdaq criteria for continued listing, our common stock would be subject to delisting. A delisting of our
common stock could negatively impact us by, among other things, reducing the liquidity and market price of our common stock;
reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise
equity financing; decreasing the amount of news and analyst coverage of us; and limiting our ability to issue additional securities or
obtain additional financing in the future. In addition, delisting from Nasdaq may negatively impact our reputation and, consequently,
our business.
If a significant number of our shares are sold into the market, it could cause the market price of our common stock to drop
significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders
sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the
market price of our common stock could decline significantly. All of our outstanding shares of common stock are available for sale in
the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates.
In addition, we have filed registration statements on Form S-8 registering the issuance of shares of common stock subject to
options or other equity awards issued or reserved for future issuance under our equity incentive plans. These registered shares will be
available for sale in the public market subject to vesting arrangements and exercise of options and, in the case of our affiliates, the
restrictions of Rule 144.
Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to
change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may
be lower as a result.
There are provisions in our certificate of incorporation and bylaws that may make it difficult for a third party to acquire, or
attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For
example, our board of directors has the authority to issue up to 10,000,000 shares of preferred stock. The board of directors can fix the
price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The
issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our
common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock
may result in the loss of voting control to other stockholders.
Our charter documents also contain other provisions that could have an anti-takeover effect, including:
•
only one of our three classes of directors are elected each year;
•
stockholders are not entitled to remove directors other than by a 66 2⁄3% vote and only for cause;

56
•
stockholders are not permitted to take actions by written consent;
•
stockholders cannot call a special meeting of stockholders; and
•
stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder
meetings.
In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which
regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with
particular stockholders of those companies. These provisions could discourage potential acquisition proposals and could delay or
prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our
common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our
management or limit the price that investors are willing to pay for our stock.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive
forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a
favorable judicial forum for disputes with us or our directors, officers or employees.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the
exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action
or proceeding brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors,
officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the
Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws or (iv)
any action asserting a claim governed by the internal affairs doctrine. However, this exclusive forum provision would not apply to
suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act. The choice of forum provision may limit
a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other
employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court
were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or
unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could
adversely affect our business and financial condition.
We are a “smaller reporting company” and as a result of the reduced disclosure and governance requirements applicable to
smaller reporting companies, our common stock may be less attractive to investors.
We are a “smaller reporting company,” meaning that the market value of our shares held by non-affiliates is less than $700
million and our annual revenue was less than $100 million during the most recently completed fiscal year. We will continue to be a
smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual
revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-
affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of
audited financial statements in our Annual Report on Form 10-K and we have reduced disclosure obligations regarding executive
compensation. In addition, as a smaller reporting company and non-accelerated filer, we are not required to comply with the auditor
attestation requirements of Section 404 of the Sarbanes-Oxley Act.
We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some
investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be
lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities
may be more volatile.
We have broad discretion in the use of our cash and cash equivalents and may invest or spend our cash in ways with which
investors do not agree.
We have broad discretion over the use of our cash and cash equivalents. Investors may not agree with our decisions, and our use
of our cash may not yield any return on investment. Our failure to apply our resources effectively could compromise our ability to
pursue our growth strategy. Investors will not have the opportunity to influence our decisions on how to use our cash and cash
equivalents.

57
Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if
any, will be the sole source of gains and investors may never receive a return on their investment.
Investors should not rely on an investment in our common stock to provide dividend income. We have not declared or paid cash
dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth
of our business. In addition, our prior loan agreement prohibited us from paying dividends without the consent of the lenders under the
agreement, and we expect that the terms of any future debt agreements would likewise preclude us from paying dividends. As a result,
capital appreciation, if any, of our common stock will be investors’ sole source of gain for the foreseeable future. Investors seeking
cash dividends should not purchase our common stock.
General Risk Factors
If our information technology systems or those third parties upon which we rely or our data are or were compromised, we could
experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or
actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and
other adverse consequences.
In the ordinary course of our business, we and the third parties upon which we rely, process, collect, receive, store, process,
generate, use, transfer, disclose, and share proprietary, confidential, and sensitive data, including personal data (such as health-related
data), intellectual property, and trade secrets.
Our internal computer systems, and those of our CROs, contract manufacturing organizations and other third parties on whom
we rely, are vulnerable to damage from computer viruses, unauthorized access, security breaches, natural disasters, terrorism, war and
telecommunication and electrical failures. Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent
and continue to increase. These threats are becoming increasingly difficult to detect and threaten the confidentiality, integrity, and
availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. These
threats come from a variety of sources. In addition to traditional computer “hackers,” threat actors, personnel (such as through theft or
misuse), sophisticated nation-states, and nation-state-supported actors now engage in attacks. We and the third parties upon which we
rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing
attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-
of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software
bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware,
telecommunications failures, earthquakes, fires, floods, and other similar threats.
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security
incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines,
penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information
(including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm;
monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial
loss; and other similar harms.
Remote work has increased risks to our information technology systems and data, as our employees may utilize network
connections, computers and devices outside our premises or network, including working at home, while in transit and in public
locations.
Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and
vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and
technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated
entities, and it may be difficult to integrate companies into our information technology environment and security program.
We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in
a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication
technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties’ information
security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party
service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be
entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may
be insufficient to cover our damages, or we may be unable to recover such award.

58
In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties’
infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised. While we have implemented
security measures designed to protect against security incidents, there can be no assurance that these measures will be effective.
Any of the foregoing could result in a material disruption of our clinical and product development activities and business
operations, in addition to possibly requiring substantial expenditures of resources to remedy. For example, the loss or compromise of
clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. To the extent that any disruption or security incident was to result in a loss or
damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, or any personal data for
which we are responsible, we could incur significant unexpected losses, expenses and liabilities, we could face litigation or suffer
reputational harm and the further development of our product candidates could be delayed. Our contracts may not contain limitations
of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us
from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage
will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such
coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.
We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules,
contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third
parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or
actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business
operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.
In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect,
secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and
confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials,
sensitive third-party data, and other sensitive data the Company may process, e.g., business plans, transactions, or financial
information. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws,
regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other
obligations relating to data privacy and security.
In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data
breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act),
and other similar laws (e.g., wiretapping laws). For example, the federal Health Insurance Portability and Accountability Act of 1996
(“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, imposes specific
requirements relating to the privacy, security, and transmission of individually identifiable protected health information.
Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses,
including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data.
As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data
processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact
our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain
personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for
statutory fines for noncompliance.
For example, the California Consumer Privacy Act of 2018, or CCPA, applies to personal data of consumers, business
representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices
and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional
violation and allows private litigants affected by certain data breaches to recover significant statutory damages. The CCPA and other
comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may
further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties with whom we work, and
our customers. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more
states to pass similar laws in the future.
Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and
security. For example, the European Union’s General Data Protection Regulation, or EU GDPR, and the United Kingdom’s GDPR, or
UK GDPR (collectively, “GDPR”), Australia’s Privacy Act, and China’s Personal Information Protection Law, or PIPL, impose strict
requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data
processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the

59
UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal
data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.
We also target customers in Asia and may be subject to new and emerging data privacy regimes in Asia, including China’s
Personal Information Protection Law, Japan’s Act on the Protection of Personal Information, and Singapore’s Personal Data
Protection Act. For example, China’s PIPL imposes a set of specific obligations on covered businesses in connection with their
processing and transfer of personal data and imposes fines of up to RMB 50 million or 5% of the prior year’s total annual revenue of
the violator. India’s new privacy legislation, the Digital Personal Data Protection Act, or DPDP, may also apply to our operations.
In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or
other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal
data to other countries. In particular, the European Economic Area, or EEA, and the United Kingdom have significantly restricted the
transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other
jurisdictions may adopt or have already adopted similarly stringent data localization and cross-border data transfer laws.
Although there are currently various mechanisms that may be used to transfer personal data from the EEA and United Kingdom
to the United States in compliance with law, such as the EEA standard contractual clauses, the United Kingdom’s International Data
Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the United Kingdom extension thereto (which allows
for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms
are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal
data to the United States.
If there is no lawful manner for us to transfer personal data from the EEA, the United Kingdom or other jurisdictions to the
United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences,
including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing
activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and
penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing
or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA
and United Kingdom to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators,
individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease
certain transfers out of Europe for allegedly violating the GDPR’s cross-border data transfer limitations.
We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such
obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to
impose specific contractual restrictions on their service providers. We also publish privacy policies, marketing materials, whitepapers,
and other statements concerning data privacy and security. Regulators in the United States are increasingly scrutinizing these
statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair,
misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other
adverse consequences.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or
incur costs that could harm our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of
hazardous materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We
generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or
injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held
liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with
civil or criminal fines and penalties for failure to comply with such laws and regulations.
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our
employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential
liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection
with our storage or disposal of biological or hazardous materials.
In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and
regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to
comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

60
The 2017 comprehensive tax reform bill, as modified by the CARES Act, the Inflation Reduction Act, and possible future changes
in tax laws or regulations could adversely affect our business and financial condition.
The Tax Act, signed into law on December 22, 2017, significantly revised the Internal Revenue Code of 1986, as amended, or
the Code. In March 2020, the Tax Act was modified in certain respects by the Coronavirus Aid, Relief, and Economic Security
(CARES) Act. More recently, the Inflation Reduction Inflation of 2022, or the IRA, was enacted which includes provisions that
impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large
corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such
stock. Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to the Tax Act, as modified by
the CARES Act, and the IRA, may affect us, and certain aspects of the Tax Act, CARES Act and IRA could be repealed or modified
in future legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the
taxation of foreign earnings, and the deductibility of expenses under the Tax Act, the CARES Act, the IRA, or future tax reform
legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the
current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future
changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. In
addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, the IRA, or any newly
enacted federal tax legislation.
Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a
combination of applicable tax rates in the various places in which we operate. In preparing our financial statements, we estimate the
amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced
in the past due to numerous factors, including changes in the mix of our profitability from state to state, the results of examinations
and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for
income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different
from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial
statements.
We plan to use potential future operating losses and our federal and state NOL carryforwards to offset future taxable income, if
any. However, our ability to use existing NOL carryforwards could be limited as a result of issuances of equity securities.
As of December 31, 2024, we had $240.6 million of federal and $96.1 million of state net operating loss, or NOL,
carryforwards. If not utilized, the portion of these federal NOL carryforwards arising in tax years beginning before 2018 will begin to
expire at various dates beginning in 2034, and these state NOL carryforwards will begin to expire at various dates beginning in 2027.
Under the Tax Act, as modified by the CARES Act, federal NOLs incurred in taxable years beginning in 2018 and in later years may
be carried forward indefinitely, but the deductibility of such federal NOLs is limited for taxable years beginning after 2021 to 80% of
taxable income. Certain states have conformed to the federal NOL rules included in the Tax Act and CARES Act. However, under
Section 382 of the Code of 1986, as interpreted by the U.S. Internal Revenue Service, the amount of benefits from our NOL
carryforwards may be impaired or limited if we incur ownership changes. The completion of our IPO, follow-on public offerings,
private placements and other transactions that have occurred, and future offerings of our securities have triggered, and may in the
future trigger additional, ownership changes.
In addition, since we will need to raise substantial additional funding to finance our operations, we may undergo ownership
changes in the future. Any such additional limitations may significantly reduce the value of our NOL carryforwards before they
expire, which could result in greater tax liabilities than we would incur in the absence of such limitations. At the state level, there may
be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or
permanently increase state taxes owed.
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis
could be impaired.
We are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act and the rules and
regulations of The Nasdaq Stock Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure
controls and procedures and internal control over financial reporting. Because we are a smaller reporting company and a non-
accelerated filer, we are not required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.
However, we must perform system and process evaluation and testing of our internal control over financial reporting to allow
management to report on the effectiveness of our internal control over financial reporting in this report and future annual reports on
Form 10-K, as required by Section 404 of the Sarbanes-Oxley Act. This requires that we incur substantial additional professional fees
and internal costs to expand our accounting and finance functions and that we expend significant management efforts.

61
We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a
material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and
all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the
control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can
provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will
be detected.
If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are
unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If
that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by The Nasdaq
Stock Market, the Securities and Exchange Commission or other regulatory authorities.
We incur significant costs and demands upon management as a result of being a public company.
As a public company listed in the United States, we incur significant legal, accounting and other costs, which we expect to
increase if we cease to be a smaller reporting company under SEC rules. These additional costs could negatively affect our financial
results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including
regulations implemented by the SEC and The Nasdaq Stock Market, may increase legal and financial compliance costs and make
some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to
invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and
administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance
activities.
If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities
may initiate legal proceedings against us and our business may be harmed. Failure to comply with these rules might also make it more
difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept
reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these
events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees
of our board of directors or as members of senior management.
Climate change, extreme weather events, earthquakes and other natural disasters could adversely affect our business.
In recent years, extreme weather events and changing weather patterns such as storms, flooding, droughts, fires and temperature
changes have become more common. As a result, we are potentially exposed to varying natural disaster or extreme weather risks such
as hurricanes, tornadoes, fires, droughts or floods, or other events that may result from the impact of climate change on the
environment, such as sea level rise. The potential impacts of climate change may also include increased operating costs associated
with additional regulatory requirements and investments in reducing energy, water use and greenhouse gas emissions.
Adverse global economic conditions and geopolitical tensions could have a negative effect on our business, results of operations
and financial condition and liquidity.
In recent years, concerns about the global economic outlook have adversely affected market and business conditions in general.
Macroeconomic weakness and uncertainty could make it more difficult for us or the licensing partners on whom we depend to
commercialize XIPERE to manage our respective operations. Geopolitical tensions, such as Russia’s recent incursion into Ukraine,
ongoing conflicts between the United States and China, tariff and trade policy changes, economic sanctions and increasing potential of
conflict involving countries in Asia, including countries that are part of the Arctic Territory under our license agreement with Arctic
Vision, create uncertainty for us and for global commerce generally. Sustained or worsening of global economic conditions and
increasing geopolitical tensions may increase our cost of doing business, limit our ability to access capital, disrupt our supply chain
operations or the supply chain operations of our licensing partners and intensify pricing pressures. Any or all of these factors could
negatively affect our business, financial condition and result of operations.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.

62
ITEM 1C. CYBERSECURITY
Risk management and strategy
We have implemented and maintain various information security processes designed to identify, assess and manage material
risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and
software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in
nature, and trade secrets, data we may collect about trial participants in connection with clinical trials, sensitive third-party data,
business plans, transactions, and financial information, or collectively Information Systems and Data.
Our cybersecurity function, which comprises, in part, our information technology team, helps identify, assess and manage our
cybersecurity threats and risks. Our cybersecurity function identifies and assesses risks from cybersecurity threats by monitoring and
evaluating our threat environment using various methods including, for example, manual tools, internal or external audits, automated
tools, subscribing to and analyzing reports and services that identify cybersecurity threats and threat actors, conducting threat
assessments for internal and external threats, conducting scans of the threat environment, evaluating our (and our industry’s) risk
profile, using external intelligence feeds, conducting vulnerability assessments to identify vulnerabilities, and evaluating threats
reported to us. Depending on the environment, we implement and maintain various technical, physical, and organizational measures
and processes designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data,
including, for example: incident detection and response, an incident response plan, a vendor risk management program, employee
training, data encryption, access controls, physical security, network security controls, systems monitoring, cyber insurance, and asset
management, tracking, and disposal.
Our assessment and management of material risks from cybersecurity threats are integrated into the Company’s overall risk
management processes. For example, the cybersecurity function works with management to prioritize our risk management processes
and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.
We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from
cybersecurity threats, including for example professional services firms (including legal counsel), threat intel service providers, and
cybersecurity software providers. We also use third-party service providers to perform a variety of functions throughout our business,
such as hosting companies, application providers, contract research organizations, supply chain resources, and contract manufacturing
organizations. We manage cybersecurity risks associated with our use of these providers by conducting audits and risk assessments on
certain vendors, requesting and analyzing responses on a security questionnaire, and reviewing relevant reports.
For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see
our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including “—If our information technology
systems or those third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences
resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties;
disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.”.
Governance
Our board of directors addresses the Company’s cybersecurity risk management as part of its general oversight function. The
audit committee is responsible for overseeing Company’s cybersecurity risk management processes, including oversight and
mitigation of risks from cybersecurity threats.
Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of
management, including our Senior Director of Information Technology, who has over 23-years of experience in IT management
(including cybersecurity) and a degree in Computer Information Systems.
Our Senior Director of IT, as part of our overall cybersecurity function, is responsible for hiring appropriate personnel, helping
to integrate cybersecurity risk considerations into the Company’s overall risk management strategy, and communicating key priorities
to relevant personnel. Our Chief Financial Officer, or CFO, is responsible for approving budgets, helping prepare for cybersecurity
incidents, approving cybersecurity processes, and reviewing security assessments and other significant security-related incidents.
Our response process to cybersecurity incidents is designed to escalate certain incidents to members of management depending
on the circumstances, including the CFO. Our CFO and Senior Director of IT work with the Company’s incident response team to
help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company’s incident
response policy includes reporting to the board of directors committee responsible for certain cybersecurity incidents.

63
The audit committee receives an annual update from our cybersecurity function concerning the Company’s significant
cybersecurity threats and risk and the processes the Company has implemented to address them. In addition, they receive timely
notifications of significant cybersecurity incidences based on our cybersecurity response plan. The audit committee also has access to
various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.
ITEM 2. PROPERTIES
Our principal offices occupy approximately 14,000 square feet of office space in Alpharetta, Georgia under a lease with an
initial term until November 2026, with a renewal option for one additional three-year term.
We believe that our current leased facilities are suitable and adequate to meet our current and anticipated needs. We believe that
suitable additional or substitute space will be available as needed to accommodate any expansion of our operations.
ITEM 3. LEGAL PROCEEDINGS
We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal
proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASE OF EQUITY SECURITIES
Market Information for Common Stock
Our common stock is listed on The Nasdaq Global Market under the symbol “CLSD.”
Dividend Policy
We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings,
if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future.
Stockholders
As of March 24, 2025, we had 77,143,872 shares of common stock outstanding held by 7 holders of record. The actual number
of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares
are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose
shares may be held in trust by other entities.
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Parties
None.
ITEM 6. [Reserved].

64
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with
the consolidated financial statements and the related notes to those statements included later in this Annual Report. In addition to
historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs
and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those
discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed
below and elsewhere in this Annual Report, particularly in Item 1A. “Risk Factors” and “Special Note Regarding Forward-Looking
Statements.”
Overview
We are a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the
suprachoroidal space, or SCS. Our SCS injection platform, utilizing our proprietary SCS Microinjector, enables an in-office,
repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina
or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Our suprachoroidal injection
technology can be used in conjunction with existing drugs designed for delivery to the SCS, novel therapies, and future therapeutic
innovations. We believe our proprietary suprachoroidal administration platform has the potential to become a standard for delivery of
therapies intended to treat chorioretinal diseases.
We are leveraging our SCS injection platform by building an internal research and development pipeline targeting retinal
diseases and by creating external collaborations with other companies. We are developing our own pipeline of small molecule product
candidates for administration via our SCS Microinjector, and we also strategically partner with companies developing other
ophthalmic therapeutic innovations to be administered using our SCS injection platform. Our first product, XIPERE (triamcinolone
acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration, or the FDA, in
October 2021. Approval of XIPERE was a significant milestone for us as it is the first approved therapeutic delivered into the SCS,
the first commercial product developed by us, and the first therapy for macular edema associated with uveitis.
Our operations to date have been limited to organizing and staffing our company, raising capital, conducting preclinical studies
and clinical trials and undertaking other research and development initiatives. To date, we have only generated revenue through
upfront payments and milestone payments related to license agreements and other revenue generated from collaboration agreements.
We have primarily financed our operations through public offerings and private placements of our equity securities, issuances of
convertible promissory notes and loan agreements. As of December 31, 2024, we had an accumulated deficit of $355.3 million. We
recorded net losses of $34.4 million, $32.5 million and $32.9 million for the years ended December 31, 2024, 2023 and 2022,
respectively. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on
completing the necessary development for and obtaining regulatory approval of CLS-AX, as well as discovering compounds and
developing proprietary therapeutics to utilize with our SCS Microinjector.
We expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to
generate significant product or license and other revenue unless and until XIPERE is successfully commercialized by its licensees or
until we successfully complete development of, obtain regulatory approval for and commercialize additional product candidates, either
on our own or together with a third party. Our financial results may fluctuate significantly from quarter to quarter and year to year,
depending on the timing of our clinical trials and our expenditures on other research and development activities. We expect clinical
trial expenses to increase in 2025 as a result of our planned Phase 3 clinical trial of CLS-AX as well as continuing our pipeline
development. We also will continue our efforts to seek to discover, research and develop additional product candidates and seek
regulatory approvals in additional regions for XIPERE for the treatment of macular edema associated with uveitis. Based on our
current research and development plans, we expect to have sufficient resources to fund our planned operations into the fourth quarter
of 2025. We will require additional capital in order to complete clinical development of CLS-AX.
These factors raise substantial doubt regarding our ability to continue as a going concern. Our consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the
recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result should we
be unable to continue as a going concern.
Components of Operating Results
License and Other Revenue

65
We have not generated any revenue from the sale of XIPERE and we do not expect to generate any other product revenue unless
or until we obtain regulatory approval of and commercialize our other product candidates, either on our own or with a third party. The
revenue received under the Bausch license agreement, as well as other certain payments from our licensees, will be recorded as non-
cash revenue until we have fulfilled our obligations under the Purchase and Sale Agreement. Our revenue in recent years has been
generated primarily from our license agreements. We continue to seek to enter into additional license and other agreements with third
parties to evaluate the potential use of our proprietary SCS Microinjector with the third party’s product candidates for the treatment of
various eye diseases. These agreements may include payments to us for technology access, upfront license payments, regulatory and
commercial milestone payments and royalties.
Cost of Goods Sold
Cost of goods sold are related to the sales of our SCS Microinjector kits to our licensees for approved products.
Research and Development
Research and development expenses consist primarily of costs incurred for the research and development of our preclinical and
clinical product candidates, which include:
•
employee-related expenses, including salaries, benefits, travel and share-based compensation expense for research and
development personnel;
•
expenses incurred under agreements with contract research organizations, or CROs, as well as contract manufacturing
organizations and consultants that conduct clinical trials and preclinical studies;
•
costs associated with preclinical activities and clinical trials;
•
costs associated with submitting regulatory approval applications for our product candidates;
•
costs associated with training physicians on the suprachoroidal injection procedure and educating and providing them with
appropriate product candidate information;
•
costs associated with technology and intellectual property licenses;
•
costs for our research and development facility; and
•
depreciation expense for assets used in research and development activities.
We expense research and development costs to operations as incurred. These costs include preclinical activities, such as
manufacturing and stability and toxicology studies, that are supportive of a product candidate itself. In addition, there are expenses
related to clinical trials and similar activities for each program, including costs associated with CROs. Clinical costs are recognized
based on the terms of underlying agreements, as well as an evaluation of the progress to completion of specific tasks using data such
as patient enrollment, clinical site activations and additional information provided to us by our vendors about their actual costs
incurred. Expenses related to activities that support more than one development program or activity, such as salaries, share-based
compensation and depreciation, are not classified as direct preclinical costs or clinical costs and are separately classified as
unallocated.
The following table shows our research and development expenses by program for the years ended December 31, 2024, 2023
and 2022.
Year Ended
December 31,
2024
2023
2022
(in thousands)
XIPERE (uveitis program)
$
85
$
132
$
339
CLS-AX (wet AMD program)
6,428
9,170
5,449
Total program expense
6,513
9,302
5,788
Unallocated
12,077
11,544
13,842
Total research and development expense
$
18,590
$
20,846
$
19,630
Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator
sites as well as estimates for the services received and efforts expended under contracts with research institutions, consultants and
CROs that conduct and manage clinical trials on our behalf. We generally accrue expenses related to clinical trials based on contracted

66
amounts applied to the level of patient enrollment and activity according to the protocol. If future timelines or contracts are modified
based upon changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued
expenses accordingly on a prospective basis.
Research and development activities are central to our business model. Product candidates in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily due to the
increased size and duration of later-stage clinical trials. However, it is difficult to determine with certainty the duration and completion
costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will
generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may
never succeed in achieving regulatory approval for any of our product candidates.
The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors
that may include, among other things, the following:
•
the costs associated with process development, scale-up and manufacturing of our product candidates including the SCS
Microinjector for clinical trials and for requirements associated with regulatory filings;
•
the number of trials required for approval and any requirement for extension trials;
•
per patient trial costs;
•
the number of patients that participate in the trials;
•
the number of sites included in the trials;
•
the countries in which the trials are conducted;
•
the length of time required to enroll eligible patients;
•
the number of doses that patients receive;
•
the drop-out or discontinuation rates of patients;
•
potential additional safety monitoring or other studies requested by regulatory agencies;
•
the duration of patient follow-up; and
•
the efficacy and safety profiles of the product candidates.
In addition, the probability of success for each product candidate will depend on numerous factors, including competition,
manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program
in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate’s
commercial potential.
General and Administrative
General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation,
for personnel in executive, finance and administrative functions. General and administrative costs historically included commercial
pre-launch preparations for XIPERE, and also include facility related costs not otherwise included in research and development
expenses, as well as professional fees for legal, patent, consulting, and accounting and audit services.
Interest Income
Interest income consists of the accrued interest and interest income earned on our cash and cash equivalents.

67
Other Income, Net
Other income, net consists of expenses allocated to the warrants issued in connection with our registered direct offering in
February 2024 and the change in fair value of the warrants during the period.
Non-cash Interest Expense on Liability Related to the Sales of Future Royalties
Non-cash interest expense on liability related to the sales of future royalties consists of imputed interest on the carrying value of
the liability and the amortization of the related issuance costs.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated
financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The
preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the consolidated balance
sheets and the reported amounts of expenses during the reporting periods. In accordance with U.S. GAAP, we evaluate our estimates
and judgments on an ongoing basis. Significant estimates include certain assumptions used in royalty financing obligation, certain
assumptions used in the valuation of warrant liabilities and certain assumptions used to estimate research and development expenses,
including clinical trials. We base our estimates on historical experience and on various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or
conditions.
We define our critical accounting policies, in accordance with U.S. GAAP, as those that require us to make subjective estimates
and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of
operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully
described in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the
following are the critical accounting policies used in the preparation of our consolidated financial statements that require significant
estimates and judgments.
Revenue recognition
We recognize revenue from our contracts with customers under Financial Accounting Standards Board, or FASB, Accounting
Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, or ASC 606. Under ASC 606, we recognize
revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of promised goods
or services to customers. To determine revenue recognition for contracts with customers that are within the scope of ASC 606, we
perform the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3)
determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize
revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable
that we will collect the consideration we are entitled to in exchange for the goods or services transferred to the customer.
As part of the accounting for our revenue arrangements, we develop assumptions that require judgment such as the estimate of
the stand-alone selling price for each performance obligation identified in the contract.
Licenses of intellectual property: If the license to our intellectual property is determined to be distinct from the other
performance obligations identified in the arrangement, we recognize revenue allocated to the license when the license is transferred to
the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promised goods or
services, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined
performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for
purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of
performance and related revenue recognition.
Milestone Payments: At the inception of each arrangement that includes development, commercialization, and regulatory
milestone payments, we evaluate whether the achievement of the milestones is considered probable and estimate the amount to be
included in the transaction price using the most likely amount method. Performance milestone payments represent a form of variable
consideration. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the
transaction price. Achievement of milestones that are not within our or our licensee’s control, such as regulatory approvals, are not

68
considered probable until the approvals are achieved. The transaction price is then allocated to each performance obligation on a
relative stand-alone selling price basis and we recognize revenue as or when the performance obligations under the contract are
satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related
constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative
catch-up basis, which would affect revenues and earnings in the period of adjustment.
Manufacturing Supply Services: Arrangements that include a promise for future supply of drug substance or drug product for
either clinical development or commercial supply at the customer’s discretion are generally considered options. The arrangements
may also include assistance and oversight of the customer’s use of the drug substance or drug product. We assess if these options
provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the
arrangement.
Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and
the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related
sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or
partially satisfied). To date, we have not received any royalty revenue resulting from any of our licensing arrangements.
Accrued expenses
As part of the process of preparing our consolidated financial statements, we are required to estimate accrued expenses. This
process involves reviewing open contracts and purchase orders, communicating with applicable vendor personnel to identify services
that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service
when we have not yet been invoiced or otherwise notified of actual cost. We make estimates of our accrued expenses as of each
consolidated balance sheet date in our consolidated financial statements based on facts and circumstances known to us. We
periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of
estimated accrued expenses include fees paid to CROs and investigative sites in connection with clinical trials.
We accrue our expenses related to clinical trials based on our estimates of the services received and efforts expended pursuant to
contracts with multiple research institutions and CROs that conduct research activities or manage clinical trials on our behalf. The
financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows.
Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical
trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to
be expended in each period. If the level of effort varies from our estimate, we will adjust the accrual accordingly. If we underestimate
or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.
Although we do not currently anticipate the future settlement of existing accruals to differ materially from our estimates, our
understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary
and could result in us reporting amounts that are too high or too low for any period.
Share-based compensation
Compensation cost related to share-based awards granted to employees, directors and consultants is measured based on the
estimated fair value of the award at the grant date. We estimate the fair value of stock options using a Black-Scholes option pricing
model. Share-based compensation costs are expensed on a straight-line basis over the relevant vesting period. The fair value of
restricted stock units, or RSUs, granted is measured based on the market value of our common stock on the date of grant and is
recognized ratably over the requisite service period, which is generally the vesting period of the awards. All share-based compensation
costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based
upon the underlying employees’ roles.
Determining the appropriate fair value measurement of share-based awards requires the use of subjective assumptions. The
determination of the fair value measurement of options using the Black-Scholes option pricing model is affected by our estimated
common stock fair values as well as assumptions regarding a number of other subjective variables. These other variables include the
expected term of the options, our expected stock price volatility over the expected term of the options, stock option exercise, risk-free
interest rates and expected dividends.

69
We estimate the fair value of stock options at the grant date using Black-Scholes option pricing model with the following
assumptions:
•
Fair value of our common stock. The fair value of our common stock is the closing price of our common stock on The
Nasdaq Global Market on the date of grant.
•
Volatility. We calculate expected volatility based on the historical volatility of our common stock.
•
Expected term. We calculate the expected term using historical data.
•
Risk-free rate. The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the
expected time to liquidity.
•
Forfeitures. Forfeitures are accounted for as they occur.
•
Dividend yield. We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the
foreseeable future.
We have an employee stock purchase plan that is considered a compensatory plan. The fair value of the discount and the look-
back period of the employee stock purchase plan are estimated using the Black-Scholes option pricing model and expense is
recognized over the six-month withholding period prior to the purchase date.
Share-based compensation expense related to stock options, the employee stock purchase plan and RSUs aggregated $4.5
million, $4.2 million and $4.9 million for the years ended December 31, 2024, 2023 and 2022, respectively.
Liabilities Related to the Sales of Royalties and Non-Cash Interest Expense
In connection with the Purchase and Sale Agreement, we recognized a liability related to the sales of future royalties under ASC
470-10 Debt and ASC 835-30 Interest - Imputation of Interest. The initial funds received by us pursuant to the terms of the Purchase
and Sale Agreement were recorded as a liability and are accreted under the effective interest method up to the estimated amount of
future royalties and milestone payments to be made under the Purchase and Sale Agreement. The issuance costs were recorded as a
direct deduction to the carrying amount of the liability and are being amortized under the effective interest method over the estimated
period the liability will be repaid. We estimate the total amount of future royalty revenue and milestone payments to be generated over
the life of the Purchase and Sale Agreement, and a significant increase or decrease in these estimates could materially impact the
liability balance and the related interest expense. If the timing of the receipt of royalty payments or milestones is materially different
from the original estimates, we will prospectively adjust the effective interest and the related amortization of the liability and related
issuance costs.
Warrant Liabilities
We account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s
specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815,
Derivatives and Hedging (ASC 815). The assessment considers whether the warrants (i) are freestanding financial instruments
pursuant to ASC 480, (ii) meet the definition of a liability pursuant to ASC 480, and (iii) meet all of the requirements for equity
classification under ASC 815, including whether the warrants are indexed to our own stock and whether the warrant holders could
potentially require “net cash settlement” in a circumstance outside of our control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each
subsequent quarterly period end date while the warrants are outstanding.
For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital, on the consolidated statement of stockholders’ deficit at the time of issuance. For warrants that do not meet all the
criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and on each
consolidated balance sheet date thereafter.
Our warrant liabilities are measured at fair value using a simulation model which takes into account, as of the valuation date,
factors including the current exercise price, the expected life of the warrant, the current price of our common stock, the expected
volatility, holding cost, the risk-free interest rate for the term of the warrant and the likelihood of achieving certain future milestone
events and the related impact to the price of our common stock. The warrant liabilities are revalued at each reporting period and
changes in fair value are recognized in other income, net in the consolidated statements of operations. The selection of the appropriate
valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires
management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the
change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known.

70
Results of Operations for the Years Ended December 31, 2024 and 2023
The following table sets forth our results of operations for the years ended December 31, 2024 and 2023.
Year Ended
Period-to-
December 31,
Period
2024
2023
Change
(in thousands)
License and other revenue
$
1,664
$
8,226
$
(6,562)
Operating expenses:
Cost of goods sold
149
355
(206)
Research and development
18,590
20,846
(2,256)
General and administrative
11,807
11,869
(62)
Total operating expenses
30,546
33,070
(2,524)
Loss from operations
(28,882)
(24,844)
(4,038)
Interest income
1,462
1,719
(257)
Other income, net
2,847
—
2,847
Non-cash interest expense on liability
related to the sales of future royalties
(9,779)
(9,360)
(419)
Net loss
$
(34,352)
$
(32,485)
$
(1,867)
Revenue. In the years ended December 31, 2024 and 2023, we recognized $1.7 million and $8.2 million, respectively, of
revenue associated with our license agreements. License and other revenue for the year ended December 31, 2024 was primarily from
providing training materials and clinical trial products to our licensees. License and other revenue for the year ended December 31,
2023 was primarily a result of the upfront license fee payment of $5.0 million from BioCryst, $1.4 million of milestone payments
from Aura and $1.0 million from providing training materials and clinical trial products to our licensees.
Cost of Goods Sold. In the years ended December 31, 2024 and 2023, we recognized $0.1 million and $0.4 million, respectively,
in cost of goods sold related to the sales of our SCS Microinjector kits to our licensees.
Research and development. Research and development expense decreased by $2.3 million, from $20.8 million for the year
ended December 31, 2023 to $18.6 million for the year ended December 31, 2024. This was primarily due to a $2.7 million decrease
for the costs of ODYSSEY, a Phase 2b clinical trial of CLS-AX and related manufacturing costs for formulation and production.
Additionally, there was $0.8 million decrease in costs related to our development programs. This was partially offset by a $0.5 million
increase in employee related costs, a $0.3 million increase in consulting fees and the receipt of $0.8 million in research and
development tax credits received in the prior year.
General and administrative. General and administrative expenses were consistent for the years ended December 31, 2024 and
2023. In 2024 compared to 2023, there was a $0.5 million decrease in professional fees and a $0.3 million decrease for insurance
costs, partially offset by a $0.5 million increase in consulting fees and a $0.2 million increase in miscellaneous expenses.
Interest income. Interest income for the year ended December 31, 2024 and 2023 was $1.4 million and $1.7 million,
respectively, and was primarily comprised of interest income from the cash and cash equivalents. The decrease for the year ended
December 31, 2024 was due to a lower balance of the cash and cash equivalents.
Other income, net. Other income, net was $2.8 million for the year ended December 31, 2024 and was due to the decrease in fair
value of the warrant liabilities of $3.6 million from February 9, 2024, the issuance date of the warrants, to December 31, 2024
partially offset by $0.8 million of direct registered offering costs that were allocated to the warrants.
Non-cash interest expense from liability related to the sales of future royalties. Non-cash interest expense for the years ended
December 31, 2024 and 2023 was $9.8 million and $9.4 million, respectively, and was comprised of imputed interest on the liability
related to the sales of future royalties and the amortization of the associated issuance costs.

71
Results of Operations for the Years Ended December 31, 2023 and 2022
The following table sets forth our results of operations for the years ended December 31, 2023 and 2022.
Year Ended
Period-to-
December 31,
Period
2023
2022
Change
(in thousands)
License and other revenue
$
8,226
$
1,327
$
6,899
Operating expenses:
Cost of goods sold
355
204
151
Research and development
20,846
19,630
1,216
General and administrative
11,869
11,770
99
Total operating expenses
33,070
31,604
1,466
Loss from operations
(24,844)
(30,277)
5,433
Interest income
1,719
669
1,050
Non-cash interest expense on liability
related to the sales of future royalties
(9,360)
(3,339)
(6,021)
Net loss
$
(32,485)
$
(32,947)
$
462
Revenue. In the years ended December 31, 2023 and 2022, we recognized $8.2 million and $1.3 million, respectively, of
revenue associated with our license agreements. License revenue for the year ended December 31, 2023 was primarily a result of the
upfront license fee payment of $5.0 million from BioCryst, $1.4 million of milestone payments from Aura and $1.0 million from
providing training materials and clinical trial products to our licensees. License revenue for the year ended December 31, 2022 was
primarily from providing training materials and clinical trial products to our licensees.
Cost of Goods Sold. In the years ended December 31, 2023 and 2022, we recognized $0.4 million and $0.2 million, respectively,
in cost of goods sold related to the sales of our SCS Microinjector kits to our licensees.
Research and development. Research and development expense increased by $1.2 million, from $19.6 million for the year ended
December 31, 2022 to $20.8 million for the year ended December 31, 2023. This increase was primarily due to a $6.8 million increase
for the costs of ODYSSEY, a Phase 2b clinical trial of CLS-AX and related manufacturing costs for formulation and production. This
was offset by a $2.2 million decrease in costs for OASIS, a Phase 1/2a clinical trial of CLS-AX and the OASIS extension study.
Additionally, there was $1.4 million decrease in costs related to our development programs, a $0.2 million decrease in costs related to
XIPERE, a $0.7 million decrease in employee related costs and the receipt of $0.8 million in research and development tax credits
received in the year ended December 31, 2023.
General and administrative. General and administrative expenses increased by $0.1 million for the years ended December 31,
2023 and 2022. This increase was primarily a result of a $0.7 million increase in professional fees, partially offset by a $0.2 million
decrease in patent related expenses and a $0.3 million decrease for insurance costs.
Interest income. Interest income for the years ended December 31, 2023 and 2022 was $1.7 million and $0.7 million,
respectively, and was primarily comprised of interest income from the cash and cash equivalents. The increase for the year ended
December 31, 2023 was due to higher interest rates.
Non-cash interest expense from liability related to the sales of future royalties. Non-cash interest expense for the years ended
December 31, 2023 and 2022 was $9.4 million and $3.3 million, respectively, and was comprised of imputed interest on the liability
related to the sales of future royalties and the amortization of the associated issuance costs. The increase was due to a full year of
interest expense for the year ended December 31, 2023 versus five months of interest expense for the year ended December 31, 2022.
Liquidity and Capital Resources
Sources of Liquidity
We have funded our operations primarily through the proceeds from public offerings of our common stock, sales of convertible
preferred stock and the issuance of long-term debt. As of December 31, 2024, we had cash and cash equivalents of $20.0 million. We

72
invest any cash in excess of our immediate requirements primarily with a view to liquidity and capital preservation. As of December
31, 2024, our funds were held in cash and money market funds.
On February 6, 2024, we entered into a securities purchase agreement with institutional investors and an existing stockholder,
pursuant to which we issued and sold, in a registered direct offering, or the Registered Direct Offering: (i) an aggregate of 11,111,111
shares of our common stock, or Shares; and (ii) warrants to purchase up to 11,111,111 shares of common stock, or Warrants.
The combined purchase price of each Share and accompanying Warrants was $1.35. The exercise price for the Warrants is $1.62
per share. The Warrants are exercisable and will expire on August 9, 2029. The net proceeds to us from the Registered Direct Offering
were $13.9 million.
On January 31, 2024, or the Amendment Effective Date, we entered into a fourth amendment to the license agreement, or the
Emory License Agreement, with Emory University and Georgia Tech Research Corporation (collectively, the “Licensor”) pursuant to
which the parties agreed to reduce the Sublicense Percentage (as defined in the Emory License Agreement) from a low double digit
percentage to a high single digit percentage that we will pay the Licensor applicable to any fees or payments paid to us by any
Sublicensee (as defined in the Emory License Agreement) of the Licensed Patents and/or Licensed Technology (each as defined in the
Emory License Agreement), on or after July 1, 2023, excluding (i) amounts paid to us by a Sublicensee to reimburse us for certain
research and development costs pursuant to a written agreement between us and such Sublicensee, (ii) the value of intellectual
property transferred or granted to us if necessary or helpful to the development or commercialization of Licensed Products (as defined
in the Emory License Agreement) and (iii) amounts paid for shares of our stock. The payment to Licensor of any such Sublicense
Percentage is due within 30 days of receipt by us of a qualifying payment from a Sublicensee, provided however, with respect to any
qualifying payments received by us from a Sublicensee after July 1, 2023 but prior to January 1, 2025, the payment to Licensor of any
such Sublicensee Percentage is due to Licensor by March 31, 2025. The parties also agreed to a revised annual license maintenance
fee due each year, or the Maintenance Fee, starting in 2023 through 2028, as follows: $0.3 million for 2023 through 2025, $0.4 million
for 2026, $400,000 for 2027 and $0.5 million for 2028. We paid the Maintenance Fee for 2023 in February 2024 and the Maintenance
Fee for 2024 in October 2024. The remaining annual Maintenance Fee payments are due on October 1st of each year.
On December 22, 2023, we, through our wholly owned subsidiary Royalty Sub, entered into a letter agreement, or the Letter
Agreement, with HCR and HCR Clearside SPV, LLC (as assignee of HCR Collateral Management, LLC), or the Agent, amending
that certain Purchase and Sale Agreement, dated as of August 8, 2022, by and among Royalty Sub, HCR and Agent. Pursuant to the
terms of the Letter Agreement, Royalty Sub and Agent mutually agreed that Royalty Sub waived any and all rights to the $12.5
million milestone payment which was deposited in an escrow account, or the First Milestone Payment, in connection with the closing
of the transactions contemplated by the Purchase and Sale Agreement and agreed to the release of the First Milestone Payment to
Agent.
On November 1, 2023, we, entered into a license agreement, or the BioCryst License Agreement, with BioCryst
Pharmaceuticals, Inc., or BioCryst, pursuant to which we granted BioCryst an exclusive, worldwide and sublicensable license to our
SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor known as avoralstat for the treatment and
prevention of diabetic macular edema, or DME.
We received an upfront license fee payment of $5.0 million in connection with signing of the BioCryst License Agreement. In
addition, we are eligible to receive up to an additional $30.0 million in clinical and regulatory milestone payments, and up to a total of
$47.5 million in a series of post-approval sales-based milestone payments based on the achievement of annual global net product sales
milestones up to $2.0 billion. Further, during the royalty term, BioCryst has also agreed to pay us tiered mid-single digit royalties on
annual global net product sales, with the highest royalty rate applied to sales over $1.5 billion, subject to reductions in specified
circumstances. Our rights to these royalties and milestone payments have been sold pursuant to the terms and conditions of the
Purchase and Sale Agreement described above in "Business—Royalty Purchase and Sale Agreement."
In May 2023, we terminated our at-the-market sales agreement with Cowen and Company, LLC, or the Prior ATM Agreement.
We sold 515,959 shares of its common stock for net proceeds of $0.7 million under the Prior ATM Agreement with Cowen and
Company, LLC during the six months ended June 30, 2023, prior to the termination of the Prior ATM Agreement. During the year
ended December 31, 2022, we sold 425,460 shares of common stock for net proceeds of $0.6 million under the Prior ATM
Agreement.
In May 2023, we entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald
& Co., or Cantor under which we may offer and sell, from time to time at its sole discretion, shares of its common stock, having an
aggregate offering price of up to $50.0 million through Cantor as our sales agent. During the year ended December 31, 2024, we sold
2,172,723 shares of our common stock for net proceeds of $2.5 million under the Sales Agreement. During the year ended December
31, 2023, we sold 1,073,740 shares of our common stock for net proceeds of $1.1 million under the Sales Agreement. Subsequent to

73
December 31, 2024, we sold an additional 297,908 shares of our common stock pursuant to the Sales Agreement for net proceeds of
$0.3 million.
On August 8, 2022, or the Closing Date, we, through our wholly-owned subsidiary Clearside Royalty LLC, a Delaware limited
liability company, or Royalty Sub, entered into a Purchase and Sale Agreement with entities managed by HealthCare Royalty
Management, LLC, or HCR, pursuant to which Royalty Sub sold to HCR certain of its rights to receive royalty and milestone
payments payable to Royalty Sub under the Arctic Vision License Agreement, Bausch License Agreement, that certain License
Agreement, effective as of July 3, 2019, by and between us and Aura Biosciences, Inc., that certain Option and License Agreement,
dated as of August 29, 2019, by and between REGENXBIO Inc. and us, and any and all out-license agreements following the Closing
Date for, or related to XIPERE or the SCS Microinjector technology to be used in connection with compounds or products of any third
parties delivered, in whole or in part, by means of the SCS Microinjector technology, excluding, for the avoidance of doubt, any in-
licensed or internally developed therapies following the Closing Date, in exchange for up to $65 million. Under the terms of the
Purchase and Sale Agreement, Royalty Sub received a payment of $32.1 million, representing the $32.5 million to which we were
entitled less certain expenses. There were additional issuance costs of $1.5 million related to the Purchase and Sale Agreement
resulting in net proceeds of $30.6 million. An additional $12.5 million was deposited in an escrow account, which was released to
HCR pursuant to the Letter Agreement described above.
Funding Requirements
Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, research and
development costs to build our product candidate pipeline, legal and other regulatory expenses and general overhead costs. In
addition, we have certain contractual obligations for future payments. Refer to Footnote 10 to our consolidated financial statements
included in this Annual Report on Form 10-K.
The successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate
or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of
CLS-AX or any future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from
product sales. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:
•
successful enrollment in, and completion of, clinical trials;
•
receipt of marketing approvals from applicable regulatory authorities;
•
establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
•
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; and
•
launching commercial sales of the products, if and when approved, whether alone or in collaboration with others.
A change in the outcome of any of these variables with respect to the development of any of our product candidates would
significantly change the costs and timing associated with the development of that candidate.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a
combination of equity offerings, debt financings and potential collaboration, license and development agreements. Other than potential
payments we may receive under our license and other agreements, we do not currently have any committed external source of funds,
though, as described above, we may also be able to sell our common stock under the Sales Agreement subject to the terms of that
agreement and depending on market conditions. We expect that we will require additional capital to fund our ongoing operations.
Additional funds may not be available to us on a timely basis, on commercially reasonable terms, or at all. Our ability to raise
additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to, and volatility in,
the credit and financial markets in the United States and worldwide and related macroeconomic changes, such as rising inflation. To
the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common
stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we raise funds through additional collaborations, strategic alliances or marketing, distribution or licensing arrangements with
third parties, including any future collaboration or licensing arrangement for XIPERE outside of the territories in which we have
previously licensed or granted options to license XIPERE, we may be required to relinquish additional rights to our technologies,
future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we
are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or

74
terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we
would otherwise prefer to develop and market ourselves.
We also incur costs as a public company, including costs and expenses for fees to members of our board of directors, accounting
and finance personnel costs, directors and officers insurance premiums, audit and legal fees, investor relations fees and expenses for
compliance with reporting requirements under the Exchange Act and rules implemented by the SEC and Nasdaq.
Outlook
We have suffered recurring losses and negative cash flows from operations since inception and anticipate incurring additional
losses until such time, if ever, that we can generate significant milestone payments and royalties from XIPERE and other licensing
arrangements or revenues from other product candidates. We will need additional financing to fund our operations. Our plans
primarily consist of raising additional capital, potentially in a combination of equity or debt financings, monetizing royalties, or
restructurings, or potentially entering into additional collaborations, partnerships and other strategic arrangements.
Based on our current plans and forecasted expenses, we expect that our cash and cash equivalents as of the filing date, March 27,
2025, will enable us to fund our planned operating expenses and capital expenditure requirements into the fourth quarter of 2025. We
have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we
expect. We will require additional capital in order to initiate the Phase 3 clinical trials of CLS-AX, which we expect could be initiated
as early as the second half of 2025.
These factors raise substantial doubt regarding our ability to continue as a going concern. Our consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the
recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result should we
be unable to continue as a going concern.
Cash Flows
The following is a summary of the net cash flows (used in) provided by our operating, investing and financing activities:
Year Ended
December 31,
2024
2023
2022
(in thousands)
Net cash (used in) provided by:
Operating activities
$
(24,698)
$
(18,135)
$
(13,365)
Investing activities
(638)
(1,777)
(246)
Financing activities
16,436
414
31,333
Net change in cash and cash equivalents
$
(8,900)
$
(19,498)
$
17,722
During the years ended December 31, 2024, 2023 and 2022, our operating activities used net cash of $24.7 million, $18.1
million and $13.4 million, respectively. The net cash used in operating activities for the year ended December 31, 2024 was due to
ongoing research and development expenses to develop our pipeline and ongoing costs for ODYSSEY, the Phase 2b clinical trial for
CLS-AX, as well as the supporting general and administrative costs. The net cash used in operating activities for the year ended
December 31, 2023 was due to ongoing research and development expenses to develop our pipeline and ongoing costs for ODYSSEY,
as well as the supporting general and administrative costs. This was partially offset by the receipt of research and development tax
credits. The net cash used for the year ended December 31, 2022 was primarily due to research and development expenses related to
the preclinical and clinical programs offset by the receipt of the $10.0 million milestone payment received from Bausch in connection
with pre-launch activities for XIPERE.
During the years ended December 31, 2024, 2023 and 2022, our investing activities used net cash of $0.6 million, $1.8 million
and $0.2 million, respectively. The net cash used in investing activities for the year ended December 31, 2024 was primarily due to
$1.0 million for the purchase of property and equipment, partially offset by $0.3 million of cash provided by the maturity of short-term
investments. The net cash used for investing activities for the years ended December 31, 2023 and 2022 was for the purchase of
property and equipment.

75
During the years ended December 31, 2024, 2023 and 2022, our net cash provided by financing activities was $16.4 million,
$0.4 million and $31.3 million, respectively. The cash provided by financing activities for the year ended December 31, 2024
consisted primarily of $13.9 million of net proceeds from the sale of shares of our common stock in a registered direct offering and
$2.5 million of net proceeds from the sale of shares of our common stock under the Sales Agreement. The cash provided by financing
activities for the year ended December 31, 2023 consisted primarily of $1.7 million of net proceeds from the sale of shares of our
common stock under the Prior ATM Agreement and the Sales Agreement partially offset by a payment of $1.4 million related to the
Purchase and Sale Agreement. The net cash provided by financing activities for the year ended December 31, 2022 was primarily
comprised of $30.6 million from the Purchase and Sale Agreement, net of issuance costs and $0.6 million of net proceeds from the
sale of shares of our common stock under the Prior ATM Agreement.
Cybersecurity
For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk
factors under Part 1. Item 1A. Risk Factors and Item 1C. Cybersecurity in this Annual Report on Form 10-K, including “—If our
information technology systems or those third parties upon which we rely or our data, are or were compromised, we could experience
adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation;
fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse
consequences.”
Recent Accounting Pronouncements
See Item 8. “Consolidated Financial Statements and Supplementary Data – Note 2, Significant Accounting Policies” for a
discussion of recent accounting pronouncements and their effect on us.
Smaller Reporting Company Status
We are a “smaller reporting company,” meaning that the market value of our shares held by non-affiliates is less than $700
million and our annual revenue was less than $100 million during the most recently completed fiscal year. We will continue to be a
smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual
revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-
affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of
audited financial statements in our Annual Report on Form 10-K and we have reduced disclosure obligations regarding executive
compensation.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the
information required under this item.

76
ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Index to financial statements
Page
Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)............................................................
77
Consolidated Balance Sheets as of December 31, 2024 and 2023 ..............................................................................
80
Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022 ...........................
81
Consolidated Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2024, 2023
and 2022...................................................................................................................................................................
82
Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 ............................
83
Notes to the Consolidated Financial Statements..........................................................................................................
84

77
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Clearside Biomedical, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Clearside Biomedical, Inc. (the Company) as of December 31, 2024
and 2023, the related consolidated statements of operations, stockholders' equity (deficit) and cash flows for each of the three years in
the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024,
in conformity with U.S. generally accepted accounting principles.
The Company's Ability to Continue as a Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
As discussed in Note 1 to the financial statements, the Company has recurring losses, negative cash flows from operations and has stated
that substantial doubt exists about the Company’s ability to continue as a going concern. Management's evaluation of the events and
conditions and management’s plans regarding these matters are also described in Note 1. The consolidated financial statements do not
include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that
our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were
communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to
the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical
audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by
communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or
disclosures to which they relate.

78
Valuation of warrants issued as part of equity offerings
Description of the
Matter
As discussed in Note 7 to the consolidated financial statements, on February 6, 2024, the
Company entered into a securities purchase agreement with institutional investors and an
existing stockholder, pursuant to which the Company issued and sold, in a registered direct
offering: (i) an aggregate of 11,111,111 shares of its common stock; and (ii) warrants to
purchase up to 11,111,111 shares of common stock. The net proceeds to the Company from the
registered direct offering were $13.9 million.
The Company accounts for warrants as liability-classified instruments based on an assessment
of the warrants’ specific terms and applicable authoritative guidance. The Company’s warrant
liabilities are measured at fair value using a simulation model which takes into account, as of
the valuation date, factors including the current exercise price, the expected life of the warrant,
the current price of the Company's common stock, the expected volatility, the risk-free interest
rate for the term of the warrants and the likelihood of achieving certain future milestone events
and the related impact to the price of the Company's common stock. The warrant liabilities are
remeasured at each reporting period and changes in fair value are recognized in other income,
net in the consolidated statements of operations. The Company recorded the warrant liabilities
on the consolidated balance sheet at its fair value of $6.7 million as of December 31, 2024. The
Company recorded the change in the fair value of the warrant liabilities during the year ended
December 31, 2024, of $3.6 million, as an increase in other income, net in the consolidated
statements of operations.
Auditing the Company’s measurement of the fair value of the warrant liabilities was complex
due to the methodology used and significant estimation uncertainty of certain assumptions,
specifically the likelihood of achieving certain future milestone events and related impact on
the Company's common stock price.
How We Addressed
the Matter in Our
Audit
To test the valuation of warrant liabilities as of December 31, 2024, our audit procedures
included, among others, with the assistance of our valuation specialists, we (a) evaluated the
methodologies used to measure the fair value of the warrant liabilities; and (b) we performed
independent calculations to test the reasonableness of the measurement of the fair value for
warrant liabilities recorded by the Company. Such independent calculations assessed the
mathematical accuracy of the Company’s valuation model and the mathematical accuracy of
the underlying valuation assumptions used in the model to measure the fair value of the warrant
liabilities. We also assessed the reasonableness of assumptions utilized in the measurement of
the fair value of the warrant liabilities, including the likelihood of achieving certain future
milestone events and related impact on the Company's common stock price by evaluating
Company-specific information, comparing the assumptions to available external industry data
and sensitizing the change in common stock price applied to the valuation.

79
Valuation of Liability Related to the Sales of Future Royalties, Net
Description of the
Matter
As discussed in Note 5 to the consolidated financial statements, on August 8, 2022, the
Company entered into a Royalty Purchase and Sale Agreement with a third party, pursuant to
which the Company sold certain of its rights to receive royalty and milestone payments. The
Company received proceeds of $32.1 million, representing the $32.5 million to which the
Company was entitled, net of certain transaction related expenses. The Company will repay
the lender at a multiple of the initial proceeds received, which may vary based on timing and
amount of cash flows received from its licensing partners.
The Company recorded the financing as a liability related to the sales of future royalties, net
on the balance sheet at its carrying value of $51.8 million as of December 31, 2024. The
Company imputes interest expense associated with this liability using the effective interest rate
method. Such interest expense is recorded in the statement of operations for the year ended
December 31, 2024 as Non-cash interest expense on liability related to the sales of future
royalties. The effective interest rate is calculated based on the rate that would enable the
estimated liability to be repaid in full over the anticipated life of the arrangement. The
Company utilizes the prospective method to record interest expense by updating its estimate
of the new effective interest rate each period, based on its current estimate of remaining cash
flows under the arrangement. The Company estimates the amount and timing of expected
payments based on historical experience and its expectations of future activities from its
license partners, as well as current market conditions.
Auditing the liability related to the sales of future royalties, net was complex and highly
judgmental due to the estimation uncertainty in determining the effective interest rate. The
Company’s effective interest rate model includes cash flow projections for future royalty and
milestone payments, which are sensitive to certain assumptions that are forward looking and
could be affected by future market conditions.
How We Addressed
the Matter in Our
Audit
To test the liability related to the sales of future royalties, net as of December 31, 2024, our
audit procedures included, among others, assessing the underlying data and significant
assumptions used by the Company in determining the timing and amount of future cash flows
used within its effective interest rate model. We assessed the reasonableness of the significant
assumptions used in the cash flow projections by inspecting third party evidence to support
management’s projections. We also assessed the reasonableness of future projections based
on activity to date. We recalculated the current year interest expense and performed sensitivity
analyses to evaluate the changes in the effective interest rate, and associated interest expense,
that would result from changes in certain assumptions.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2014.
Atlanta, Georgia
March 27, 2025

80
CLEARSIDE BIOMEDICAL, INC.
Consolidated Balance Sheets
(in thousands, except share and per share data)
December 31,
2024
2023
Assets
Current assets:
Cash and cash equivalents
$
20,020
$
28,920
Accounts receivable
507
467
Prepaid expenses
734
722
Other current assets
13
14
Total current assets
21,274
30,123
Property and equipment, net
3,225
2,996
Operating lease right-of-use asset
597
869
Other assets
30
30
Total assets
$
25,126
$
34,018
Liabilities and stockholders’ deficit
Current liabilities:
Accounts payable (includes $491 and $331 to a related party as of
December 31, 2024 and 2023, respectively)
$
1,452
$
2,205
Accrued liabilities (includes $304 and $215 to a related party as of
December 31, 2024 and 2023, respectively)
2,967
4,169
Current portion of operating lease liabilities
375
364
Deferred revenue
—
75
Total current liabilities
4,794
6,813
Liability related to the sales of future royalties, net
51,767
41,988
Warrant liabilities
6,692
—
Operating lease liabilities
328
649
Other non-current liabilities
400
480
Total liabilities
63,981
49,930
Commitments and contingencies
Stockholders’ deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at
December 31, 2024 and 2023
—
—
Common stock, $0.001 par value; 200,000,000 shares authorized
at December 31, 2024 and 2023; 76,578,383 and 62,850,841 shares
issued and outstanding at December 31, 2024 and 2023, respectively
77
63
Additional paid-in capital
316,343
304,948
Accumulated deficit
(355,275)
(320,923)
Total stockholders’ deficit
(38,855)
(15,912)
Total liabilities and stockholders’ deficit
$
25,126
$
34,018
See accompanying notes to the financial statements

81
CLEARSIDE BIOMEDICAL, INC.
Consolidated Statements of Operations
(in thousands, except share and per share data)
Year Ended
December 31,
2024
2023
2022
License and other revenue (includes $321 and $5,050 from a
related party for the years ended December 31, 2024 and 2023,
respectively)
$
1,664
$
8,226
$
1,327
Operating expenses:
Cost of goods sold
149
355
204
Research and development (includes $1,051 and $1,109 to
a related party for the years ended December 31, 2024 and
2023, respectively)
18,590
20,846
19,630
General and administrative
11,807
11,869
11,770
Total operating expenses
30,546
33,070
31,604
Loss from operations
(28,882)
(24,844)
(30,277)
Interest income
1,462
1,719
669
Other income, net
2,847
—
—
Non-cash interest expense on liability
related to the sales of future royalties
(9,779)
(9,360)
(3,339)
Net loss
$
(34,352)
$
(32,485)
$
(32,947)
Net loss per share of common stock — basic and diluted
$
(0.47)
$
(0.53)
$
(0.55)
Weighted average shares outstanding — basic and diluted
73,803,348
61,806,959
60,204,862
See accompanying notes to the financial statements.

82
CLEARSIDE BIOMEDICAL, INC.
Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share data)
Total
Common Stock
Additional
Accumulated
Stockholders'
Shares
Amount
Paid-In-Capital
Deficit
Equity (Deficit)
Balance at December 31, 2021
59,722,930
$
60
$
293,406
$
(255,491)
$
37,975
Issuance of common shares under
at-the-market sales agreement
425,460
1
565
—
566
Issuance of common shares under
employee stock purchase plan
66,919
—
112
—
112
Exercise of stock options
49,187
—
17
—
17
Vesting and settlement of restricted
stock units
375,331
—
—
—
—
Share-based compensation expense
—
—
4,884
—
4,884
Net loss
—
—
—
(32,947)
(32,947)
Balance at December 31, 2022
60,639,827
61
298,984
(288,438)
10,607
Issuance of common shares under
at-the-market sales agreement
1,589,699
2
1,664
—
1,666
Issuance of common shares under
employee stock purchase plan
68,109
—
65
—
65
Exercise of stock options
81,816
—
33
—
33
Vesting and settlement of restricted
stock units
471,390
—
—
—
—
Share-based compensation expense
—
—
4,202
—
4,202
Net loss
—
—
—
(32,485)
(32,485)
Balance at December 31, 2023
62,850,841
63
304,948
(320,923)
(15,912)
Issuance of common stock under registered
direct offering
11,111,111
11
4,309
—
4,320
Issuance of common shares under
at-the-market sales agreement
2,172,723
2
2,527
—
2,529
Issuance of common shares under
employee stock purchase plan
36,114
1
34
—
35
Exercise of stock options
10,000
—
12
—
12
Vesting and settlement of restricted
stock units
397,594
—
—
—
—
Share-based compensation expense
—
—
4,513
—
4,513
Net loss
—
—
—
(34,352)
(34,352)
Balance at December 31, 2024
76,578,383
$
77
$
316,343
$
(355,275)
$
(38,855)
See accompanying notes to the financial statements.

83
CLEARSIDE BIOMEDICAL, INC.
Consolidated Statements of Cash Flows
(in thousands)
Year Ended
December 31,
2024
2023
2022
Operating activities
Net loss
$
(34,352)
$
(32,485)
$
(32,947)
Adjustments to reconcile net loss to net cash used in
operating activities:
Non-cash interest expense on liability related to the sales of future
royalties, net of issuance costs accretion
9,779
9,361
3,339
Depreciation
226
67
145
Share-based compensation expense
4,513
4,202
4,884
Change in fair value of warrant liabilities
(3,635)
—
—
Issuance costs allocated to warrant liabilities
787
—
—
Amortization and accretion of available-for-sale investments, net
(339)
—
—
Gain on termination of operating lease
—
—
(55)
Loss on disposal of fixed assets
—
—
33
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other current assets
(51)
(220)
10,420
Other assets and liabilities
(118)
456
(83)
Accounts payable and accrued liabilities (includes $248 and $82
to a related party for the year ended December 31, 2024 and
2023, respectively)
(1,433)
614
694
Deferred revenue
(75)
(130)
205
Net cash used in operating activities
(24,698)
(18,135)
(13,365)
Investing activities
Purchase of short-term investments
(16,911)
—
—
Maturity of short-term investments
17,250
—
—
Acquisition of property and equipment
(977)
(1,777)
(246)
Net cash used in investing activities
(638)
(1,777)
(246)
Financing activities
Proceeds from issuance of common stock and warrants in
registered direct offering, net of issuance costs
13,860
—
—
Proceeds from royalty purchase and sale agreement, net of
$1,862 of issuance costs
—
—
30,638
Payments on royalty purchase and sale agreement
—
(1,350)
—
Proceeds from at-the-market sales agreement, net of issuance costs
2,529
1,666
566
Proceeds from shares issued under employee stock purchase plan
35
65
112
Proceeds from exercise of stock options
12
33
17
Net cash provided by financing activities
16,436
414
31,333
Net (decrease) increase in cash, cash equivalents and restricted cash
(8,900)
(19,498)
17,722
Cash, cash equivalents and restricted cash, beginning of period
28,920
48,418
30,696
Cash, cash equivalents and restricted cash, end of period
$
20,020
$
28,920
$
48,418
Supplemental disclosure
Purchase of property and equipment in accounts payable
and accrued liabilities
$
9
$
531
$
282
Reconciliation of cash, cash equivalents and restricted cash:
December 31,
2024
2023
2022
Cash and cash equivalents
$
20,020
$
28,920
$
48,258
Restricted cash (recorded in other current assets)
—
—
160
Cash, cash equivalents and restricted cash at end of period
$
20,020
$
28,920
$
48,418
See accompanying notes to the financial statements.

84
CLEARSIDE BIOMEDICAL, INC.
Notes to the Consolidated Financial Statements
1. The Company
Clearside Biomedical, Inc. (the “Company”) is a biopharmaceutical company focused on revolutionizing the delivery of
therapies to the back of the eye through the suprachoroidal space (SCS). Incorporated in the State of Delaware on May 26, 2011, the
Company has its corporate headquarters in Alpharetta, Georgia.
The Company’s activities since inception have primarily consisted of developing product and technology rights, raising capital
and performing research and development activities. The Company is subject to a number of risks and uncertainties similar to those of
other life science companies at a similar stage of development, including, among others, the need to obtain adequate additional
financing, successful development efforts including regulatory approval of products, compliance with government regulations,
successful commercialization of potential products, protection of proprietary technology and dependence on key individuals.
Liquidity
The Company had cash and cash equivalents of $20.0 million as of December 31, 2024.
Historically, the Company has funded its operations primarily through the sale of common stock and convertible preferred
stock, the issuance of long-term debt, and license agreements. On October 25, 2021, the Company announced that the U.S. Food and
Drug Administration (the "FDA") approved XIPERE® (triamcinolone acetonide injectable suspension) for the treatment of macular
edema associated with uveitis, a form of eye inflammation. In January 2022, the Company received $10.0 million from Bausch +
Lomb, a division of Bausch Health Companies, Inc. ("Bausch"), upon completion of pre-launch activities for XIPERE pursuant to the
license agreement granting Bausch an exclusive license to develop and commercialize XIPERE in the United States and Canada.
Bausch launched XIPERE in the United States in the first quarter of 2022.
On February 6, 2024, the Company entered into a securities purchase agreement with institutional investors and an existing
stockholder, pursuant to which the Company issued and sold, in a registered direct offering (the “Registered Direct Offering”): (i) an
aggregate of 11,111,111 shares (the “Shares”) of its common stock; and (ii) warrants to purchase up to 11,111,111 shares of common
stock (the “Warrants”).
The combined purchase price of each Share and accompanying Warrant was $1.35. The exercise price for the Warrants is $1.62
per share. The Warrants are exercisable and will expire on August 9, 2029. The net proceeds to the Company from the Registered
Direct Offering were $13.9 million.
On January 31, 2024 (the “Amendment Effective Date”), the Company entered into a fourth amendment to the license
agreement (as amended, the “Emory License Agreement”) with Emory University and Georgia Tech Research Corporation
(collectively, the “Licensor”) pursuant to which the parties agreed to reduce the Sublicense Percentage (as defined in the Emory
License Agreement) from a low double digit percentage to a high single digit percentage that the Company will pay the Licensor
applicable to any fees or payments paid to the Company by any Sublicensee (as defined in the Emory License Agreement) of the
Licensed Patents and/or Licensed Technology (each as defined in the Emory License Agreement), on or after July 1, 2023, excluding
(i) amounts paid to the Company by a Sublicensee to reimburse the Company for certain research and development costs pursuant to a
written agreement between the Company and such Sublicensee, (ii) the value of intellectual property transferred or granted to the
Company if necessary or helpful to the development or commercialization of Licensed Products (as defined in the Emory License
Agreement) and (iii) amounts paid for shares of the Company’s stock. The payment to Licensor of any such Sublicense Percentage is
due within 30 days of receipt by the Company of a qualifying payment from a Sublicensee, provided however, with respect to any
qualifying payments received by the Company from a Sublicensee after July 1, 2023 but prior to January 1, 2025, the payment to
Licensor of any such Sublicensee Percentage is due to Licensor by March 31, 2025. The parties also agreed to a revised annual license
maintenance fee due each year (the “Maintenance Fee”) starting in 2023 through 2028, as follows: $0.3 million for 2023 through
2025, $0.4 million for 2026 and for 2027 and $0.5 million for 2028. The Company paid the Maintenance Fee for 2023 in February
2024 and the Maintenance Fee for 2024 in October 2024. The remaining annual Maintenance Fee payments are due on October 1st of
each year.
On December 22, 2023, Clearside Biomedical, Inc., through its wholly owned subsidiary Royalty Sub, entered into a letter
agreement (the “Letter Agreement”) with HCR and HCR Clearside SPV, LLC (as assignee of HCR Collateral Management, LLC)
(“Agent”) amending that certain Purchase and Sale Agreement, dated as of August 8, 2022, by and among Royalty Sub, HCR and Agent.

85
Pursuant to the terms of the Letter Agreement, Royalty Sub and Agent mutually agreed that Royalty Sub waived any and all rights to
the $12.5 million milestone payment which was deposited in an escrow account (“First Milestone Payment") in connection with the
closing of the transactions contemplated by the Purchase and Sale Agreement and agreed to the release of the First Milestone Payment
to Agent.
On November 1, 2023, the Company, entered into a license agreement (the “BioCryst License Agreement”) with BioCryst
Pharmaceuticals, Inc. (“BioCryst”) pursuant to which the Company granted BioCryst an exclusive, worldwide and sublicensable license
to the Company’s SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor known as avoralstat for the
treatment and prevention of diabetic macular edema (“DME”).
The Company received an upfront license fee payment of $5.0 million in connection with signing of the BioCryst License
Agreement. In addition, the Company is eligible to receive up to an additional $30.0 million in clinical and regulatory milestone
payments, and up to a total of $47.5 million in a series of post-approval sales-based milestone payments based on the achievement of
annual global net product sales milestones up to $2.0 billion. Further, during the royalty term, BioCryst has also agreed to pay the
Company tiered mid-single digit royalties on annual global net product sales, with the highest royalty rate applied to sales over $1.5
billion, subject to reductions in specified circumstances. The Company’s rights to these royalties and milestone payments have been
sold pursuant to the terms and conditions of the Purchase and Sale Agreement described above in in Note 5 to the consolidated
financial statements.
In May 2023, the Company terminated its at-the-market sales agreement with Cowen and Company, LLC (the "Prior ATM
Agreement"). The Company sold 515,959 shares of its common stock for net proceeds of $0.7 million under its Prior ATM Agreement
with Cowen and Company, LLC during the year ended December 31, 2023, prior to the termination of the Prior ATM Agreement.
In May 2023, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the "Sales Agreement") with Cantor
Fitzgerald & Co. ("Cantor") under which the Company may offer and sell, from time to time at its sole discretion, shares of its
common stock, having an aggregate offering price of up to $50.0 million through Cantor as its sales agent. During the year ended
December 31, 2024, the Company sold 2,172,723 shares of its common stock for net proceeds of $2.5 million under the Sales
Agreement. During the year ended December 31, 2023, the Company sold 1,073,740 shares of its common stock for net proceeds of
$1.1 million under the Sales Agreement. Subsequent to December 31, 2024, the Company sold an additional 297,908 shares of its
common stock pursuant to the Sales Agreement for net proceeds of $0.3 million.
On August 8, 2022, the Company entered into a Purchase and Sale Agreement (the "Purchase and Sale Agreement") pursuant to
which it sold its rights to receive royalty and milestone payments due to the Company from XIPERE and certain SCS Microinjector
license agreements subject to a cap which may be increased under certain circumstances. The Company received a payment of $32.1
million in September 2022, representing the $32.5 million to which the Company was entitled, net of certain of HCR's transaction-
related expenses which the Company agreed to reimburse. There were additional issuance costs of $1.5 million related to the Purchase
and Sale Agreement resulting in net proceeds of $30.6 million.
The Company has suffered recurring losses and negative cash flows from operations since inception and anticipates incurring
additional losses until such time, if ever, that it can generate significant revenue. The Company has no current source of revenue to
sustain present activities. The Company does not expect to generate other meaningful revenue until and unless the Company's
licensees successfully commercialize XIPERE and the Company has fulfilled its obligations under the Purchase and Sale Agreement,
its other licensees receive regulatory approval and successfully commercialize its product candidates, or the Company commercializes
its product candidates either on its own or with a third party. In the absence of product or other revenues, the amount, timing, nature or
source of which cannot be predicted, the Company’s losses will continue as it conducts its research and development activities.
The Company will continue to need to obtain additional financing to fund future operations, including completing the
development, partnering and potential commercialization of its primary product candidates. The Company will need to obtain
financing to complete the development and conduct clinical trials for the regulatory approval of its product candidates if requested by
regulatory bodies. If such product candidates were to receive regulatory approval, the Company would need to obtain financing to
prepare for the potential commercialization of its product candidates, if the Company decides to commercialize the products on its
own.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the
date the financial statements are issued. Based on its current plans and forecasted expenses, the Company expects that its cash and
cash equivalents as of the filing date, March 27, 2025, will enable the Company to fund its planned operating expenses and capital
expenditure requirements into the fourth quarter of 2025. The Company has based this estimate on assumptions that may prove to be
wrong, and it could exhaust its capital resources sooner than expected. Until the Company can generate sufficient revenue, the
Company will need to finance future cash needs through public or private equity offerings, license agreements, debt financings or
restructurings, collaborations, strategic alliances and marketing or distribution arrangements.

86
The Company’s consolidated financial statements have been prepared on a going concern basis, which contemplates the
realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not
include any adjustments to reflect the possible future effects on the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might result should the Company be unable to continue as a going concern.
2. Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The Company's consolidated financial statements include the results of the financial operations of Clearside Biomedical, Inc.
and its wholly-owned subsidiary, Clearside Royalty LLC. a Delaware limited liability company, which was formed for the purposes of
the transactions contemplated by the Purchase and Sale Agreement described in Note 5. All intercompany balances and transactions
have been eliminated.
The Company’s financial statements have been prepared in conformity with U.S. generally accepted accounting principles in the
United States of America (“U.S. GAAP”). Certain amounts reported in prior periods have been reclassified to conform to the current
period financial statement presentation. These reclassifications are not material and have no effect on the previously reported
consolidated financial statements and related disclosures.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date
of the consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items
subject to such estimates and assumptions include the estimate of the total amount of future royalty revenue and milestone payments
to be generated over the life of the Purchase and Sale Agreement, certain assumptions used in the valuation of warrant liabilities,
revenue recognition, the accounting for useful lives to calculate depreciation and amortization, clinical trial expense accruals, share-
based compensation expense and income tax valuation allowance. Actual results could differ from these estimates.
Revenue Recognition
The Company recognizes revenue from its contracts with customers under Financial Accounting Standards Board Accounting
Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The Company’s primary revenue arrangements are
license agreements which typically include upfront payments, regulatory and commercial milestone payments and royalties based on
future product sales. The arrangements may also include payments for the Company’s SCS Microinjector devices as well as payments
for assistance and oversight of the customer’s use of the Company’s technology. In determining the amount of revenue to be
recognized under these agreements, the Company performs the following steps: (i) identifies the promised goods and services to be
transferred in the contract, (ii) identifies the performance obligations, (iii) determines the transaction price, (iv) allocates the
transaction price to the performance obligations and (v) recognizes revenue as the performance obligations are satisfied.
The Company receives payments from its customers based on billing schedules established in each contract. Up-front and other
payments may require deferral of revenue recognition to a future period until the Company performs its obligations under the
arrangement. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.
In the years ended December 31, 2024, 2023, and 2022, the Company recognized $1.7 million, $8.2 million, and $1.3 million of
revenue associated with its license agreements, respectively. License revenue for the year ended December 31, 2024 was primarily
from providing $0.9 million of training materials and clinical trial products to the Company's licensees and from $0.7 million of other
services provided to the Company's licensees. License revenue for the year ended December 31, 2023 was primarily for a non-
refundable $5.0 million upfront license fee payment from BioCryst and $1.4 million of milestone payments from Aura Biosciences,
Inc. The $5.0 million non-refundable upfront payment was recognized upon transfer of control of the license to BioCryst. The $1.4
million in milestone payments from Aura were recognized upon satisfaction of the related performance obligations. Remaining
revenue for the year ended December 31, 2023 was generated by providing $1.2 million of training materials and clinical trial
products to the Company's licensees and $0.6 million from other services provided to the Company's licensees. License revenue for

87
the year ended December 31, 2022 was primarily from providing $1.2 million of training materials and clinical trial products to the
Company's licensees and $0.1 million of other services to the Company's licensees.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for
evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing
performance. The Company views its operations and manages its business in one operating segment.
Property and Equipment, Net
Property and equipment is recorded at historical cost. Depreciation is calculated using the straight-line method over the
estimated useful lives of the related assets, or for leasehold improvement the lesser of the useful life or remaining lease term. Repairs
and maintenance are expensed when incurred. Upon retirement or sale, the cost of the assets disposed of and the related accumulated
depreciation are removed from the accounts, and any resulting gain or loss is included in the determination of net loss.
Income Taxes
Deferred tax assets or liabilities are recorded for temporary differences between financial statement and tax basis of assets and
liabilities, using enacted rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded
if it is more likely than not that a deferred tax asset will not be realized. The Company has provided a full valuation allowance on its
deferred tax assets, which primarily consist of cumulative net operating losses for the period from May 26, 2011 (inception) to
December 31, 2024. Due to its history of operating losses since inception and losses expected to be incurred in the foreseeable future,
a full valuation allowance was considered necessary.
Liabilities for uncertain tax positions are recognized based on a two-step process. The first step is to evaluate the tax position for
recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be
sustained on audit, including resolution of related appeals or litigation processes, if any. Once it is determined that the position meets
the recognition threshold, the second step requires estimating and measuring the largest amount of tax benefit that is more likely than
not to be realized upon ultimate settlement. The difference between the amount of recognizable tax benefit and the total amount of tax
benefit from positions filed or to be filed with the tax authorities is recorded as a liability for uncertain tax benefits.
Research and Development Costs
Research and development costs are charged to expense as incurred and include:
•
employee-related expenses, including salaries, benefits, travel and share-based compensation expense for research and
development personnel;
•
expenses incurred under agreements with contract research organizations, contract manufacturing organizations and
consultants that conduct preclinical studies and clinical trials;
•
costs associated with preclinical and clinical development activities;
•
costs associated with submitting regulatory approval applications for the Company’s product candidates;
•
costs associated with training physicians on the suprachoroidal injection procedure and educating and providing them with
appropriate product candidate information;
•
costs associated with technology and intellectual property licenses;
•
costs for the Company’s research and development facility; and
•
depreciation expense for assets used in research and development activities.
Costs for certain development activities, such as clinical trial activities, are recognized based on an evaluation of the estimated
total costs for the clinical trial, progress to completion of specific tasks, using data such as patient enrollment, pass through expenses,
clinical site activations, data from the clinical sites or information provided to the Company by its vendors on their actual costs
incurred. Payments for these activities are based on the terms of the individual contracts and any subsequent amendments, which may
differ from the patterns of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses.

88
Share-Based Compensation
Compensation cost related to share-based awards granted to employees, directors and consultants is measured based on the
estimated fair value of the award at the grant date. The fair value of restricted stock units granted is measured based on the market
value of the Company’s common stock on the date of grant. Share-based compensation costs are expensed on a straight-line basis over
the relevant vesting period.
Compensation cost related to shares purchased through the Company’s employee stock purchase plan, which is considered
compensatory, is based on the estimated fair value of the shares on the offering date, including consideration of the discount and the
look back period. The Company estimates the fair value of the shares using a Black-Scholes option pricing model. Compensation
expense is recognized over the six-month withholding period prior to the purchase date.
All share-based compensation costs are recorded in general and administrative or research and development costs in the
consolidated statements of operations based upon the underlying employees’ roles within the Company.
Cash Equivalents
Cash equivalents consist of short-term, highly liquid investments with an original term of three months or less at the date of
purchase.
Restricted Cash
The Company was required to maintain a stand-by letter of credit as a security deposit for its facility lease in Alpharetta,
Georgia. The Company’s bank required the Company to maintain a restricted cash balance to serve as collateral for the letter of credit
issued to the landlord by the bank.
Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits
The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not
experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash
balances.
Liability Related to the Sales of Future Royalties and Non-Cash Interest Expense
In connection with the Purchase and Sale Agreement, the Company recognized a liability related to the sales of future royalties
under ASC 470-10 Debt and ASC 835-30 Interest - Imputation of Interest. The initial funds received by the Company pursuant to the
terms of the Purchase and Sale Agreement were recorded as a liability and are accreted under the effective interest method up to the
estimated amount of future royalties and milestone payments to be made under the Purchase and Sale Agreement. The issuance costs
were recorded as a direct deduction to the carrying amount of the liability and are being amortized under the effective interest method
over the estimated period the liability will be repaid. The Company estimates the total amount of future royalty revenue and milestone
payments to be generated over the life of the Purchase and Sale Agreement, and a significant increase or decrease in these estimates
could materially impact the liability balance and the related interest expense. If the timing of the receipt of royalty payments or
milestones is materially different from the original estimates, the Company will prospectively adjust the effective interest and the
related amortization of the liability and related issuance costs.
Warrant Liabilities
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the
warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC
815, Derivatives and Hedging (ASC 815). The assessment considers whether the warrants (i) are freestanding financial instruments
pursuant to ASC 480, (ii) meet the definition of a liability pursuant to ASC 480, and (iii) meet all of the requirements for equity
classification under ASC 815, including whether the warrants are indexed to the Company's own stock and whether the warrant
holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions
for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

89
For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital, on the consolidated statements of stockholders’ deficit at the time of issuance. For warrants that do not meet all the
criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and on each
consolidated balance sheet date thereafter.
The Company’s warrant liabilities are measured at fair value using a simulation model which takes into account, as of the
valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the Company's
common stock, the expected volatility, the risk-free interest rate for the term of the warrant and the likelihood of achieving certain
future milestone events and the related impact to the price of the Company's common stock. The warrant liabilities are revalued at
each reporting period and changes in fair value are recognized in other income (expense) in the consolidated statements of operations.
The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires
significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related
liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these
estimates are recorded when known.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements
to Income Tax Disclosures. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures
primarily related to the rate reconciliation and income taxes paid information. The main provisions to the rate reconciliation disclosure
require public entities to disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information
for reconciling items that meet a quantitative threshold. The main provisions to the income taxes paid disclosure require that all
entities disclose on an annual basis: the amount of income taxes paid disaggregated by federal, state and foreign taxes and the amount
of income taxes paid disaggregated by individual jurisdictions in which income taxes paid meets a quantitative threshold. This ASU
also requires all entities to disclose income (loss) from continuing operations before income tax expense (benefit) disaggregated
between domestic and foreign and income tax expense (benefit) from continuing operations disaggregated by federal, state and
foreign.
This ASU is to be applied on a prospective basis with an effective date for all public entities for annual periods beginning after
December 15, 2024. Early adoption is permitted. The Company will adopt ASU No. 2023-09 on January 1, 2025 and does not expect
the adoption to have a material the impact on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense
Disaggregation Disclosures. The ASU requires disclosure of disaggregated income statement expense information about specific
categories including purchases of inventory, employee compensation expense, depreciation and amortization in the notes to the
financial statements. This ASU is effective January 1, 2027 for annual reporting periods and January 1, 2028 for interim reporting
periods. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.
3. Property and Equipment, Net
Property and equipment, net consisted of the following (dollar amounts in thousands):
Estimated
Useful Lives
(Years)
December 31,
2024
2023
Furniture and fixtures
5
$
249
$
249
Machinery and equipment
5
1,756
581
Computer equipment
3
20
20
Leasehold improvements
Lesser of
useful life or
remaining
lease term
476
476
Work in process
1,870
2,590
Total property and equipment
4,371
3,916
Less: Accumulated depreciation
(1,146)
(920)
Property and equipment, net
$
3,225
$
2,996

90
4. Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):
December 31,
2024
2023
Accrued research and development
$
545
$
2,078
Accrued employee costs
2,159
1,862
Accrued professional fees
37
38
Accrued expense
226
191
$
2,967
$
4,169
5. Royalty Purchase and Sale Agreement
On August 8, 2022 (the “Closing Date”), the Company, through its wholly-owned subsidiary Clearside Royalty LLC, a
Delaware limited liability company (“Royalty Sub”), entered into a Purchase and Sale Agreement (the “Purchase and Sale
Agreement”) with entities managed by HealthCare Royalty Management, LLC (“HCR”), pursuant to which Royalty Sub sold to HCR
certain of its rights to receive royalty and milestone payments payable to Royalty Sub under the Arctic Vision License Agreement, the
Bausch License Agreement, that certain License Agreement, effective as of July 3, 2019, by and between the Company and Aura
Biosciences, Inc. (the “Aura License Agreement”), that certain Option and License Agreement, dated as of August 29, 2019, by and
between REGENXBIO Inc. and the Company (the “REGENXBIO License Agreement”) and any and all out-license agreements
following the Closing Date for, or related to XIPERE or the SCS Microinjector technology (to be used in connection with compounds
or products of any third parties) delivered, in whole or in part, by means of the SCS Microinjector technology), excluding, for the
avoidance of doubt, any in-licensed or internally developed therapies following the Closing Date (collectively, the “Royalties”), in
exchange for up to $65 million. In connection with this transaction, the Company assigned the Arctic Vision License Agreement,
Bausch License Agreement, Aura License Agreement, REGENXBIO License Agreement, the Company's license agreement with
Emory University and The Georgia Tech Research Corporation and related intellectual property rights to Royalty Sub.
Under the terms of the Purchase and Sale Agreement, Royalty Sub received an initial payment of $32.1 million, representing the
$32.5 million to which the Company was entitled, net of certain of HCR's transaction-related expenses which the Company agreed to
reimburse. There were additional issuance costs of $1.5 million related to the Purchase and Sale Agreement resulting in net proceeds
of $30.6 million. An additional $12.5 million (the "First Milestone Payment") was deposited by HCR in an escrow account which was
released to HCR pursuant to the Letter Agreement described below.
The Purchase and Sale Agreement will automatically expire, and the payment of Royalties from the Royalty Sub to HCR will
cease, when HCR has received payments of the Royalties equal to 3.4 times the aggregate amount of payments made by HCR under
the Agreement (the “Cap Amount”). In the event of a change in control, the acquiror will have the option to make a payment to HCR
of the Cap Amount, less the aggregate amount of Royalty payments made by Royalty Sub to HCR under the Purchase and Sale
Agreement as a one-time payment at which time, payment of Royalties to HCR will cease. Alternatively, in the event of a change in
control, the acquiror will have the option to make an initial payment of 1.0 times the aggregate amount of payments made by HCR
under the Purchase and Sale Agreement as of the date of such change in control, then in that event, payment of Royalties from Royalty
Sub to HCR will cease when HCR has received total Royalties payments (including the initial payment) equal to the Cap Amount.
After the Purchase and Sale Agreement expires, all rights to receive the Royalties return to Royalty Sub.
On December 22, 2023, the Company, through its wholly owned subsidiary Royalty Sub, entered into the Letter Agreement
with the Agent amending that certain Purchase and Sale Agreement, dated as of August 8, 2022, by and among Royalty Sub, HCR and
Agent. Pursuant to the terms of the Letter Agreement, Royalty Sub and Agent mutually agreed that Royalty Sub waived any and all
rights to the First Milestone Payment in connection with the closing of the transactions contemplated by the Purchase and Sale
Agreement and agreed to the release of the First Milestone Payment to Agent.
Issuance costs pursuant to the Purchase and Sale Agreement consisting primarily of advisory and legal fees, totaled $1.9 million
including the amount of HCR's transaction-related expenses that the Company reimbursed. The effective interest rate includes cash
flow projections for future royalty and milestone payments that are forward looking and could be affected by future market conditions.
The Company estimates the amount and timing of expected payments based on historical experience and its expectations of future
activities from its license partners, as well as current market conditions.

91
The following table summarizes the activity of the Purchase and Sale Agreement (in thousands):
Balance at December 31, 2022
$
33,977
Payments
(1,350)
Non-cash interest expense
9,361
Balance at December 31, 2023
41,988
Non-cash interest expense
9,779
Balance at December 31, 2024
$
51,767
Effective interest rate
22.0%
6. Preferred and Common Stock
The Company’s amended and restated certificate of incorporation authorizes the Company to issue 10,000,000 shares of $0.001
par value of preferred stock. As of December 31, 2024 and 2023, there were 10,000,000 shares of preferred stock authorized, none of
which were issued and outstanding.
The Company's amended and restated certificate of incorporation authorizes the Company to issue 200,000,000 shares of $0.001
par value common stock. As of December 31, 2024 and 2023, there were 76,578,383 and 62,850,841 shares of common stock
outstanding, respectively.
7. Common Stock Warrants
In September 2016, in connection with a loan agreement, the Company issued warrants to the lenders to purchase up to 29,796
shares of common stock at a price per share of $10.74. The warrants are fully exercisable and expire in September 2026, or earlier
upon the occurrence of specified mergers or acquisitions of the Company. The warrants were recorded in equity at the time of issuance
and had a remaining life of 1.75 years as of December 31, 2024.
On February 6, 2024, the Company entered into a securities purchase agreement with institutional investors and an existing
stockholder, pursuant to which the Company issued and sold, in a registered direct offering (i) an aggregate of 11,111,111 shares (the
“Shares”) of its common stock; and (ii) warrants to purchase up to 11,111,111 shares of common stock (the “Warrants”).
The combined purchase price of each Share and accompanying Warrant was $1.35. The exercise price for the Warrants is $1.62
per share. The Warrants are exercisable and will expire on August 9, 2029. The Company recorded the initial fair value of the
Warrants of $10.3 million as warrant liabilities and $4.7 million attributable to common stock as additional paid in capital in the
consolidated balance sheets. The issuance costs were allocated among the Warrants and common stock consistent with the allocation
between amounts recorded as warrant liabilities and common stock. The issuance costs allocated to the Warrants as well as the change
in the fair value of the Warrants during the period are recorded in other income, net in the consolidated statements of operations. The
issuance costs allocated to common stock were recorded as a reduction to additional paid in capital.
The following table summarizes the change in fair value of the warrant liabilities during the year ended December 31, 2024 (in
thousands):
Fair value of warrants at issuance February 9, 2024
$
10,327
Change in fair value during the period
(3,635)
Fair value of warrants at December 31, 2024
$
6,692
The following table summarizes certain key inputs for the valuation of the Warrants at December 31, 2024:
Common stock price
$
0.95
Exercise price per share
$
1.62
Expected volatility
64.80 %
Risk-free interest rate
4.26 %
Contractual term (in years)
4.60
Expected dividend yield
— %
As described in Note 2, the measurement of the warrant liabilities is impacted by the likelihood of achieving certain events and
the related impact to the Company’s stock price. In determining the likelihood of achieving certain future milestone events, the

92
Company considers its current financial position and ability to fund future clinical activities as described in Note 1. The Company
utilizes publicly available information from external parties to assess the related impact to the Company’s stock price from the success
of these activities.
8. Share-Based Compensation
Stock Options
In January 2016, the Company’s board of directors adopted and approved the Clearside Biomedical, Inc. 2016 Equity Incentive
Plan (the “2016 Plan”) which became effective on June 1, 2016. The 2016 Plan provides for the grant of share-based awards to
employees, directors and consultants of the Company. The 2016 Plan provides for the grant of incentive stock options to employees,
and for the grant of nonqualified stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights,
performance stock awards and other forms of stock compensation to the Company’s employees, directors, and non-employee third
parties. The number of shares of common stock reserved for issuance under the 2016 Plan will automatically increase on January 1
each year, through January 1, 2026, by 4% of the total number of shares of the Company’s common stock outstanding on December
31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company’s board of directors. At
December 31, 2024, under the 2016 Plan, options to purchase 12,539,984 shares of the Company’s common stock were outstanding at
a weighted average price of $2.44 per share and 172,497 shares remained available for future grant. As of January 1, 2025, the number
of shares of common stock that may be issued under the 2016 Plan was automatically increased by 3,063,135 shares, representing 4%
of the total number of shares of common stock outstanding on December 31, 2024, increasing the number of shares of common stock
available for issuance under the 2016 Plan as of that date to 3,235,632 shares.
As a result of the adoption of the 2016 Plan, no further grants may be made under the Company’s 2011 Stock Incentive Plan
(the “2011 Plan”). The 2011 Plan provided for the grant of share-based awards to employees, directors and consultants of the
Company. At December 31, 2024, options to purchase 87,385 shares of the Company’s common stock were outstanding under the
2011 Plan at a weighted average exercise price of $5.57 per share.
The Company has granted stock option awards to employees, directors and consultants. The total share-based compensation
expense recognized is reflected in the consolidated statements of operations as follows (in thousands):
Year Ended
December 31,
2024
2023
2022
Research and development
$
1,577
$
1,200
$
1,616
General and administrative
1,903
1,758
1,785
Total
$
3,480
$
2,958
$
3,401
Share-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation.
The estimated fair value of options granted is determined as of the date of grant using the Black-Scholes option pricing model. The
resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the awards.
The following table sets forth the weighted average assumptions utilized in the Black-Scholes option pricing model to calculate
the fair value of the underlying common stock for the years ended December 31, 2024, 2023 and 2022.
Year Ended
December 31,
2024
2023
2022
Expected term (years)
6.00
6.00
6.00
Expected stock price volatility
97.74%
95.55%
98.24%
Risk-free interest rate
4.15%
4.07%
2.09%
Expected dividend yield
0.00%
0.00%
0.00%
Expected term (in years): The Company calculates the expected term using historical data.
Risk-free interest rate: The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the
expected time to a possible liquidity event.

93
Expected dividend yield: The Company has not paid and does not anticipate paying any dividends in the foreseeable future.
Expected stock price volatility: The Company calculates expected volatility based on the historical volatility of its common
stock.
Forfeitures: The Company records forfeitures as they occur.
The following table summarizes the activity related to stock options during the year ended December 31, 2024:
Weighted
Number of
Average
Shares
Exercise Price
Options outstanding at December 31, 2023
9,865,770
$
2.83
Granted
3,034,375
1.32
Exercised
(10,000)
1.24
Forfeited or expired
(245,540)
3.10
Options outstanding at December 31, 2024
12,644,605
2.46
Options exercisable at December 31, 2023
5,494,746
3.83
Options exercisable at December 31, 2024
7,643,102
3.19
The following table provides additional information about the Company’s stock options that were outstanding and exercisable at
December 31, 2024 (aggregate intrinsic values in thousands):
Weighted
Weighted
Weighted
Average
Weighted
Average
Average
Aggregate
Remaining
Average
Aggregate
Remaining
Exercise
Options
Exercise
Intrinsic
Contractual
Options
Exercise
Intrinsic
Contractual
Price
Outstanding
Price
Value
Life (Years)
Exercisable
Price
Value
Life (Years)
$0.00 - $2.99
9,821,220
7.51
4,844,946
6.28
$3.00 - $6.99
2,202,299
4.54
2,177,070
4.53
$7.00 - $8.99
419,308
2.18
419,308
2.18
$9.00 - $20.84
201,778
2.76
201,778
2.76
12,644,605
$
2.46
$
110
6.74
7,643,102
$
3.19
$
46
5.46
As of December 31, 2024, the Company had $3.9 million of unrecognized compensation expense related to unvested stock
options, which is expected to be recognized over a weighted average period of 2.4 years. The weighted average fair values of all stock
options granted for the years ended December 31, 2024, 2023 and 2022 was $1.05 per share, $1.55 per share and $3.24 per share,
respectively. The intrinsic value is calculated as the difference between the fair market value and the exercise price per share of the
stock options. The fair market value per share of common stock as of December 31, 2024 was $0.95, which was the closing sale price
of the Company’s common stock on the Nasdaq Global Market on that date.
Restricted Stock Units
The Company has granted restricted stock units (“RSUs”) to employees under the 2016 Plan. The shares underlying the RSU
awards have vesting terms of four years from the date of grant, subject to the employees’ continuous service and subject to accelerated
vesting in specified circumstances. The fair value of the RSUs granted is measured based on the market value of the Company’s
common stock on the date of grant and is recognized ratably over the requisite service period, which is generally the vesting period of
the awards.
The total share-based compensation expense related to RSUs is reflected in the consolidated statements of operations as follows
(in thousands):

94
Year Ended
December 31,
2024
2023
2022
Research and development
$
474
$
585
$
794
General and administrative
547
646
658
Total
$
1,021
$
1,231
$
1,452
The following table summarizes the activity related to RSUs during the year ended December 31, 2024:
Weighted
Average
Number of
Grant Date
Shares
Fair Value
Non-vested RSUs outstanding at December 31, 2023
834,899
$
3.01
Vested
(397,594)
3.07
Non-vested RSUs outstanding at December 31, 2024
437,305
2.96
As of December 31, 2024, the Company had $0.3 million of unrecognized compensation expense related to the RSUs, which
amount is expected to be recognized over a weighted average period of 0.9 years.
Employee Stock Purchase Plan
In January 2016, the Company’s board of directors adopted and approved the Clearside Biomedical, Inc. 2016 Employee Stock
Purchase Plan (the “2016 ESPP”) which became effective on June 1, 2016. The 2016 ESPP permits employees to purchase shares of
the Company’s common stock through payroll deductions up to 15% of their earnings. The number of shares reserved for issuance
under the 2016 ESPP will automatically increase on January 1 of each year, through January 1, 2026, by the lesser of (i) 1% of the
total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 454,545
shares of common stock or (iii) a lesser number of shares as may be determined by the Company’s board of directors. The Company’s
board of directors elected not to increase the shares reserved for issuance on January 1, 2025. The number of shares of common stock
available for issuance under the 2016 ESPP as of December 31, 2024 was 318,127 shares.
The 2016 ESPP is considered a compensatory plan and the fair value of the discount and the look-back period are estimated
using the Black-Scholes option pricing model and expense is recognized over the six-month withholding period prior to the purchase
date. During the years ended December 31, 2024, 2023 and 2022, the Company issued 36,114, 68,109 and 66,919 shares, respectively,
of common stock purchased under the 2016 ESPP.
The share-based compensation expense recognized for the 2016 ESPP is reflected in the consolidated statements of operations
as follows (in thousands):
Year Ended
December 31,
2024
2023
2022
Research and development
$
9
$
10
$
21
General and administrative
3
3
10
Total
$
12
$
13
$
31

95
9. Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred
income tax assets consist of the following (in thousands):
December 31,
2024
2023
2022
Deferred tax asset (liability):
Net operating loss carryforwards
$
56,019
$
52,657
$
50,267
Non-deductible accrued expenses
608
562
386
Right-of-use asset
(139)
(210)
(238)
Lease liability
164
246
274
Share-based compensation expense
3,585
3,339
2,678
Depreciation differences
(199)
(71)
(40)
Federal tax credits
12,035
10,908
9,742
State tax credits
302
342
326
Royalty purchase and sale agreement
12,357
10,495
7,247
Capitalized research and development expenses
7,656
5,777
3,057
Valuation allowance
(92,388)
(84,045)
(73,699)
Net deferred tax asset
$
—
$
—
$
—
A reconciliation of the statutory tax rates and the effective tax rates is as follows:
Year Ended
December 31,
2024
2023
2022
U.S. federal tax rate
21.00%
21.00%
21.00%
State tax rate
(0.14)
8.59
(0.85)
Permanent difference
0.25
(1.44)
(1.34)
Tax credit
3.17
3.64
2.18
Valuation allowance
(24.29)
(31.85)
(21.57)
Adjustment to prior year tax provision
—
—
0.67
Other
0.01
0.06
(0.09)
0.00%
0.00%
0.00%
Certain items of income and expense are not reported in tax returns and consolidated financial statements in the same year. The
tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if
necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes
a valuation allowance for deferred tax assets for which realization is not likely. As of each reporting date, management considers new
evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.
At December 31, 2024, the Company had a valuation allowance of $92.4 million recorded against the benefit of certain deferred
tax assets. The valuation allowance was primarily related to federal and state net operating loss ("NOL") carryforwards that, in the
judgment of management, are not more likely than not to be realized. In assessing the recoverability of the Company’s deferred tax
assets, management considered, among other things, its deferred tax liabilities, its historical earnings and losses, projections of future
income, and tax-planning strategies available to the Company in the relevant jurisdiction. The Company will release this valuation
allowance when management determines that it is more likely than not that its deferred tax asset will be realized.
At December 31, 2024, the Company had income tax NOL carryforwards for federal and state purposes of $240.6 million and
$96.1 million, respectively. The Company has recorded a deferred tax asset for both federal and state NOL carryforwards of $50.5
million and $5.5 million, respectively. If not utilized, the federal NOL carryforwards will begin to expire beginning in 2034, and the
state NOL carryforwards will begin to expire at various dates beginning in 2027. Additionally, under the 2017 Tax Cuts and Jobs Act,
federal net operating losses incurred in 2018 and beyond may be carried forward indefinitely. However, the deductibility of such
federal net operating losses is limited beginning in 2021. Certain states have also adopted the indefinite carryforward period beginning
with the 2018 tax year, but state conformity varies state by state.

96
Liabilities for uncertain tax positions are recognized based on a two-step process. The first step is to evaluate the tax position for
recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be
sustained on audit, including resolution of related appeals or litigation processes, if any. Once it is determined that the position meets
the recognition threshold, the second step requires the Company to estimate and measure the largest amount of tax benefit that is more
likely than not to be realized upon ultimate settlement. The difference between the amount of recognizable tax benefit and the total
amount of tax benefit from positions filed or to be filed with the tax authorities is recorded as a liability for uncertain tax benefits.
The following is a roll forward of the Company’s uncertain tax positions (in thousands):
Year Ended
December 31,
2024
2023
Balance of uncertain tax positions at the beginning of the year
$
7,520
$
7,520
Gross decreases - tax positions in prior period
(471)
—
Balance of uncertain tax positions at the end of the year
$
7,049
$
7,520
As of December 31, 2024 and 2023, there was $7.0 million and $7.5 million, respectively, of unrecognized tax benefit that if
recognized would be in the form of a net operating loss carryforward, which is expected to require a full valuation allowance based on
present circumstances. The Company recognizes accrued interest related to unrecognized tax expenses and penalties as income tax
expense. No significant amounts of interest or penalties have been recorded as of December 31, 2024.
Ownership changes, as defined by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), may limit the
amount of net operating losses that a company may utilize to offset future taxable income and taxes payable. In general, if the
Company experiences a greater than 50% aggregate change in ownership over a 3-year period (a Section 382 ownership change),
utilization of the Company’s pre-change NOL carryforwards may be subject to limitation under the Code. The annual limitation
generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain
adjustments) by the applicable long-term tax-exempt rate for the month in which the ownership change occurred. Such limitation may
result in expiration of a portion of the NOL carryforwards before utilization. The Company has completed an owner shift analysis to
determine the dates in which the Company may have experienced a Section 382 ownership change, and determined that the Company
experienced ownership changes for Section 382 purposes in January 2012, December 2013, and July 2016.
The NOL DTA has a full valuation allowance as it is deemed that it is more likely than not to be utilized. The Company will
continue to monitor equity movement and its impact on the utilization of the NOLs and credits. The Company’s ability to use the
remaining NOL carryforwards may be further limited if the Company experiences an additional Section 382 ownership change as a
result of future changes in its stock ownership.
The Company is subject to taxation in the United States and certain state jurisdictions. As of December 31, 2024, the
Company’s tax returns for 2021, 2022 and 2023 are subject to full examination by the tax authorities. As of December 31, 2024, the
Company is generally no longer subject to state or local examinations by tax authorities for years before 2021, except to the extent of
NOLs generated in prior years claimed on a tax return.
10. Commitments and Contingencies
Lease Commitment Summary
The Company leases its facilities and some of its equipment under noncancelable operating lease arrangements that expire at
various dates through 2026. In November 2022, the Company signed an amended office lease agreement and decreased the square
footage to approximately 14,000 square feet. The amended office lease agreement is for a four-year term with a renewal option for an
additional thirty-eight months. Rental payments are $30,437 per month subject to an increase of 3% per year. Operating lease cost
under this lease and the amendment is recognized on a straight-line basis over the term of the lease. In addition, the office lease
agreement requires payment of the pro-rata share of the annual operating expenses associated with the premises.

97
The Company’s operating leases included on the consolidated balance sheet are as follows (in thousands):
December 31,
2024
Operating lease right-of-use asset
$
597
Liabilities
Current portion of operating lease liabilities
$
375
Operating lease liabilities
328
Total operating lease liabilities
$
703
The Company recognizes a right-of-use asset for the right to use the underlying asset for the lease term, and a lease liability,
which represents the present value of the Company’s obligation to make payments over the lease term. The renewal option is not
included in the calculation of the right-of-use asset and the lease liabilities as the Company is not reasonably certain if the Alpharetta,
Georgia lease will be renewed. The present value of the lease payments is calculated using an incremental borrowing rate as the
Company’s leases do not provide an implicit interest rate. The Company’s incremental borrowing rate was 8.0%. The remaining lease
term was 2.0 years. Cash payments included in operating activities on the consolidated statement of cash flows for operating lease
liabilities were $0.4 million for each of the years ended December 31, 2024 and 2023 and $0.3 million for the year ended December
31, 2022.
Minimum lease payments were as follows at December 31, 2024 (in thousands):
Year ending December 31,
2025
$
389
2026
367
Total minimum lease payments
756
Less imputed interest
(53)
Total operating lease liabilities
$
703
Equipment leases with an initial term of 12 months or less are not recorded with operating lease liabilities. The Company
recognizes expense for these leases on a straight-line basis over the lease term. The equipment leases were deemed to be immaterial.
Operating lease cost was $0.3 million for the each of the years ended December 31, 2024, 2023 and 2022. Variable lease cost
was $25,000, $19,000 and $87,000 for the years ended December 31, 2024, 2023 and 2022, respectively. Short-term lease cost was
$92,000, $93,000 and $86,000 for the years ended December 31, 2024, 2023 and 2022, respectively.
Georgia Tech License Agreement
As described in Footnote 1, the Company entered into a fourth amendment to the Georgia Tech License Agreement pursuant to
which the parties agreed to revised Maintenance Fee payments in exchange for a reduction to the contractual Sublicense Percentage
owed by the Company on certain fees and other payments it may receive from future sublicensing activities. The Company paid the
Maintenance Fee for 2023 in February 2024 and the Maintenance Fee for 2024 in October 2024. The remaining annual Maintenance
Fee payments are due on October 1st of each year from 2025 through 2028, as show in the table below.

98
The annual Maintenance Fee will be paid as follows (in thousands):
Year Ending December 31,
2025
$
250
2026
350
2027
400
2028
500
$
1,500
Contract Service Providers
In the course of the Company’s normal business operations, it has agreements with contract service providers to assist in the
performance of its research and development, clinical research and manufacturing. Substantially all of these contracts are on an as
needed basis.
In May 2018, the Company entered into a manufacturing supply agreement (the “Supply Agreement”), with Gerresheimer
Regensburg GmbH, a company incorporated under the laws of Germany (“Gerresheimer”). Gerresheimer will manufacture and supply
the Company’s proprietary SCS Microinjector. The Company will provide Gerresheimer with a rolling forecast schedule of its
projected purchase orders for at least the next four calendar quarters. The Supply Agreement contains an initial five-year term that will
automatically renew for successive periods of three years, unless terminated by either party at least 12 months prior to the end of the
applicable term.
11. License and Other Agreements
Bausch + Lomb
On October 22, 2019, the Company entered into a License Agreement (as amended, the "Bausch License Agreement") with
Bausch + Lomb, a division of Bausch Health Companies, Inc. (“Bausch”). Pursuant to the Bausch License Agreement, the Company
has granted an exclusive license to Bausch to develop, manufacture, distribute, promote, market and commercialize XIPERE using the
Company’s proprietary SCS Microinjector (the “Device”), as well as specified other steroids, corticosteroids and NSAIDs in
combination with the Device (“Other Products,” and together with XIPERE, the “Products”), subject to specified exceptions, in the
United States and Canada (the “Territory”) for the treatment of ophthalmology indications, including non-infectious uveitis.
Pursuant to the Bausch License Agreement, Bausch paid the Company an upfront payment of $5.0 million (the “Upfront
Payment”) in October 2019. In October 2021, the FDA approved XIPERE. The Company received $5.0 million from Bausch as a
result of the approval. In December 2021, $10.0 million was recorded upon completion of pre-launch activities for XIPERE and
payment was received in January 2022. In addition, Bausch has agreed to pay up to an aggregate of $55.0 million in additional
milestone payments upon the achievement of (i) specified regulatory approvals for specified additional indications of XIPERE and
(ii) specified levels of annual net sales (as defined in the Bausch License Agreement). Further, during the applicable royalty term, the
Company will also be entitled to receive tiered royalties at increasing percentages, from the high-teens to twenty percent, based on
XIPERE achieving certain annual net sales thresholds in the Territory, in each case subject to reductions in specified circumstances;
provided that the Company will not receive any royalties on the first $45.0 million of cumulative net sales of all products in the
Territory. Bausch launched XIPERE in the United States in the first quarter of 2022. The Company's rights to these royalties and
milestone payments have been sold pursuant to the terms and conditions of the Purchase and Sale Agreement described in Note 5.
The Company was responsible for all development expenses for XIPERE in the Territory until the Company's New Drug
Application ("NDA") was approved by the FDA, subject to specified exceptions, as well as manufacturing costs in connection with the
NDA. The Company was also responsible for all clinical and development expenses conducted to satisfy the FDA’s requests in the
complete response letter issued on October 18, 2019 related to the NDA and any subsequent complete response letter related to the
NDA. Following FDA approval of XIPERE, Bausch is responsible for all such expenses.
REGENXBIO, Inc.
On August 29, 2019, the Company entered into an option and license agreement with REGENXBIO, Inc. (“REGENXBIO”)
pursuant to which the Company granted REGENXBIO an exclusive option to enter into a commercial license agreement (the
“Option”), which grants REGENXBIO an exclusive, worldwide and sublicensable license to the Company’s SCS Microinjector for
the delivery of adeno-associated virus-based gene therapies for the treatment of wet age-related macular degeneration, diabetic
retinopathy and other conditions for which anti-vascular endothelial growth factor treatment is currently the standard of care.

99
REGENXBIO exercised the Option in October 2019 and paid the Company an option fee equal to $2.0 million, less a credit of $0.5
million previously received under a technology access agreement. In addition, REGENXBIO has agreed to pay the Company up to an
aggregate of $31.0 million in milestone payments upon the achievement of specified development milestones and up to an aggregate
of $102.0 million in sales-based milestone payments, as well as mid-single digit royalties on net sales of products using the SCS
Microinjector during the royalty term. In September 2020, the Company received $3.0 million in milestone payments under the
Option. The Company's rights to these royalties and milestone payments have been sold pursuant to the terms and conditions of the
Purchase and Sale Agreement described in Note 5.
Arctic Vision (Hong Kong) Limited
On March 10, 2020, the Company entered into a License Agreement (the “Arctic Vision License Agreement”) with Arctic
Vision (Hong Kong) Limited (“Arctic Vision”). Pursuant to the Arctic Vision License Agreement, the Company has granted an
exclusive license to Arctic Vision to develop, distribute, promote, market and commercialize XIPERE, subject to specified exceptions
in China, Hong Kong, Macau, Taiwan and South Korea (the “Arctic Territory”). Under the terms of the Arctic Vision License
Agreement, neither party may commercialize XIPERE in the other party’s territory. Arctic Vision has agreed to use commercially
reasonably efforts to pursue development and commercialization of XIPERE for indications associated with uveitis in the Arctic
Territory. In addition, upon receipt of the Company’s consent, Arctic Vision will have the right, but not the obligation, to develop and
commercialize XIPERE for additional indications in the Arctic Territory.
Pursuant to the Arctic Vision License Agreement, Arctic Vision paid the Company an upfront payment of $4.0 million in March
2020. In December 2021, the Company received a milestone payment of $4.0 million following the receipt of FDA approval of
XIPERE in the United States. In addition, Arctic Vision has agreed to pay the Company up to $22.5 million in development and sales
milestones. Further, during the applicable royalty term, the Company will also be entitled to receive tiered royalties of ten to twelve
percent of net sales based on achieving certain annual net sales thresholds in the Arctic Territory, subject to customary reductions,
payable on a product-by-product and country-by-country basis, commencing at launch in such country and lasting until the latest of (i)
the date that all valid claims within the licensed patent rights covering XIPERE have expired, (ii) the date of the loss of marketing or
regulatory exclusivity of XIPERE in a given country, or (iii) ten years from the first commercial sale of XIPERE in a given country.
The Company's rights to these royalties and milestone payments have been sold pursuant to the terms and conditions of the Purchase
and Sale Agreement described in Note 5.
In August 2021, the Company entered into an amendment to the Arctic Vision License Agreement to expand the territories
covered by the license to include India and the ASEAN Countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the
Philippines, Singapore, Thailand, and Vietnam). In September 2021, the Company entered into a second amendment to the Arctic
Vision License Agreement to expand the Arctic Territory to include Australia and New Zealand. The Company received an aggregate
of $3.0 million in consideration for the expansion of the Arctic Territory.
BioCryst Pharmaceuticals, Inc.
On November 1, 2023, the Company entered into the BioCryst License Agreement pursuant to which the Company granted
BioCryst an exclusive, worldwide and sublicensable license to the Company’s SCS Microinjector for the delivery of BioCryst’s
proprietary plasma kallikrein inhibitor known as avoralstat for the treatment and prevention of DME.
The Company received an upfront license fee payment of $5.0 million in connection with signing of the BioCryst License
Agreement. In addition, the Company is eligible to receive up to an additional $30.0 million in clinical and regulatory milestone
payments, and up to a total of $47.5 million in a series of post-approval sales-based milestone payments based on the achievement of
annual global net product sales milestones up to $2.0 billion. Further, during the royalty term, BioCryst has also agreed to pay the
Company tiered mid-single digit royalties on annual global net product sales, with the highest royalty rate applied to sales over $1.5
billion, subject to reductions in specified circumstances. The Company's rights to these royalties and milestone payments have been
sold pursuant to the terms and conditions of the Purchase and Sale Agreement described in Note 5.
BioCryst will be responsible for all development, regulatory and commercialization activities for avoralstat. The Company is
responsible for supplying SCS Microinjectors to meet BioCryst’s reasonable needs.
The BioCryst License Agreement, unless earlier terminated, will expire (a) on a country-by-country basis upon the expiration of
the royalty term in such country or (b) in its entirety upon the expiration of all payment obligations of BioCryst under the BioCryst
License Agreement in all countries pursuant to clause (a). Each party has the right terminate the License Agreement (i) upon a
material breach of the BioCryst License Agreement by the other party, subject to a specified cure period and specified exceptions, or
(ii) if the other party encounters bankruptcy or insolvency. The Company may terminate the BioCryst License Agreement if BioCryst
or any of its sublicensees (a “Sublicensee”) commences a legal action challenging the validity, enforceability or scope of any of the

100
licensed patents, provided that with respect to any such action initiated by a Sublicensee (a “Sublicensee Action), the Company may
terminate the BioCryst License Agreement if the Sublicensee Action is not terminated within a specified period of time following
BioCryst’s receipt of written notice from the Company or if BioCryst does not terminate the applicable sublicense, in each case within
a specified period of time. BioCryst may terminate the BioCryst License Agreement (i) immediately upon written notice to the
Company if, after exercising commercially reasonable efforts, BioCryst determines in good faith that it is not advisable to continue
development or commercialization of avoralstat as a result of a material safety issue and (ii) in its entirety or in part on a country-by-
country basis, for any or no reason, upon prior written notice to the Company, provided that in the event of such a termination,
BioCryst shall not, for a period of two years from the date of such a termination, initiate in the territory subject to the termination a
Phase 3 clinical trial in which avoralstat is administered to the suprachoroidal space using a device other than the SCS Microinjector.
Emory and Georgia Tech
On January 31, 2024 (the “Amendment Execution Date”), the Company and the Licensor, entered into the Amendment to the
Company’s License Agreement with Licensor dated July 4, 2012 (as amended, the “License Agreement”), pursuant to which the
Company received a worldwide exclusive license to specified patents relating to methods and devices for drug delivery using a
microinjector.
Pursuant to the Amendment, the parties agreed to reduce the Sublicense Percentage (as defined in the License Agreement) from
a low double digit percentage to a high single digit percentage that the Company will pay the Licensor applicable to any fees or
payments paid to the Company by any Sublicensee (as defined in the License Agreement) of the Licensed Patents and/or Licensed
Technology (each as defined in the License Agreement), on or after July 1, 2023, excluding (i) amounts paid to the Company by a
Sublicensee to reimburse the Company for certain research and development costs pursuant to a written agreement between the
Company and such Sublicensee, (ii) the value of intellectual property transferred or granted to the Company if necessary or helpful to
the development or commercialization of Licensed Products (as defined in the License Agreement) and (iii) amounts paid for shares of
the Company’s stock. The payment to Licensor of any such Sublicense Percentage is due within 30 days of receipt by the Company of
a qualifying payment from a Sublicensee, provided however, with respect to any qualifying payments received by the Company from
a Sublicensee after July 1, 2023 but prior to January 1, 2025, the payment to Licensor of any such Sublicensee Percentage is due to
Licensor by March 31, 2025.
In addition, the parties agreed to a revised annual license maintenance fee due each year, or the Maintenance Fee, starting in
2023 through 2028, as follows: $0.3 million for 2023 through 2025, $0.4 million for 2026 and 2027 and $0.5 million for 2028. The
Company paid the Maintenance Fee for 2023 in February 2024 and the Maintenance Fee for 2024 in October 2024. The remaining
annual Maintenance Fee payments are due on October 1st of each year.
Other
The Company periodically enters into short-term agreements with other customers to evaluate the potential use of its proprietary
SCS Microinjector with third-party product candidates for the treatment of various diseases. Funds received from these agreements are
recognized as revenue over the term of the agreement. The Company recorded $50,000 and $13,000 of revenue from these agreements
during the years ended December 31, 2023 and 2022, respectively.
12. Fair Value Measurements
The Company’s material financial instruments at December 31, 2024 and 2023, consisted primarily of cash and cash
equivalents. The fair value of cash and cash equivalents, other current assets and accounts payable approximate their respective
carrying values due to the short-term nature of these instruments and are classified as Level 1 in the fair value hierarchy. The fair
value of the warrant liabilities (see Note 7) requires significant unobservable inputs and is classified as Level 3 in the fair value
hierarchy.
There were no transfers between Levels 1, 2 and 3 during the years ended December 31, 2024 and 2023.
13. Related Party Transactions
During 2023, a member of the Company's Board of Directors took a position as Chief Executive Officer of a company that is a
vendor of the Company. As of December 31, 2024, the Company has recorded $0.5 million in accounts payable and $0.3 million in
accrued expense with this vendor in the consolidated balance sheets. For the year ended December 31, 2024, the Company has
recorded $1.1 million of expense in the consolidated statements of operations. As of December 31, 2023, the Company has recorded

101
$0.3 million in accounts payable and $0.2 million in accrued expense with this vendor in the consolidated balance sheets. For the year
ended December 31, 2023, the Company has recorded $1.1 million of expense in the consolidated statements of operations.
The Chair of the Board of Directors of BioCryst also serves on the Company’s Board of Directors. For the years ended
December 31, 2024 and 2023, there was $0.3 million and $5.0 million, respectively, related to the License Agreement recorded in
license and other revenue in the consolidated statements of operations.
14. Net Loss Per Share
Basic net loss per share is calculated by dividing the net (loss) income by the weighted average number of shares of common
stock outstanding for the period, without consideration of the dilutive effect of potential common stock equivalents. Diluted net loss
income per share gives effect to all dilutive potential shares of common stock outstanding during this period. For all periods presented,
the Company’s potential common stock equivalents, which included stock options, restricted stock units and common stock warrants,
have been excluded from the computation of diluted net loss per share as their inclusion would have the effect of reducing the net loss
per share. Therefore, the denominator used to calculate both basic and diluted net loss per share is the same in all periods presented.
The Company’s potential common stock equivalents that have been excluded from the computation of diluted net loss per share
for all periods presented because of their antidilutive effect consisted of the following:
Year Ended
December 31,
2024
2023
2022
Outstanding stock options
12,644,605
9,865,770
6,915,330
Non-vested restricted stock units
437,305
834,899
1,462,932
Stock purchase warrants
11,140,907
29,796
29,796
24,222,817
10,730,465
8,408,058

102
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), refers to controls and procedures that are designed to ensure that information required to
be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s
management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding
required disclosure.
In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and
procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management
necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and
procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events,
and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time,
controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may
deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the
effectiveness of our disclosure controls and procedures as of December 31, 2024. Based on that evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period
covered by this report at the reasonable assurance level.
Changes in Internal Controls over Financial Reporting
There has been no change in our internal control over financial reporting during the quarter ended December 31, 2024 that has
materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Management’s Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting
Firm
Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting,
as defined in the Exchange Act Rule 13a-15(f). Management conducted an assessment of our internal control over financial reporting
based on the framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in Internal
Control—Integrated Framework. Based on the assessment, management concluded that, as of December 31, 2024, our internal control
over financial reporting was effective.
This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control
over financial reporting as required by Section 404(c) of the Sarbanes Oxley Act of 2002. Because we qualify as a non-accelerated
filer and a smaller reporting company under SEC rules, management's report was not subject to attestation by our independent
registered public accounting firm.
ITEM 9B. OTHER INFORMATION
During the quarter ended December 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange
Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term
is defined in Item 408 of Regulation S-K).
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.

103
PART III
We will file a definitive Proxy Statement for our 2025 Annual Meeting of Stockholders (the “2025 Proxy Statement”) with the
SEC, pursuant to Regulation 14A, not later than 120 days after the end of our fiscal year. Accordingly, certain information required by
Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2025 Proxy Statement that
specifically address the items set forth herein are incorporated by reference.
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this item is hereby incorporated by reference to the 2025 Proxy Statement under the captions
"Information Regarding the Board of Directors and Corporate Governance," "Election of Directors," and "Information About Our
Executive Officers."
We have adopted a Code of Business Conduct and Ethics (the “Code of Conduct”) applicable to all of our employees, executive
officers and directors. The Code of Conduct is available on our website at www.clearsidebio.com. The Audit Committee is responsible
for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for executive officers and directors. If we
make any substantive amendments to the Code of Conduct or grant any waiver from a provision of the Code of Conduct to any
executive officer or director, we will promptly disclose the amendment or waiver on our website.
We have adopted an insider trading policy governing the purchase, sale, and/or other dispositions of our securities and those of
public companies in which we have a business relationship by our directors, executive officers, employees and consultants, that is
designed to promote compliance with insider trading laws, rules and regulations, as well as provides for procedures designed to further
the foregoing purposes. This policy prohibits, among other things, trading in our common stock that would violate these laws and
regulations, and it also imposes other restrictions such as event-driven trading blackout periods and pre-clearance requirements for
trading intended to protect against inadvertent violations of these laws and regulations. Pursuant to our insider trading policy, it is the
Company’s policy to comply with applicable laws and regulations relating to insider trading when engaging in transactions in the
Company’s securities. A copy of our insider trading policy, including any amendments thereto, is filed incorporated by reference as
Exhibit 19 to this Annual Report on Form 10-K.
ITEM 11. EXECUTIVE COMPENSATION
The information required by Item 11 is hereby incorporated by reference to the sections of the 2025 Proxy Statement under the
captions "Executive Compensation" and "Non-Employee Director Compensation."
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
The information required by Item 12 is hereby incorporated by reference to the sections of the 2025 Proxy Statement under the
captions "Security Ownership of Certain Beneficial Owners and Management" and "Securities Authorized for Issuance under Equity
Compensation Plans."
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by Item 13 is hereby incorporated by reference to the sections of the 2025 Proxy Statement under the
captions "Transactions with Related Persons" and "Independence of the Board of Directors."
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by Item 14 is hereby incorporated by reference to the sections of the 2025 Proxy Statement under the
caption "Ratification of Selection of Independent Auditors."

104
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a) We have filed the following documents as part of this Annual Report:
1. Financial Statements
The financial statements are included in Item 8. “Financial Statements and Supplementary Data.”
2. Financial Statement Schedules
All schedules are omitted as information required is inapplicable or the information is presented in the financial statements
and the related notes.
3. Exhibits
Exhibit
number
Description of document
3.1
Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the
Registrant’s Current Report on Form 8-K (File No. 001-37783) filed with the SEC on June 7, 2016).
3.2
Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated herein by reference
to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37783) filed with the SEC on June 23,
2022).
3.3
Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report
on Form 8-K (File No. 001-37783) filed with the SEC on June 7, 2016).
4.1
Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to Exhibit 4.1 to
Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916) filed with the
SEC on March 18, 2016).
4.2
Form of Warrant to Purchase Common Stock issued to lenders in September 2016 in connection with Amended and
Restated Loan and Security Agreement (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current
Report on Form 8-K (File No. 001-37783), filed with the Commission on October 4, 2016).
4.3
Form of Warrant to Purchase Common Stock issued to investors in February 2024 in connection with Securities
Purchase Agreement (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-
K (File No. 001-37783), filed with the Commission on February 8, 2024).
4.4
Description of Common Stock of Clearside Biomedical, Inc. (incorporated herein by reference to Exhibit 4.4 to the
Registrant’s Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 13, 2020).
10.1
#
License Agreement, by and among the Registrant, Emory University and The Georgia Tech Research Corporation,
dated as of July 4, 2012, as amended by the First Amendment to License Agreement, dated April 2, 2014
(incorporated herein by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-1 (File No.
333-208916), filed with the Commission on January 8, 2016).
10.2
+
2011 Stock Incentive Plan, as amended to date (incorporated herein by reference to Exhibit 10.3 to the Registrant’s
Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on January 8, 2016).
10.3
+
Form of Incentive Stock Option Grant Notice and Incentive Stock Option Agreement under 2011 Stock Incentive
Plan (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 (File
No. 333-208916), filed with the Commission on January 8, 2016).
10.4
+
Form of Nonqualified Stock Option Grant Notice and Nonqualified Stock Option Agreement under 2011 Stock
Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form
S-1 (File No. 333-208916), filed with the Commission on January 8, 2016).
10.5
+
2016 Equity Incentive Plan (incorporated herein by reference to Exhibit 4.7 to the Registrant’s Registration
Statement on Form S-8 (File No. 333-212014), file with the Commission on June 14, 2016).

105
10.6
+
Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan (incorporated
herein by reference to Exhibit 10.7 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1
(File No. 333-208916), filed with the Commission on March 18, 2016).
10.7
+
Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2016 Equity
Incentive Plan (incorporated herein by reference to Exhibit 10.8 to Amendment No. 1 to the Registrant’s
Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on March 18, 2016).
10.8
+
Form of Indemnification Agreement with non-employee directors (incorporated herein by reference to Exhibit 10.9
to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on
January 8, 2016).
10.9
+
Form of 2016 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.12 to Amendment No.
1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on
March 18, 2016).
10.10
Office Lease Agreement, dated November 21, 2016, by and between the Registrant and BRE/COH GA LLC
(incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-
37783), filed with the Commission on November 23, 2016).
10.11
Second Amendment to License Agreement, by and among the Registrant, Emory University and The Georgia Tech
Research Corporation, dated December 12, 2016 (incorporated herein by reference to Exhibit 10.21 to the
Registrant’s Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 16, 2017).
10.12
+
Amended and Restated Executive Employment Agreement, by and between Clearside Biomedical, Inc. and Charles
A. Deignan, dated as of August 3, 2017 (incorporated herein by reference to Exhibit 10.2 to the Registrant’s
Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on November 9, 2017).
10.13
+
Fifth Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to
Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission
on May 10, 2024).
10.14
#
Supply Agreement, by and among the Registrant and Gerresheimer Regensburg GmbH, dated as of May 8, 2018
(incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-
37783), filed with the Commission on August 8, 2018).
10.15
+
Change in Control Equity Acceleration Plan, amending the Registrant’s 2016 Equity Incentive Plan (incorporated
herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37783), filed
with the Commission on August 8, 2018).
10.16
Third Amendment to License Agreement, by and among the Registrant, Emory University and The Georgia Tech
Research Corporation, dated April 1, 2018 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s
Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on August 8, 2019).
10.17
##
License Agreement, by and between the Registrant and Bausch Health Ireland Limited, dated as of October 22,
2019 (incorporated herein by reference to Exhibit 10.26 to the Registrant’s Annual Report on Form 10-K (File No.
001-37783), filed with the Commission on March 13, 2020).
10.18
##
First Amendment to License Agreement, by and between the Registrant and Bausch Health Ireland Limited, dated
as of April 27, 2020. (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form
10-Q (File No. 001-37783), filed with the Commission on August 10, 2020).
10.19
+
Letter Agreement, by and between the Registrant and George Lasezkay, dated April 16, 2019 (incorporated herein
by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the
Commission on April 17, 2019).
10.20
+
Amendment to Offer Letter Agreement, by and between the Registrant and George Lasezkay, dated as of August 6,
2019 (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q (File No.
001-37783), filed with the Commission on August 8, 2019).
10.21
##
Option and License Agreement by and between the Registrant and REGENXBIO Inc., dated as of August 29, 2019
(incorporated herein by reference to Exhibit 10.30 to the Registrant’s Annual Report on Form 10-K (File No. 001-
37783), filed with the Commission on March 13, 2020).

106
10.22
##
License Agreement by and between the Registrant and Arctic Vision (Hong Kong) Limited, dated as of March 20,
2020 (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No.
001-37783), filed with the Commission on May 8, 2020).
10.23
##
First Amendment to the License Agreement, by and between the Registrant and Arctic Vision (Hong Kong)
Limited, dated as of August 15, 2021 (incorporated herein by reference to Exhibit 10.1 to the Registrant's Quarterly
Report on Form-10 (File No. 001-37783), filed with the Commission on November 10, 2021.
10.24
##
Second Amendment to the License Agreement, by and between the Registrant and Arctic Vision (Hong Kong)
Limited, dated as of September 9, 2021 (incorporated herein by reference to Exhibit 10.2 to the Registrant's
Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on November 10, 2021.
10.25
Second Amendment to the License Agreement, by and between the Registrant and Bausch + Lomb Ireland Limited
(as assignee of Bausch Health Ireland Limited), dated as of September 27, 2021 (incorporated herein by reference to
Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37783), filed with the Commission on
November 10, 2021.
10.26
##
Purchase and Sale Agreement, by and among Clearside Royalty LLC, Healthcare Royalty Partners IV, L.P. and
HCR Collateral Management, LLC (in its capacity as agent for Purchaser), dated as of August 8, 2022 (incorporated
herein by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37783), filed
with the Commission on November 9, 2022).
10.27
First Amendment to Office Lease Agreement, by and between the Registrant and Radiant-North Point Properties,
LLLP, dated as of November 1, 2022 (incorporated herein by reference to Exhibit 10.29 to the Registrant’s Annual
Report on Form 10-K (File No. 001-37783), filed with the Commission on March 14, 2023).
10.28
##
First Amendment to Option and License Agreement, by and between the Registrant and REGENXBIO, Inc., dated
as of January 14, 2023 (incorporated herein by reference to Exhibit 10.30 to the Registrant’s Annual Report on
Form 10-K (File No. 001-37783), filed with the Commission on March 14, 2023).
10.29
##
License Agreement, by and between the Registrant and BioCryst Pharmaceuticals, Inc., dated as of November 1,
2023 (incorporated herein by reference to Exhibit 10.31 to the Registrant’s Annual Report on Form 10-K (File No.
001-37783), filed with the Commission on March 12, 2024).
10.30
Letter Agreement, by and among Clearside Royalty LLC, Healthcare Royalty Partners IV, L.P. and HCR Clearside
SPV, LLC (as assignee of HCR Collateral Management, LLC), dated as of December 22, 2023 (incorporated herein
by reference to Exhibit 10.1 to the (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current
Report on Form 8-K (File No. 001-37783), filed with the Commission on December 28, 2023).
10.31
*##
Fourth Amendment to License Agreement, by and among the Registrant, Emory University and The Georgia Tech
Research Corporation, dated January 31, 2024 (incorporated herein by reference to Exhibit 10.33 to the Registrant’s
Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 12, 2024).
10.32
Controlled Equity OfferingSM Sales Agreement, by and between the Registrant and Cantor Fitzgerald & Co., dated
as of May 12, 2023 (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-
K (File No. 001-37783), filed with the Commission on May 12, 2023).
10.33
First Amendment to License Agreement, by and among the Registrant and BioCryst Pharmaceuticals, Inc., dated as
of May 20, 2024 (incorporated herein by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-
Q (File No. 001-37783), filed with the Commission on August 12, 2024).
10.34
+
Employment Agreement, by and between Registrant and Victor Chong, dated as of June 19, 2024 (incorporated
herein by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37783), filed
with the Commission on August 12, 2024).
19
*
Clearside Biomedical, Inc. Amended and Restated Insider Trading Policy.
23.1
*
Consent of Ernst & Young LLP, independent registered public accounting firm.
24.1
*
Power of Attorney (included on signature page).
31.1
*
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the
Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
*
Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the
Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

107
32.1
*^
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) and 15d-
14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of The Sarbanes-Oxley Act of 2002.
97
Clearside Biomedical, Inc. Clawback Policy (incorporated herein by reference to Exhibit 97 to the Registrant’s
Annual Report on Form 10-K (File No. 001-37783), filed with the Commission on March 12, 2024).
101.INS
Inline XBRL Instance Document
101.SCH
Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
*
Filed herewith.
+
Indicates management contract or compensatory plan.
#
Confidential treatment has been granted with respect to portions of this exhibit (indicated by asterisks) and those portions have been
separately filed with the Securities and Exchange Commission.
^
These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any
filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
##
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the Securities and Exchange Commission, certain portions of this
exhibit (indicated by asterisks) have been omitted because they are not material and are the type that the Registrant treats as private or
confidential. The Registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission, upon its request, an
unredacted copy of this exhibit.

Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees
to furnish a copy of all omitted exhibits and schedules to the SEC upon request.

Table of Contents
108
ITEM 16. FORM 10-K SUMMARY
Not applicable.

Table of Contents
109
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
CLEARSIDE BIOMEDICAL, INC.
By:
/s/ George Lasezkay, Pharm.D., J.D.
March 27, 2025
George Lasezkay, Pharm.D., J.D.
President and Chief Executive Officer
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints George
Lasezkay and Charles A. Deignan, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of
substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign this Annual Report on Form
10-K of Clearside Biomedical, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full
power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby
ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause
to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ George Lasezkay, Pharm.D., J.D.
George Lasezkay, Pharm.D., J.D.
President, Chief Executive Officer
and Director
(Principal Executive Officer)
March 27, 2025
/s/ Charles A. Deignan
Charles A. Deignan
Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)
March 27, 2025
/s/ Anthony S. Gibney
Anthony S. Gibney
Director
March 27, 2025
/s/ Richard Croarkin
Richard Croarkin
Director
March 27, 2025
/s/ Jeffrey L. Edwards
Jeffrey L. Edwards
Director
March 27, 2025
/s/ William D. Humphries
William D. Humphries
Director
March 27, 2025
/s/ Nancy J. Hutson
Nancy J. Hutson
Director
March 27, 2025
/s/ Christy L. Shaffer, Ph.D.
Christy L. Shaffer, Ph.D.
Director
March 27, 2025
/s/ Clay B. Thorp
Clay B. Thorp
Director
March 27, 2025
/s/Benjamin R. Yerxa
Benjamin R. Yerxa
Director
March 27, 2025